South African National Essential Medicine List Primary Healthcare Medication Review Process Component:

MEDICINE REVIEW

Guideline question: In adults diagnosed with RR-TB, should a 6-month treatment regimen composed of bedaquiline, pretomanid, linezolid (600mg) and a fluoroquinolone be used rather than 9-month or longer (18-month) regimen?

Adolopment of the WHO consolidated guidelines on tuberculosis: Drug-resistant tuberculosis treatment 2022

1. Executive Summary

Date: 30 March 2023 Medicine (INN): bedaquiline, pretomanid, linezolid, moxifloxacin Medicine (ATC): J04AK05; J01XX08, J04AK08, J01MA14 Indication (ICD10 code): A15.0-3/A15.7-8/A16.0-2/A16.7-8/B20.0 + (U50.00-01) Patient population: Adults with rifampicin resistant tuberculosis (RR-TB) Prevalence of condition:

- In a cross-sectional study of identified tuberculosis cases in South Africa between 2012 and 2014, prevalence of multidrug resistant tuberculosis (MDR-TB) was 2.8% (95% CI 2.0, 3.6) and of extensively drug resistant tuberculosis (XDR-TB) was 4.9% (95% CI 1.0, 8.8). (Ismail et al. 2018)(1) https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30222-6/fulltext#supplementaryMaterial
- In 2021, there were approximately 21 000 incident cases of RR-TB in South Africa, as reported by WHO. (WHO Global Tuberculosis Report, 2022)(2) <u>https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022/tb-disease-burden/2-3-drug-resistant-tb</u>

Level of Care: Primary healthcare

Prescriber Level: Medical officer in consultation with a dedicated specialist center.

Motivator/reviewer name(s): Adolopment review team: Jessica Taylor (JT), Natasha Gloeck (NG), Sumayya Ebrahim (SE), Funeka Bango (FB), Norbert Ndjeka (NN), Gary Maartens (GM), Michael McCaul (MM) (methodologist), Jeremy Nel (JN), Tamara Kredo (TK) (methodologist), Karen Cohen (KC), Zahiera Adam (ZA). **Declarations of interest:** The review team have no interests to declare in the establishment of this evidence summary. KC, TK, MM, FB, NG, and SE are members of the South African GRADE Network.

Funding and acknowledgments:

NG, TK, MM, SE, FB are partly supported by the Research, Evidence and Development Initiative (READ-It) project. READ-It (project number 300342-104) is funded by UK aid from the UK government; however, the views expressed do not necessarily reflect the UK government's official policies. ZA is a consultant for Right to Care.

We would like to thank and acknowledge the following people:

- Trudy Leong, who supported FB with planning the economic analyses and presenting the results.
- Greg Fox, the reviewer of the WHO systematic review, for sharing the results.
- Fuad Mirzayev and Samuel Schumacher from WHO's TB Programme, for their engagement and willingness to share the WHO guideline information prior to publication.
- Beverly Stringer, Karen Lowton, Katherine Fielding, Martina Cusinato and the TB-PRACTECAL-PRO team for presenting the results of the qualitative component of the trial conducted in South Africa.

PTC affiliation: n/a

Key findings

- The South African TB programme is seeking to find the most efficacious, safe, acceptable, and cost-effective regimens to treat people with RR-TB. Therefore, we aimed to review whether a 6-month treatment regimen composed of bedaquiline, pretomanid, linezolid (600mg) and a fluoroquinolone be used rather than 9-month or longer (18-month) regimen in adults with RR-TB?
- Current South African standard of care regimens for the treatment of RR-TB include the following:
 - A short-course treatment regimen for less extensive RR-TB disease, without fluoroquinolone resistance. This regimen consists of two months of linezolid (600mg daily), four to six months of high-dose isoniazid, six to nine months of bedaquiline and nine months of levofloxacin, pyrazinamide, ethambutol and clofazimine.
 - An 18-month long-course treatment regimen for RR-TB without additional fluoroquinolone resistance, but with extensive pulmonary or disseminated disease. This regimen consists of six months of bedaquiline and linezolid (600mg daily), and 18 months of clofazimine, terizidone and levofloxacin.
 - An 18-month long-course treatment regimen for RR-TB with additional fluoroquinolone resistance. This regimen consists of six months of bedaquiline and delamanid, and 18 months of clofazimine, terizidone and linezolid (600mg daily).
- In 2022, the WHO published an update of consolidated guidelines on drug-resistant tuberculosis treatment, in which they recommended the use of a 6-month treatment regimen composed of bedaquiline, pretomanid, linezolid (600mg) and moxifloxacin (BPaLM) rather than 9-month or longer (18-month) regimens in MDR/RR-TB patients. (Conditional, very low certainty of evidence).
- Additional remarks published alongside the above recommendation included:
 - "Results of drug susceptibility testing for fluoroquinolone resistance were recommended to guide the decision on whether moxifloxacin should be retained or dropped from the regimen."
 - "In cases of documented resistance to fluoroquinolones, it was recommended that BPaL without moxifloxacin should be initiated or continued."
 - "This recommendation applies only to the following populations: people with MDR/RR-TB or with MDR/RR-TB and resistance to fluoroquinolones (pre-XDR TB); people with confirmed pulmonary TB and all forms of extrapulmonary TB except for TB involving the CNS, osteoarticular and disseminated (miliary) TB; adults and adolescents aged 14 years and older; all people regardless of HIV status; patients with less than 1-month previous exposure to bedaquiline, linezolid, pretomanid or delamanid. When exposure is greater than 1 month, these patients may still receive these regimens if resistance to the specific medicines with such exposure has been ruled out."
 - "This recommendation does not apply to pregnant and breastfeeding women owing to limited evidence on the safety of pretomanid."
 - "The recommended dose of linezolid is 600mg once daily, both for the BPaLM and the BPaL regimen."
- To efficiently use available resources and to avoid duplication we conducted an adaptation of these guidelines using the GRADE 'adolopment' methodology.
 - The guideline was appraised in duplicate using the AGREE II instrument and found to be of sufficient quality for adolopment with an overall assessment score of 83%.

- The systematic review that underpinned the WHO guideline was appraised in duplicate using the AMSTAR II critical appraisal tool and found to be of "critically low quality" as several aspects of reporting a systematic review were not available or were unclear. Despite the critically low quality we considered the WHO review and underlying evidence synthesis to be the most up to date (i.e., not missing important evidence), relevant (i.e., directly addressing our target PICOs) and GRADE evidence-to-decision aligned evidence available, and sufficient for guideline adaptation.
- We considered the evidence and judgements published in the WHO guideline evidence to decision framework with respect to effectiveness criteria (benefit, harms and balance of effects), economic criteria (resources and cost-effectiveness), and qualitative criteria (values, equity, feasibility and acceptability). Aligned with the purpose of adaptation to consider local context, we collected evidence of resources and economic consequences and data on acceptability from the perspective of patients from a trial specifically conducted in South Africa.
- The BPAL regimen (with linezolid dosed at 600mg daily for 26 weeks) compared to a WHO long course regimen may result in improved treatment success rates in pre-XDR TB RR 1.34, 95% CI 1.20 to 1.40, NNT 4, n = 872, very low certainty evidence) and MDR TB (RR 1.32, 95% CI 1.19 to 1.39, NNT 4, n = 893,very low certainty evidence), and lower levels of treatment failure, recurrence, death and loss to follow up (very low certainty evidence). Additionally, participants from the ZeNix trial receiving the BPaL (n = 43) regimen may have higher levels of treatment success (RR 1.52, 95% CI 1.38 to 1.55, NNT 3, very low certainty evidence) when compared to a cohort receiving the current South African short course regimen (n = 4 216), as well as reduced rates of death and loss to follow up. However, the risk grade 3 5 adverse events associated with BPaL in these comparisons was increased 3 to 4-fold and were judged to be moderate (very low certainty evidence).
- The BPaLM regimen (with linezolid dosed at 600mg daily for 16 weeks, then reduced to 300mg for 8 weeks) compared to local standard of care regimens in a study population with predominantly MDR-TB from the randomised control trial, TB-PRACTECAL, may result in improved treatment success rates (aRR 1.73, 95% CI 1.31 to 2.27, NNT 3, n = 128, very low certainty evidence), lower rates of treatment failure and recurrence (aRR 0.26, 95% CI 0.1 to 0.71, NNT 6, n = 128, very low certainty evidence), lower levels of grade 3 to 5 adverse events (aRR 0.41, 95% CI 0.04 to 0.61, NNT 3, n = 213, very low certainty evidence), and lower levels of loss to follow up (RR 0.16, 95% CI 0.12 to 0.52, NNT 6, n = 128, very low certainty evidence).
- As a result of the associated reduction in pill burden and treatment duration, both BPaL and BPaLM regimens were judged to probably be acceptable, feasible and to increase health equity.
- BPaL and BPaLM are both likely to have lower resource requirements and cost than the current South African long regimens, with similar costs when compared to the current South African short course regimen.

PHC/ADULT HOSPITAL LEVEL EXPERT REVIEW COMMITEE RECOMMENDATION:

	We recommend	We suggest not to	We suggest using	We suggest	We
	against the option	use the option	either the option or	using the	recommend
	and for the	(conditional)	the alternative	option	the option
-	alternative.		(conditional)	(conditional)	(strong)
Type of	(strong)				
recommendation				х	

Recommendation: The PHC/Adult hospital ERC suggests the use of the 6-month treatment regimen composed of bedaquiline, pretomanid, linezolid (600mg) and a fluoroquinolone rather than 9-month or longer (18-month) regimens in MDR/RR-TB patients. (Conditional recommendation, very low certainty of evidence)

Although WHO recommend moxifloxacin for inclusion in their updated regimen (BPaLM), the PHC/Adult hospital level committee suggest that levofloxacin to be used as fluoroquinolone of choice.

Rationale: The recommended regimen is shorter in duration, less complex and may be cost-saving, particularly for those patients requiring treatment with current South African long regimens. Additionally, the recommended regimen was judged to probably be feasible and acceptable and to improve equity. However, the committee noted the very low quality of evidence on which WHO recommendations are based. In view of the paucity of evidence, the committee felt that the implementation of operational research and enhanced pharmacovigilance to detect safety signals is essential.

Level of Evidence: Very low quality evidence

Review indicator: New high quality evidence

NEMLC RECOMMENDATION (30 March 2023):

The committee supports the ERC's adapted recommendation as follows:

We suggest the use of the 6-month treatment regimen composed of bedaquiline, pretomanid, linezolid (600mg) and a fluoroquinolone rather than 9-month or longer (18-month) regimens in MDR/RR-TB patients. (Conditional recommendation, very low certainty of evidence) Levofloxacin to be used instead of moxifloxacin as fluoroquinolone of choice for inclusion in the revised regimen.

Monitoring and evaluation considerations

Operational research and enhanced pharmacovigilance essential.

Research priorities

Shortened regimens for paediatric and pregnant populations

2. Name of author(s)/motivators/Author affiliation and conflict of interest details

Dr. Jessica Taylor^{1,7}, Dr. Natasha Gloeck^{2,3}, Ms. Sumayya Ebrahim^{2,3}, Dr. Funeka Bango², Prof. Norbert Ndjeka⁵, Prof. Gary Maartens^{1,5}, Dr. Michael McCaul^{4,6}, Dr. Jeremy Nel⁶, Prof. Tamara Kredo^{2,4}, Prof Karen Cohen^{1,6}

- 1. Division of Clinical Pharmacology, University of Cape Town
- 2. Health Systems Research Unit, South African Medical Research Council
- 3. Cochrane South Africa, South African Medical Research Council
- 4. Division of Epidemiology and Biostatistics, Department of Global Health, Stellenbosch University.
- 5. National Department of Health TB Programme
- 6. Adult-PHC Evidence Review Committee

3. Introduction/ Background

In 2021, approximately 450 000 people developed rifampicin resistant tuberculosis (RR-TB), and 191 000 deaths due to RR-TB were recorded globally.(2) A further 20% of these RR-TB cases were estimated to have additional fluoroquinolone resistance. In South Africa, at least 21 000 incident cases of RR-TB occurred during the year 2021. (2)

RR-TB is associated with poor treatment outcomes as a result of prolonged (9 - 18 months) treatment regimens that are difficult to adhere to, and consist of less effective and more toxic drugs.(3) Historically,

aminoglycosides in particular, were associated with both treatment limiting nephrotoxicity and ototoxicity, leaving patients who had successfully completed RR-TB treatment with significant morbidity. The introduction of novel and repurposed drugs to achieve injectable-free regimens heralded a new era in RR-TB treatment, with some improvement in treatment outcomes. For example, a 2018 cohort of South African patients with RR-TB and additional fluoroquinolone resistance, recorded 73% of treatment outcomes as favorable when using bedaquiline containing regimens. ((3)

Since 2019, three all-oral treatment regimens have been made available in South Africa for the management of RR-TB in adults with pulmonary tuberculosis (TB)(4):

- 1. The shorter RR-TB regimen (SCR) is available for patients with RR-TB without additional fluoroquinolone resistance and less severe pulmonary disease. This 9-month treatment regimen consists of two months of linezolid, four to six months of high-dose isoniazid, six to nine months of bedaquiline and nine months of levofloxacin, pyrazinamide, ethambutol and clofazimine.
- 2. The longer RR-TB regimen (LCR-1) is available for patients with RR-TB without additional fluoroquinolone resistance but with extensive pulmonary disease. This 18-month treatment regimen consists of six months of bedaquiline and linezolid, and 18 months of clofazimine, terizidone and levofloxacin.
- 3. The fluroquinolone-resistant RR-TB regimen (LCR-2) is available for patients with RR-TB and additional fluoroquinolone resistance. This 18-month treatment regimen consists of six months of bedaquiline and delamanid, and 18 months of clofazimine, terizidone and linezolid.

Despite the national implementation of all-oral treatment regimens, free of the toxicities associated with aminoglycosides, these regimens are not without their own concerns. (5) These regimens remain long and are complicated for both patients to adhere to and healthcare workers to implement and are associated with a significant pill burden. Furthermore, the oral drugs included in these regimens are still associated with the potential for significant toxicity, some of which may be related to treatment duration. (6)

In 2022, the World Health Organization (WHO) recommended the use of a six month treatment regimen composed of bedaquiline, pretomanid, linezolid (600mg) and moxifloxacin (BPaLM), rather than the nine month or longer regimens, for the treatment of pulmonary TB and all forms of extrapulmonary TB, except for TB involving the central nervous system, osteoarticular TB, and disseminated (miliary) TB.(7) Desirable characteristics of this regimen include the use of fewer drugs with a reduced pill burden and a shorter treatment duration.(8) To efficiently use available resources and to avoid duplication we conducted an adaptation of these guidelines using the GRADE 'adolopment' methodology. (7,9)

3. Purpose/Objective and PICO prioritization

To determine if, in adults diagnosed with RR-TB, a 6-month treatment regimen composed of bedaquiline, pretomanid, linezolid (600mg) and a fluoroquinolone is non-inferior to and/or safer than current standard-ofcare regimens (9-month or 18-months). Table 1 DICO ali mibilitre anitania

able 1. PICO eligibil	ny crneria:
Population	Adults with RR-TB
Intervention	1. BPaL (bedaquiline, pretomanid, linezolid)
	2. BPaLM (bedaquiline, pretomanid, linezolid, moxifloxacin)
Comparator	1. South African RR-TB short course regimen (SCR)
	2. South African RR-TB long course regimen (LCR-1)
	3. South African RR-TB with additional fluoroquinolone resistance long course regimen (LCR-2)
Outcome	1. Efficacy
	1.1 Mortality
	1.2 Treatment failure
	1.3 Treatment success
	1.4 Loss to follow-up
	1.5 Time to sputum culture conversion
	2. Safety
	2.1 Adverse events
	2.2 Treatment interruption/substitution due to adverse events

Three specific PICO questions were prioritized by the review team:

- a) Is BPaL (intervention 1) non-inferior to, and/or safer than the South African standard of care (comparator 3) in the treatment of adults with or without fluoroquinolone-resistant tuberculosis?
- b) Is BPaLM (intervention 2) non-inferior to, and/or safer than the South African standard of care (comparator 1 and 2) in the treatment of adults with rifampicin-resistant tuberculosis without additional fluoroquinolone resistance?
- c) Is BPaL (intervention 1) non-inferior to, and/or safer than BPaLM (intervention 2) in the treatment of rifampicin-resistant tuberculosis without additional fluoroquinolone resistance?

4. Methods:

We conducted a guideline adaptation process using the GRADE adolopment methodology (9) which aims to use existing high-quality, timely and relevant clinical practice guidelines (CPGs) and evidence synthesis (i.e., systematic reviews) to answer prioritised guideline questions. We drew on supporting resources in evidence synthesis and rapid guideline development to further guide methods and processes.(10-12) The adolopment approach to guideline production combines guideline adoption, adaptation, and, as needed, *de novo* development of recommendations, by assessing the underlying relevance, timeliness and directness of synthesised evidence from a source guideline and translating this to the GRADE Evidence-to-Decision (EtD) table. In summary, steps include i) selection of the guideline topic, ii) PICO prioritisation and outcome ranking, iii) identification of appropriate source guidelines, iv) matching source guidelines and recommendations, v) assessment of the underlying evidence according to the EtD criteria and vi) populating the EtD framework and developing a recommendation.

The matched source guideline was appraised using the AGREE II Tool (13) with guideline appraisal by two authors independently for credibility. The underlying evidence synthesis was appraised using the AMSTAR II (14) tool for systematic reviews. We reviewed and extracted the underlying evidence per PICO for the effectiveness EtD criteria (benefit, harms and balance of effects), economic criteria (resources and cost-effectiveness) and qualitative criteria (values, equity, feasibility and acceptability) from the WHO guideline and assessed this for sufficiency. We aimed to supplement this with local contextual evidence (e.g. resources, acceptability, equity).

a. Identification of appropriate sources guideline

The <u>WHO consolidated guidelines on tuberculosis</u>: <u>Drug-resistant tuberculosis treatment</u> 2022 was identified as the most appropriate source guideline for adolopment.

b. Matching source guideline recommendations to each prioritized PICO and determining if a direct matching recommendation exists.

The specific PICO questions prioritized by the review team were matched to recommendations and sub-PICOs with corresponding evidence-to-decision frameworks (EtDs) from the WHO consolidated guidelines on tuberculosis: Drug-resistant tuberculosis treatment. All matched recommendations and sub-PICOs from the WHO consolidated guidelines were considered sufficiently direct. Table 2 outlines the matching process and directness of each matching recommendation and sub-PICO. Directness refers to the concept that the recommendations are appropriate to the context of the health care setting of interest by addressing population, intervention and prioritised outcomes of interest.

WHO sub-PICO questions 7.1, 7.2, 8.2, 8.3 and 8.5 were not linked to EtDs within the published guideline. These EtDs were requested from the guideline but unfortunately were not available, although additional data analysis was provided. Additional data analysis from original study authors was also requested.

Table 2.

Review target PICO questions	Matching WHO consolidated guideline recommendation	WHO Sub- PICO Number	WHO Target PICO or Sub-PICO	WHO Sub-PICO Recommendation	Directness
		5.2	Should BPaL vs. WHO_long be used for pulmonary MDR/RR-TB? BPAL compared to WHO_Long in pulmonary MDR/RR TB	Conditional for the intervention. The use of the 6-month treatment regimen, composed of bedaquiline, pretomanid and linezolid (BPaL), rather than longer (18-month) regimens is suggested in patients with MDR/ RR-TB and without resistance to fluoroquinolones, who have either had no previous exposure to bedaquiline and linezolid or have been exposed for less than 1 month.	Considered sufficiently direct by review team. Although intervention is BPaL not BPaLM, comparator and population is appropriate.
Is BPaLM (intervention 2)	WHO suggests the use of the 6-month	5.3	Should BPaL vs. SA_new be used for pulmonary MDR/RR-TB? BPAL compared to SA_new in MDR/RR TB	Conditional for the intervention. The use of the 6-month treatment regimen, composed of bedaquiline, pretomanid and linezolid (BPaL), rather than the 9-month regimen (with linezolid) is suggested in patients with MDR/RR-TB without resistance to fluoroquinolones, who have either had no previous exposure to bedaquiline and linezolid or have been exposed for less than 1 month.	Considered sufficiently direct by review team. Although intervention is BPaL and not BPaLM, comparator and population is appropriate.
non-inferior to, and/or safer than the South African standard of care (comparator 1 and 2) in the treatment of adults with	treatment regimen composed of bedaquiline, pretomanid, linezolid (600mg) and moxifloxacin (BPaLM) rather than 9-monht or longer (18-month)	6.1	Should BPaLM vs local SoC (TB-PRACTECAL comparator) be used for pulmonary MDR/RR-TB or pre-XDR-TB? BPaLM compared to TB-PRACTECAL comparator in pulmonary MDR/RRTB and pre-XDR TB	Conditional for the intervention. The use of the 6-month treatment regimen, composed of bedaquiline, pretomanid and linezolid (BPaL), rather than 9-month or longer (18-month) regimens is suggested in patients MDR/RR-TB patients with or without resistance to fluoroquinolones, who have either had no previous exposure to bedaquiline and linezolid or have been exposed for less than 1 month.	Considered sufficiently direct. Appropriate intervention and comparator consists of regimens that are South African standard of care. However, population includes both MDR/RR-TB and pre-XDR-TB.
rifampicin- resistant tuberculosis without additional fluoroquinolone resistance?	regimens in MDR/RR- TB patients. (Conditional recommendation, very low certainty of evidence)	6.6	"Should BPaL (linezolid 600mg/300mg) vs. local SoC regimens (TB-PRACTECAL comparator) be used for pulmonary MDR/RR-TB and pre-XDR-TB? BPaL (linezolid 600mg/300mg) compared to TB PACTECAL comparator in pulmonary MDR/RR-TB and pre-XDR-TB	Conditional for the intervention. The use of the 6-month treatment regimen, composed of bedaquiline, pretomanid and linezolid (BPaL), rather than 9-month or longer (18- month) regimens is suggested in patients MDR/RR-TB patients with or without resistance to fluoroquinolones, who have either had no previous exposure to bedaquiline and linezolid or have been exposed for less than 1 month.	Considered sufficiently direct. Although intervention considered is BPaL not BPaLM, the comparator includes regimens that are South African standard of care. However, population includes both MDR/RR-TB and pre-XDR-TB.
		8.2	Should 6-month regimen using bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM) be used in patients with pulmonary MDR/RR-TB and without fluoroquinolone resistance? TB PRACTECAL BPaLM vs WHO long-IPD 2021 in pulmonary MDR/RR TB	Not found	Considered sufficiently direct.
		8.3	Should 6-month regimen using bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM) be used in patients with pulmonary MDR/RR-TB and without fluoroquinolone resistance? TB PRACTECAL BPALM vs SA_new in pulmonary MDR/RR-TB	Not found	Considered sufficiently direct.
Is BPaL (intervention 1) non-inferior to,	WHO suggests the use of the 6-month treatment regimen	4.1	Should a 6-month regimen using bedaquiline, pretomanid, linezolid vs. longer regimens be used for pulmonary pre-XDR- TB?	Conditional for the intervention. The use of the 6-month treatment regimen, composed of bedaquiline, pretomanid and linezolid (BPaL), rather than longer	Considered sufficiently direct.

and/or safer than the South African standard of care (comparator 3) in the treatment of adults with	composed of bedaquiline, pretomanid, linezolid (600mg) and moxifloxacin (BPaLM) rather than		BPAL compared to WHO_Long in pulmonary pre-XDR TB	(18-month) regimen is suggested in patients with MDR/RR-TB and resistance to fluoroquinolones (pre- XDR-TB), who have either had no previous exposure to bedaquiline and linezolid or have been exposed for less than 1 month.	
fluoroquinolone- resistant tuberculosis?	9-monht or longer (18-month) regimens in MDR/RR-TB patients. (Conditional recommendation, very low certainty of evidence)	7.1	Should a 6-month regimen using bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM) be used in patients with pulmonary pre-XDR-TB? TB PRACTECAL BPaLM vs WHO long-IPD 2021	Not found	Considered sufficiently direct by the review team. Although the intervention is BPaLM not BPaL, the comparators consists of regimens that are South African standard of care.
Is BPaL (intervention 1)	WHO suggests the use of the 6-month treatment regimen composed of	6.2	Should BPaLM vs BPaL (LD 600mg/300mg) be used for pulmonary MDR/RR-TB and pre-XDR-TB? BPaLM compared to BPAL (linezolid 600/300mg)	Conditional for the intervention. The use of the 6-month treatment regimen, composed of bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM), rather than BPaL is suggested in MDR/RR-TB patients with or without resistance to fluoroquinolones, who have either had no previous exposure to bedaquiline and linezolid or have been exposed for less than 1 month.	Considered sufficiently direct by the review team, despite population including those with MDR/RR-TB and pre-XDR-TB.
(intervention 1) non-inferior to, and/or safer than BPaLM (intervention 2) in the treatment of rifampicin- resistant tuberculosis	bedaquiline, pretomanid, linezolid (600mg) and moxifloxacin (BPaLM) rather than 9-monht or longer (18-month) regimens in	7.2	Should 6-month regimen using bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM) be used in patients with pulmonary pre-XDR-TB? TB PRACTECAL BPaLM vs BPaL (excluding 1200mg regimen) from PRACTECAL, ZENIX studies (4 cohorts) in pulmonary pre-XDR TB	Not found	Considered sufficiently direct by the review team despite the population consisting of those with pre-XDR-TB.
without additional fluoroquinolone resistance?	MDR/RR-TB patients. (Conditional recommendation, very low certainty of evidence)	8.5	Should 6-month regimen using bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM) be used in patients with pulmonary MDR/RR-TB and without fluoroquinolone resistance? TB PRACTECAL BPaLM vs BPaL (excluding 1200mg regimen) from PRACTECAL, ZENIX and NIX Studies (6 cohorts) in pulmonary MDR/RR-TB.	Not found	Considered sufficiently direct

c. Assess underlying evidence per recommendation.

i. Availability of an effectiveness systematic review underlying the recommendations

The evidence underpinning the recommendations in the WHO guideline was based on evidence synthesis of the datasets from the TB-PRACTECAL trial, the NIX trial, the ZENIX trial, the South African TB Program 2019 cohort, the South African TB Program 2017 cohort and 2021 WHO individual patient data (multiple cohorts following a public call for data from the WHO).(15-17) The evidence-to-decision (EtD) frameworks based on this data were available in the guideline. Those not available were sourced from the background review authors as highlighted previously.

ii. Evidence quality:

Guideline AGREE-II appraisal.

The 2022 'WHO consolidated guidelines on tuberculosis: Drug-resistant tuberculosis treatment' was appraised by JT and NG using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument.(13) We found the guideline to be of sufficient quality, with an overall assessment score of 83% (recommended with modifications). Individual overall domain scores can be reviewed in table 2. The individual scores and judgement comments of both appraisers can be found in appendix 1.

Table 2. AGREE-II Appraisal

Guideline	Domain	Domain	Domain	Domain	Domain	Domain	Overall
	1	2	3	4	5	6	Assessment
WHO consolidated guidelines on tuberculosis: Drug-resistant tuberculosis treatment, 2022	86%	78%	63%	89%	65%	67%	83%

Domain 1: Scope and purpose Domain 2: Stakeholder involvement Domain 3: Rigor of development Domain 4: Clarity of presentation Domain 5: Applicability Domain 6: Editorial independence OA: overall assessment

Guideline AMSTAR II appraisal

The systematic review that underpinned the WHO guideline was appraised by SE and NG using the AMSTAR II critical appraisal tool.(14) Both reviewers rated this review as "**Critically low quality**" – there was no or minimal information around search strategy, study selection, data extraction, excluded studies with reasons, methods for assessing risk of bias in individual studies, sources of included study funding and meta-analysis methods. The individual AMSTAR II appraisal for both appraisers can be found in appendix 2.

Despite the critically low quality of the underpinning systematic review, the authors considered the WHO review and underlying evidence synthesis to be the most up to date (i.e. not missing important evidence), relevant (i.e. directly addressing our target PICOs) and GRADE EtD aligned evidence available, and sufficient for guideline adaptation.

iii. Qualitative evidence and sufficiency

A summary of the available qualitative evidence was presented at the ERC meeting (16 March 2023) by Beverly Stringer and team from TB-PRACTECAL-PRO, a qualitative sub study of TB-PRACTECAL that captured patient-reported experiences and quality of life outcomes. The results of this study were used to update the evidence presented by WHO and presented to the ERC.

iv. Economic evidence and sufficiency

Two studies were found to have assessed the cost effectiveness of the BPaL regimen as the intervention. Both these studies were assessed and included in the decision framework by the WHO. The studies were multinational analyses which included patients from South Africa in their study populations. The study population in the paper by Gomez et al. 2021 was patients with XDR-TB, MDR-TB failure and treatment-intolerant patients and compared BPaL to the 18-month XDR regimen.(18) Treatment outcomes for study were from the Nix and ZeNix trials. The second study which was also trial based (TB-PRACTECAL) by Sweeney et al. 2022 assessed the cost effectiveness of BPaL with or without moxifloxacin (BPaLM) or clofazimine (BPaLC).(19) Although this study focused on patients with RR-TB, the regimen used as a comparison was a mix of the long and short regimens. A summary of the economic evidence is included in table 3.We did not find a study that focused on patients with RR-TB which assessed the cost effectiveness of the BPaL regimen compared to the short oral regimen, which is one of the current standard of care regimens in South Africa.

A normative cost analysis of direct costs associated with BPaL and BPaLM regimens was conducted by the review team and included for consideration by the ERC.

Table 3. Summary of Economic Evidence

Study ID	Study Title	Participants	EE Methods	Study Perspective	Intervention	Comparison	Model	Input parameters	Outcome measure	Results	Unit costs for BPaL (M/C)	Cost for standard of care regimen (short oral regimen)
Gomez, et al. 2021.	Cost- effectivenes s of bedaquiline, pretomanid and linezolid for treatment of extensively drug- resistant tuberculosis in South Africa, Georgia and the Philippines	Patients with XDR- TB, MDR-TB failure and treatment intolerant patients.	Cost- utility analysis	Provider's perspectiv e	BPaL	Std of care (SA: 18 month regimen: 6 months of linezolid, bedaquiline, delamanid, clofazimine, terizidone, pyrazinamide, high-dose isoniazid (or ethionamide) and 12 months of linezolid, clofazimine, terizidone, pyrazinamide, high-dose isoniazid (or ethionamide)	Markov model	Demographics Treatment outcomes (Nix and ZeNix trials) Costs (drugs, visits, tests) Disability weights	1. DALYs averted 2. The potential maximum price at which the BPaL regimen could become cost neutral.	Study showed that BPaL for the treatment of XDR- TB compared to the 18 month regimen has the potential to be cost saving.	Presente d per month in 2018 US\$: \$296,4 (drugs) \$65,3 (delivery)	
Sweene y et al. 2022.	Cost- effectivenes s of short, oral treatment regimens for rifampicin resistant tuberculosis	Patients with RR-TB, also potentially including resistance to isoniazid and/or fluoroquino lones	Cost- utility analysis	Provider's perspectiv e	BPaL with and without moxifloxaci n (BPaLM) or clofazimine (BPaLC)	Current mix of long and short standard of care (SOC) regimens to treat RR-TB	Markov model	Demographics Treatment outcomes (TB-PRACTECAL trial) Costs (drugs, visits, tests) Disability weights	DALYs averted	The cost savings associated with a move from the current SOC mix to BPaL for all MDR/RR-TB patients range was \$1,173 per person in South Africa	Costs presente d in 2019 US\$ Total costs per person for South Africa: BPaL: \$3,344, BPaLM: \$3,520, and BPaLC: \$3,470	Current SOC regimen mix (74% short, 26% long): \$4,517

d. Evidence to Decision Framework

We populated one consolidated EtD framework per prioritised PICO as below. Overlapping evidence per EtD criteria from the WHO sub-PICOs were merged as necessary per target prioritised PICO.

We incorporated additional data analysis relevant to WHO sub-PICO 7.1 and 7.2, that was made available in the absence of individual EtDs in the guideline document. This data is listed as additional considerations in the EtDs labelled "b" and "c" respectively.

Subgroup analyses obtained from the authors of TB-PRACTECAL were included under additional considerations in the Etd labelled "b" due to the lack of a populated EtD for WHO sub-PICO 8.3, which was deemed to be of critical importance by the review team.

For each EtD criteria/domain the original WHO EtD evidence, judgement and if applicable additional considerations are presented alongside the PHC/Adult hospital level committee's judgements, local or updated evidence and additional considerations.

A summary of judgements per prioritised PICO is presented below:

a) Is BPaL (intervention 1) non-inferior to, and/or safer than the South African standard of care (comparator 3) in the treatment of adults with or without fluoroquinolone-resistant tuberculosis?

Should a 6-month regimen using bedaquiline, pretomanid, linezolid (600mg/300mg) vs. current South African standard-of-care regimes be used for pulmonary MDR/RR or pre-XDR TB? (Combined WHO sub-PICOs 4.1, 5.2, 5.3 and 6.6)

Problem: Is the proble	em a priority?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
• WHO Guideline pa	mel	
 No Probably no Probably yes X Yes Varies Don't know 	Research evidence The COVID-19 pandemic has reversed years of progress in providing essential TB services and reducing TB disease burden. The most obvious impact is a large global drop in the number of people newly diagnosed with TB and reported. This fell from 7.1 million in 2019 to 5.8 million in 2020, an 18% decline back to the level of 2012 and far short of the approximately 10 million people who developed TB in 2020. Reduced access to TB diagnosis and treatment has resulted in an increase in TB deaths. Best estimates for 2020 are 1.3 million TB deaths among HIV-negative people (up from 1.2 million in 2019) and an additional 214 000 among HIV-positive people (up from 209 000 in 2019), with the combined total back to the level of 2017. Other impacts include reductions between 2019 and 2020 in the number of people provided with treatment for drug-resistant TB (-15%, from 177 100 to 150 359, about 1 in 3 of those in need).	Drug-resistant TB is a global challenge and access to treatment often problematic, with regimens typically being long, toxic, and expensive. More efficacious and shorter treatment regimens for DR-TB are necessary to optimize and improve treatment outcomes while minimizing adverse events and preventing acquisition of additional drug resistance.

	Globally in 2020, 71% (2.1/3.0 million) of people diagnosed with bacteriologically confirmed pulmonary TB were tested for rifampicin resistance, up from 61% (2.2/3.6 million) in 2019 and 50% (1.7/3.4 million) in 2018. Among these, 132 222 cases of MDR/RR-TB and 25 681 cases of pre-XDR-TB or XDR-TB were detected, for a combined total of 157 903. This was a large fall (of 22%) from the total of 201 997 people detected with drug-resistant TB in 2019, consistent with similarly large reductions in the total number of people newly diagnosed with TB (18%) and the total number of people diagnosed with bacteriologically confirmed pulmonary TB (17%) observed between 2019 and 2020. Worldwide, 150 359 people with MDR/RR-TB were enrolled on treatment in 2020, down 15% from the total of 177 100 in 2019. This level of enrolment was equivalent to about one in three of the people who develop MDR/RR-TB each year. More positively, there have been improvements in treatment success rates. Globally in 2018 (the latest patient cohort for which data are available), the treatment success rate for MDR/RR-TB was 59%, reflecting steady improvements in recent years from 50% in 2012. (Global TB Report 2021)	
• PHC/ADULT HOSPIT	AL LEVEL COMMITTEE'S JUDGEMENT	
 No Probably no Probably yes X Yes Varies Don't know 	In addition to the research evidence considered by the WHO GDG, the ERC considered the burden of disease in the locally relevant population. A cross- sectional study of identified tuberculosis cases, conducted in South Africa between 2012 and 2014, reported the prevalence of RR-TB as 4.6%, MDR-TB as 2.8% (95% CI 2.0, 3.6) and the prevalence of XDR-TB as 4.9% (95% CI 1.0, 8.8). (Ismail et al. 2018). More recently for the year 2021, the WHO reported an estimated 21 000 incident cases of RR-TB in South Africa. (WHO Global Tuberculosis Report, 2022) The ERC judged the problem to be a priority.	
Desirable effects: Ho	w substantial are the desirable anticipated effects?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
• WHO Guideline pane	1	
 Trivial Small Moderate X Large Varies Don't know 	BPaL compared to WHO_Long in pulmonary pre-XDR TB (WHO sub- PICO 4.1)Research evidenceThe BPaL 600-26 arm of the ZeNix trial, where linezolid 600 mg daily was used for 26 weeks, and population included patients with MDR/RR-TB with quinolone resistance was compared to a cohort of MDR/RR-TB patients with fluoroquinolone resistance from 2021 IPD, receiving longer regimens for treatment of MDR/RR-TB designed in line with 2020 WHO guidelines.Participants with pulmonary pre-XDR-TB (MDR/RR-TB with fluoroquinolone resistance) receiving BPaL 600-26 (n=33) compared to participants receiving longer regimens for MDR/RR-TB (n=839) experienced higher levels of treatment success (100% vs 75%), i.e. a 34% relative increase (RR=1.34, 95%CI 1.20 to 1.40); lower levels of failure and recurrence (0.0% vs 6.6%), i.e. a 7% absolute reduction (RD=-0.07, 95%CI -0.08 to -0.04); lower levels of deaths (0.0% vs 9.9%), i.e. a 10% absolute reduction (RD=-0.10, 95%CI -0.12 to -0.01); lower levels of follow-up (0.0% vs 9.1%), i.e. a 9% absolute reduction (RD=-0.09, 95%CI -0.11 to -0.01); higher levels of adverse events (15% vs 4.4%), i.e. a 3.4-fold increase (RR=3.44, 95%CI 1.44 to 8.17); and lower levels of amplification of drug-resistance (0.0% vs 7.4%), i.e. a 7% absolute reduction (RD=-0.07, 95%CI -0.09 to -0.03).BPaL 600-26 may improve treatment success, failure and recurrence, death, loss to follow-up and amplification of drug-resistance while leading to more adverse events but the evidence is very uncertain.	Additional Considerations applicable to all sub-PICO's Beyond the outcomes captured directly as research evidence in the presented statistical analyses, the WHO 'Target Regimen Profile for rifampicin-resistant tuberculosis' (WHO, 2016) identified certain regimen characteristics as having desirable anticipated effects. These include a shorter treatment duration, reduced pill burden and number of component drugs and manageable DDIs. Decrease in the treatment duration is therefore an important desirable effect.

Outcomes	Nº of participants	Certainty of the evidence	Relative effect		osolute effects* % CI)	outcomes. Additionally, the pa that with the intervention regi
outcomes	(studies)	(GRADE)	(95% CI)	Risk with	Risk difference	treatment duration is reduced
Treatment success	Follow-up 872	A 000	RR 1.34	WHO_long	with BPaL opulation	months, i.e. $\frac{1}{3}$ to $\frac{1}{2}$ of durate
near nei risuccess	(15 observational	000 Very low ^{abcdef}	(1.20 to	745 per 1000	253 more per	comparator regimen (6-9 mor
	studies)	very low	1.40)	1.15 pc. 2000	1 000	24 months); and that pill burd
					(149 more to	intervention is significantly lo
					298 more)	times (on average from 3'400
	N≢ of	Certainty of the	Relative		bsolute effects*	Considering this research evid
Outcomes	participants	evidence.	effect	second process of the local distance of the	% CI)	the additional considerations,
	(studies) Follow-up	(GRADE)	(95% CI)	Risk with WHO long	Risk difference with BPaL	judged that BPaL with Linezol
Failure and	872	⊕000	RD -0.07		opulation	may have large desirable effect
recurrence	(15 observational	Very lowabilist	(-0.08 to	66 per 1000	70 fewer per	noted the very low certainty o
	studies)	 Rendentative 	-0.04)	NAMES IN TAXABLE	1 000	evidence.
					(71 fewer to 68	
Death	987	0000	RD -0.10	Study or	fewer) opulation	
Mader .	(15 observational		(-0.12 to	99 per 1000	109 fewer per	Additional considerations a
	studies)		-0.01)	000000000000	1 000	to sub-PICO 5.2 only
					(111 fewer to	m
Torrest data and		0000	00.000		100 fewer)	Treatment duration reduced h
Lost to follow up	872 (15 observational	000 Very low ^{atocat}	RD -0.09 (-0.11 to	91 per 1000	99 fewer per	months, i.e. to 1/3 to ½ of dur comparator regimen (6-9 mor
	studies)	very low-	-0.01)	at be. 1000	1 000	24 months).
			10.55		(101 fewer to 91	Pill burden: significant decrea
					fewer)	times (on average from 3'400
Amplification of drug		0000	RD -0.07	and the second s	opulation	times (on average nom 5 400
resistance	(15 observational studies)	Very low ^{atuated}	(-0.09 to -0.031	74 per 1000	79 fewer per	Considering this research evid
	sourcey		-0.051		1 000 (81 fewer to 76	the additional considerations,
					fewer)	panel judged that BPaL 600-
						may have large desirable effect
						noted the very low certainty of
BPaL compared	to WHU Long					noted the very low certainty of evidence.
Docoarab ardda	-	; III pullional y	MDR/RF	R TB (WHO s	ub-PICO 5.2)	
Research evider	-	, ili pullionary	MDR/RF	R TB (WHO s	ub-PICO 5.2)	evidence.
	nce			•	-	evidence. Additional considerations a
The BPaL 600-26	n ce arm of the ZeNi	ix trial, where li	nezolid 6(0 mg daily w	as used for 26 w	, and population included patients with MDR/RR-TB with or
The BPaL 600-26 without quinolon	nce arm of the ZeNi e resistance was	lix trial, where li s compared to co	nezolid 6(hort of MI	00 mg daily w DR/RR-TB pat	as used for 26 w	evidence. Additional considerations a
The BPaL 600-26 without quinolon	nce arm of the ZeNi e resistance was	lix trial, where li s compared to co	nezolid 6(hort of MI	00 mg daily w DR/RR-TB pat	as used for 26 w	evidence. Additional considerations a to sub-PICO 5.3 only
The BPaL 600-26 without quinolon for MDR/RR-TB c	nce arm of the ZeNi e resistance was constructed in lin	lix trial, where li s compared to co ne with 2020 W	nezolid 60 bhort of MI HO guideli	00 mg daily w DR/RR-TB pat nes.	ras used for 26 w tients (without q	evidence. Additional considerations a to sub-PICO 5.3 only Treatment duration reduced I
The BPaL 600-26 without quinolon for MDR/RR-TB c Participants with (without quinolo	nce arm of the ZeNi e resistance was constructed in lin MDR/RR-TB (w ne resistance) re	ix trial, where li s compared to co ne with 2020 W vith or without q receiving WHO r	nezolid 60 hort of MI HO guideli juinolone : ecommen	00 mg daily w DR/RR-TB pat nes. resistance) re ded longer re	ras used for 26 w tients (without q eceiving BPaL 60 gimens (n=850)	evidence. Additional considerations a to sub-PICO 5.3 only Treatment duration reduced l months (6-9 months vs 9 – 12
The BPaL 600-26 without quinolon for MDR/RR-TB c Participants with (without quinolo	nce arm of the ZeNi e resistance was constructed in lin MDR/RR-TB (w ne resistance) re	ix trial, where li s compared to co ne with 2020 W vith or without q receiving WHO r	nezolid 60 hort of MI HO guideli juinolone : ecommen	00 mg daily w DR/RR-TB pat nes. resistance) re ded longer re	ras used for 26 w tients (without q eceiving BPaL 60 gimens (n=850)	evidence. Additional considerations a to sub-PICO 5.3 only Treatment duration reduced I months (6-9 months vs 9 – 12 considering this research evid considerations a to sub-PICO 5.3 only Treatment duration reduced I months (6-9 months vs 9 – 12 Considering this research evid
The BPaL 600-26 without quinolon for MDR/RR-TB c Participants with (without quinolo i.e. a 32% relativ	nce arm of the ZeNi e resistance was constructed in lin MDR/RR-TB (w ne resistance) re e increase (RR=	ix trial, where li s compared to co ne with 2020 W vith or without o receiving WHO r =1.32, 95%CI 1.	nezolid 60 hort of MI HO guideli juinolone t ecommen 19 to 1.39	00 mg daily w DR/RR-TB pat nes. resistance) re ded longer re); lower level	ras used for 26 w tients (without q eceiving BPaL 60 gimens (n=850) ls of failure and	evidence. Additional considerations a to sub-PICO 5.3 only Treatment duration reduced I months (6-9 months vs 9 – 12 months (6-9 months vs 9 – 12 considering this research evid the additional considerations a to sub-PICO 5.3 only Treatment duration reduced I months (6-9 months vs 9 – 12 Considering this research evid the additional considerations,
The BPaL 600-26 without quinolon for MDR/RR-TB c Participants with (without quinolo i.e. a 32% relativ 95%CI 0.12 to 3.8	nce e arm of the ZeNi e resistance was constructed in lin MDR/RR-TB (w ne resistance) re e increase (RR= B); lower levels o	lix trial, where li s compared to co ne with 2020 W vith or without q receiving WHO r =1.32, 95%CI 1. of death (0% vs 1	nezolid 60 hort of MI HO guideli juinolone ecommen 19 to 1.39 11%), i.e. 1	00 mg daily w DR/RR-TB pat nes. resistance) re ded longer re); lower level 1% absolute	ras used for 26 w tients (without q eceiving BPaL 60 gimens (n=850) ls of failure and reduction (RD=	evidence. Additional considerations a to sub-PICO 5.3 only Treatment duration reduced I months (6-9 months vs 9 – 12 months (6-9 months vs 9 – 12 considering this research evid the additional considerations a to sub-PICO 5.3 only Treatment duration reduced I months (6-9 months vs 9 – 12 Considering this research evid the additional considerations, panel judged that the BPaL 60
The BPaL 600-26 without quinolon for MDR/RR-TB c Participants with (without quinolo i.e. a 32% relativ 95%CI 0.12 to 3.8 vs 12%), i.e. 12% increase (aRR=3.	nce arm of the ZeNi e resistance was constructed in lin MDR/RR-TB (w ne resistance) re e increase (RR= B); lower levels o b absolute reduc 99, 95%CI 1.67 t	lix trial, where li s compared to co ne with 2020 W vith or without of receiving WHO r =1.32, 95%CI 1. of death (0% vs 1 ction (RD= -0.1; to 9.57); and low	nezolid 60 bhort of MI HO guideli ecommen 19 to 1.39 L1%), i.e. 1 2, 95%CI ver levels	00 mg daily w DR/RR-TB pat nes. resistance) re ded longer re); lower level 1% absolute 0.14 to -0.04 of amplified r	ras used for 26 w tients (without q eceiving BPaL 60 gimens (n=850) ls of failure and reduction (RD=); higher levels o esistance (0% vs	evidence. Additional considerations a to sub-PICO 5.3 only Treatment duration reduced I months (6-9 months vs 9 – 12 considering this research evid the additional considerations a to sub-PICO 5.3 only Treatment duration reduced I months (6-9 months vs 9 – 12 Considering this research evid the additional considerations, panel judged that the BPaL 60 regimen may have large desir
The BPaL 600-26 without quinolon for MDR/RR-TB c Participants with (without quinolo i.e. a 32% relativ 95%CI 0.12 to 3.8 vs 12%), i.e. 12% increase (aRR=3.	nce arm of the ZeNi e resistance was constructed in lin MDR/RR-TB (w ne resistance) re e increase (RR= B); lower levels o b absolute reduc 99, 95%CI 1.67 t	lix trial, where li s compared to co ne with 2020 W vith or without of receiving WHO r =1.32, 95%CI 1. of death (0% vs 1 ction (RD= -0.1; to 9.57); and low	nezolid 60 bhort of MI HO guideli ecommen 19 to 1.39 L1%), i.e. 1 2, 95%CI ver levels	00 mg daily w DR/RR-TB pat nes. resistance) re ded longer re); lower level 1% absolute 0.14 to -0.04 of amplified r	ras used for 26 w tients (without q eceiving BPaL 60 gimens (n=850) ls of failure and reduction (RD=); higher levels o esistance (0% vs	 evidence. evidence. Additional considerations at to sub-PICO 5.3 only Treatment duration reduced I months (6-9 months vs 9 - 12 prence (2% vs 3%), i.e. a 29% relative reduction (RR=0.71, 95%CI -0.12 to -0.030; lower levels of loss to follow-up (0%, i.e. 2% absolute decrease (RD= - 0.02, 95%CI -0.04 to 0.06).
without quinolon for MDR/RR-TB c Participants with (without quinolo i.e. a 32% relativ 95%CI 0.12 to 3.8 vs 12%), i.e. 12%	nce arm of the ZeNi e resistance was constructed in lin MDR/RR-TB (w ne resistance) re e increase (RR= B); lower levels o b absolute reduc 99, 95%CI 1.67 t	lix trial, where li s compared to co ne with 2020 W vith or without of receiving WHO r =1.32, 95%CI 1. of death (0% vs 1 ction (RD= -0.1; to 9.57); and low	nezolid 60 bhort of MI HO guideli ecommen 19 to 1.39 L1%), i.e. 1 2, 95%CI ver levels	00 mg daily w DR/RR-TB pat nes. resistance) re ded longer re); lower level 1% absolute 0.14 to -0.04 of amplified r	ras used for 26 w tients (without q eceiving BPaL 60 gimens (n=850) ls of failure and reduction (RD=); higher levels o esistance (0% vs	Additional considerations at to sub-PICO 5.3 only regimen (n=43) compared to participants with MDR/RR-TB erienced higher levels of treatment success (100% vs 74%), rence (2% vs 3%), i.e. a 29% relative reduction (RR=0.71, ,95%CI -0.12 to -0.030; lower levels of loss to follow-up (0% the 3 to 5 adverse events (14% vs 5%), i.e. a 4 fold relative
The BPaL 600-26 without quinolon for MDR/RR-TB c Participants with (without quinolo i.e. a 32% relativ 95%CI 0.12 to 3.8 vs 12%), i.e. 12% increase (aRR=3.	nce arm of the ZeNi e resistance was constructed in lin MDR/RR-TB (w ne resistance) re e increase (RR= B); lower levels o b absolute reduc 99, 95%CI 1.67 t	lix trial, where li s compared to co ne with 2020 W vith or without of receiving WHO r =1.32, 95%CI 1. of death (0% vs 1 ction (RD= -0.1; to 9.57); and low	nezolid 60 bhort of MI HO guideli ecommen 19 to 1.39 L1%), i.e. 1 2, 95%CI ver levels	00 mg daily w DR/RR-TB pat nes. resistance) re ded longer re); lower level 1% absolute 0.14 to -0.04 of amplified r	ras used for 26 w tients (without q eceiving BPaL 60 gimens (n=850) ls of failure and reduction (RD=); higher levels o esistance (0% vs	evidence. Additional considerations at to sub-PICO 5.3 only regimen (n=43) compared to participants with MDR/RR-TB ereinenced higher levels of treatment success (100% vs 74%), rence (2% vs 3%), i.e. a 29% relative reduction (RR=0.71, ,95%CI -0.12 to -0.030; lower levels of loss to follow-up (0% dde 3 to 5 adverse events (14% vs 5%), i.e. a 4 fold relative , i.e. 2% absolute decrease (RD= - 0.02, 95%CI -0.04 to 0.06).
The BPaL 600-26 without quinolon for MDR/RR-TB c Participants with (without quinolo i.e. a 32% relativ 95%CI 0.12 to 3.8 vs 12%), i.e. 12% increase (aRR=3.	nce arm of the ZeNi e resistance was constructed in lin MDR/RR-TB (w ne resistance) re e increase (RR= B); lower levels o b absolute reduc 99, 95%CI 1.67 t	lix trial, where li s compared to co ne with 2020 W vith or without of receiving WHO r =1.32, 95%CI 1. of death (0% vs 1 ction (RD= -0.1; to 9.57); and low	nezolid 60 bhort of MI HO guideli ecommen 19 to 1.39 L1%), i.e. 1 2, 95%CI ver levels	00 mg daily w DR/RR-TB pat nes. resistance) re ded longer re); lower level 1% absolute 0.14 to -0.04 of amplified r	ras used for 26 w tients (without q eceiving BPaL 60 gimens (n=850) ls of failure and reduction (RD=); higher levels o esistance (0% vs	evidence. Additional considerations a to sub-PICO 5.3 only Treatment duration reduced I months (6-9 months vs 9 – 12 Considering this research evid the additional considerations a to sub-PICO 5.3 only Treatment duration reduced I months (6-9 months vs 9 – 12 Considering this research evid the additional considerations, panel judged that the BPaL 60 regimen may have large desir and noted the very low certain

	N? of participan	Certainty of	Belative	affects* (3									The penal place and should be de-
lutcomes	(studies) Follow-up	Une exidence	effect (95% Q)	Risk with WHO, long	Hok difference with BPaL								The panel also considered the dur and pill burden with the intervent
wadmanji sacona	u BV) (15 obterwition studiet)	HTY IDwardshi	#R 1.32 (1.1910 1.3%	Study pop 739 per 1000 - 2	1000 x14000								and comparator regimens. The du of the intervention regimen is 24 v (5.5 months) so treatment duration
ailum and Incuminien	893 D3 observation atudie()	OCC Very low ^{densel}	KR 0.71 (0.12 to 3.80)		200 mores subation 10 fermini per 1 000 (2% fermini to 92 mores)								reduced compared to the control a between 3–18 months. The exact magnitude of reduction in time on treatment depends on the specific
utcomes	NF of participants (studies)	Certainty of Relatis the evidence effect	e effects	ted absolute * (95% CI) Fisk									comparator regimen, which includ shorter (9–12 months) and longer
25	ESS (15 observational	(GRADE) (95% C +	Study p	difference with BPaL opulation 110 fewer per 1 000									24 months) regimens. The pill bur the intervention regimen is lower that for the comparator regimens.
it to follow up	mideg 893 (15 cosernational studeg)	⊕○○○ KD -0.1 Arry low ^{etcary} (-0.14 tr -0.04)	Study p 118 per 1 000	(1.30 fewer to 30 fewer) opulation									exact magnitude of reduction in pi burden depends on the specific comparator regimen.
nplification of ug resistance	#93 (15	€000 RD -0.0 Any low ^{ettala} (-0.04 st		40 tower) opulation 20 fewer per 1 000									
3PaL con	mpared t	o SA_new i	n MDR/	(43 fever to 60 mont)	WHO sub-	-PICO 5.3)	1						
<i>BPaL com</i> Research 'he BPal 6 vithout qu	<i>mpared t</i> a evidence 600-26 au uinolone	<i>o SA_new i</i> se rm of the Ze resistance w	Nix trial	/ //RR TB (, where li	inezolid 60	0 mg daily	was used for 26 w patients (without qu				,		
BPaL com Research The BPal 6 vithout qu vith linezo	mpared to a evidence 600-26 au uinolone to colid for ty	o <i>SA_new i</i> re rm of the Ze resistance w wo months.	Nix trial as comp	/ <i>RR TB (</i> , where li ared to co	inezolid 60 ohort of MD	0 mg daily)R/RR-TB j	was used for 26 w patients (without qu	uinolone resista	ance) treated	d in Ŝouth Af	frica with 9-mc	onth regimen	
BPaL com Research he BPal 6 vithout qu vith linezo articipan 1DR/RR-1 s s 66%) i. 01, 95% p (0% vs hcrease (a	mpared t a evidence 600-26 au uinolone i colid for tu nts with 1 TB (with ce. 52% r. oCI -0.02 t s 15%), i. caRR=2.92	o SA_new i re re of the Ze resistance w vo months. MDR/RR-TB but quinolor elative incre o 0.07); low e. 15% abso 2, 95%CI 1.3	Nix trial as comp (with c er resista ase (RR er levels lute red 8 to 6.18	(RR TB (, where li ared to co or withou ance) rec = 1.52, 9 s of death luction (F 3); and lo	inezolid 60 ohort of MD ut quinolor ceiving 9-m 95%CI 1.38 n (0% vs 18 RD= -0.15, wer levels o	0 mg daily DR/RR-TB p ne resistan to 1.55), h 3%), i.e. 18 95%Ci -0. of amplifier	was used for 26 w	uinolone resista with linezolio (n=4 216) expe re and recurrer on (RD= -0.18, r levels of grad	ance) treated id 600-26 (n erienced high nce (0% vs 1 3, 95%CI -0.19 de 3 to 5 adv	d in South Af 1=43) comp her levels of 1%), i.e.1% 9 to-0.1); lo verse events	frica with 9-mo pared to parti f treatment su absolute redu wer levels of l ; (14% vs 5%)	onth regimen cipants with ccess (100% ction (RD= - oss to follow , i.e. a 3 fold	
BPaL com Research The BPal 6 vithout quy vith linezon tarticipan 10R/RR-7 s 66%) i. .01, 95% p (0% vs ncrease (a the evider	mpared t a evidence 600-26 an uinolone e colid for tv hts with 1 TB (with c. 52% r bCI -0.02 t s 15%), i. aRR=2.92 ince is ver	o SA_new i re resistance w wo months. MDR/RR-TB but quinolor elative incre o 0.07); low e. 15% absc 2, 95%CI 1.3 y uncertain № of participants	Nix trial, as comp (with o e resista ase (RR er levels lute red 8 to 6.18 about th Certai	(RR TB (, where li ared to co or withou ance) rec = 1.52, 9 s of death luction (F 3); and lov ie effect o	inezolid 60 ohort of ME ut quinolor ceiving 9-m 95%CI 1.38 n (0% vs 18 RD= -0.15, wer levels o of BPaL 600	0 mg daily DR/RR-TB p ne resistan to 1.55), lu 3%), i.e. 18 95%Ci -0. of amplifieu 0-26 regimo Anticipa	was used for 26 w patients (without qu ce) receiving BPal nen with linezolid (ower levels of failur % absolute reducti 16 to -0.07); higher d resistance (0% vs en on all outcomes.	uinolone resista with linezolid n=4 216) exper- re and recurrer on (RD= -0.18, r levels of grad 1%), i.e. 1% ab	ance) treated id 600-26 (n erienced high nce (0% vs 1 3, 95%CI -0.19 de 3 to 5 adv	d in South Af 1=43) comp her levels of 1%), i.e.1% 9 to-0.1); lo verse events	frica with 9-mo pared to parti f treatment su absolute redu wer levels of l ; (14% vs 5%)	onth regimen cipants with ccess (100% ction (RD= - oss to follow , i.e. a 3 fold	
BPaL com lesearch he BPal 6 vithout qu vith linezc articipan IDR/RR-1 s 66%) i. 01, 95% p (0% vs icrease (a he evider	mpared t a evidence 600-26 an uinolone e colid for tv hts with 1 TB (with c. 52% r bCI -0.02 t s 15%), i. aRR=2.92 ince is ver	o SA_new if re resistance w wo months. MDR/RR-TB out quinolor elative incre o 0.07); low e. 15% absc 2, 95%CI 1.3 y uncertain № of	Nix trial as comp (with o e resist: ase (RR er levels lute red 8 to 6.18 about th Certai ev	(RR TB (, where li ared to co or withou ance) rec = 1.52, 9 s of death luction (F 3); and lov e effect o	inezolid 60 ohort of ME ut quinolor ceiving 9-m 15%CI 1.38 1 (0% vs 18 RD= -0.15, wer levels c of BPaL 600	0 mg daily DR/RR-TB p onth regin to 1.55), lo 3%), i.e. 18 95%Ci -0. of amplifier 0-26 regime	was used for 26 w patients (without qu ce) receiving BPal nen with linezolid (ower levels of failu % absolute reducti 16 to -0.07); higher d resistance (0% vs en on all outcomes.	uinolone resista with linezolid n=4 216) exper- re and recurrer on (RD= -0.18, r levels of grad 1%), i.e. 1% ab	ance) treated id 600-26 (n erienced high nce (0% vs 1 3, 95%CI -0.19 de 3 to 5 adv	d in South Af 1=43) comp her levels of 1%), i.e.1% 9 to-0.1); lo verse events	frica with 9-mo pared to parti f treatment su absolute redu wer levels of l ; (14% vs 5%)	onth regimen cipants with ccess (100% ction (RD= - oss to follow , i.e. a 3 fold	
BPaL com Research The BPal 6 vithout qu vith linezo Participan ADR/RR-7 rs 66%) i. J.01, 95% ap (0% vs ncrease (a	mpared t a evident 600-26 an uinolone i colid for tw hts with 1 TB (with c. 52% r oCI -0.02 t s 15%), i. aRR=2.92 ince is ver	o SA_new if re resistance w vo months. MDR/RR-TB but quinolor elative incre o 0.07); low e. 15% absc 2, 95%CI 1.3 y uncertain Nº of participants (studies)	Nix trial, as comp (with one resist ase (RR er levels lute red 8 to 6.18 about th Certai evi (G	(RR TB (, where li ared to co or withou ance) rec = 1.52, 9 s of death luction (F 3); and lov ie effect o	inezolid 60 ohort of MD ut quinolor ceiving 9-m 95%CI 1.38 n (0% vs 18 RD= -0.15, wer levels o of BPaL 600 Relative effect	0 mg daily DR/RR-TB p ne resistan to 1.55), la 3%), i.e. 18 95%Ci -0. of amplifier 0-26 regime Anticipa Risk with SA_new	was used for 26 w patients (without qu ce) receiving BPal nen with linezolid (ower levels of failur % absolute reducti 16 to -0.07); highen d resistance (0% vs en on all outcomes. sted absolute effects* (95% CI) Risk difference with	uinolone resista with linezolia (n=4 216) exper- re and recurrer on (RD= -0.18, r levels of grad 1%), i.e. 1% ab	ance) treated id 600-26 (n erienced high nce (0% vs 1 3, 95%CI -0.19 de 3 to 5 adv	d in South Af 1=43) comp her levels of 1%), i.e.1% 9 to-0.1); lo verse events	frica with 9-mo pared to parti f treatment su absolute redu wer levels of l ; (14% vs 5%)	onth regimen cipants with ccess (100% ction (RD= - oss to follow , i.e. a 3 fold	

	N? of participants	Certainty of the	Relative	Anticipated absolute effects* (95% CI)			
Outcomes	(studies) Follow-up	(GRADE)	effect (95% CI)	Risk with SA_new	Risk difference with BPaL		
Falure and	4 25 9	0000	RD -0.01	St	udy population		
recurrence	(2 observational studies)	Very low ^{assiste}	(-0.02 to 0.07)	12 per 1000	10 fewer per 1 000 (20 fewer to 70 more)		
Death	4 259	0000	RD -0.18	Study population			
	(2 observational studies)	Very low ^{aterie}	(-0.19 to -0.1.0)	180 per 1000	180 fewer per 1 000 (190 fewer to 100 fewer		
Lost to failow up	4 259	0000	RD -0.15	St	udy population		
	(2 observational studies)	Very low ^{ance}	(-0.16 to -0.07)	149 per 1000	150 fewer per 1000 (160 fewer to 70 fewer)		
Amplification of	4,259	0000	RD -0.01	51	udy population		
drug resistance	(2 observational studies)	Very low ^{abone}	(-0.01 to 0.08)	6 per 1000	10 fewer per 1 000 (10 fewer to 80 more)		

BPaL compared to TB-PRACTECAL comparator in pulmonary MDR/RR-TB and pre-XDR TB (WHO sub-PICO 6.6) Research evidence

The BPaL (B-Pa-Linezolid600->300) regimen arm of the TB-PRACTECAL trial with population including patients with MDR/RR-TB with or without quinolone resistance (MDR/RR-TB or pre-XDR-TB) was compared to comparator arm of the TB-PRACTECAL trial comprised of MDR/RR-TB or pre-XDR-TB patients treated with multiple local SoC regimens (including: 9–12-month injectable containing regimen; 18–24-month long WHO regimen (pre-2019); 9–12 month all oral regimen; 18–20 month all oral regimen).

Participants with MDR/RR-TB (with or without quinolone resistance) receiving BPaL (n=60) compared to participants receiving WHO recommended standard of care regimens used in TB-PRACTECAL trial (n=66) experienced higher levels of treatment success (77% vs 52%), i.e. a 47% relative increase (RR=1.47, 95%CI 1.09 to 1.99); lower levels of failure and recurrence (13% vs 26%), i.e. a 48% relative reduction (RR=0.52, 95%CI 0.22 to 1.18); lower levels of deaths (0.0% vs 3.0%), i.e. a 3% absolute reduction (RD=-0.03, 95%CI -0.10 to 0.03); lower levels of follow-up (10% vs 20%), i.e. a 40% relative reduction (RR=0.60, 95%CI 0.24 to 1.56); lower levels of adverse events (20% vs 51%), i.e. a 62% relative reduction (RR=0.38, 95%CI 0.24 to 0.60); and higher levels of amplification of drug-resistance (2.9% vs 1.9%), i.e. a 59% relative increase (RR=1.59, 95%CI 0.32 to 7.84).

BPaL may improve treatment success, failure and recurrence, death, loss to follow-up and adverse events while leading to more amplification of drugresistance but the evidence is very uncertain.

		Nº of	Certainty of Relative		Anticipated at	osolute effects* (95% CI)		
	Outcomes	participants (studies) Follow-up	Certainty of the evidence (GRADE)	effect (95% CI)	Risk with TB-PRACTECAL comparator	Risk difference with BPaL (Lzd 600mg/300mg)		
	Treatment success	126 (1 RCT)	000 Very low ^{abcidiatg}	RR 1.47 (1.09 to 1.99)	Stu 515 per 1 000	dy population 242 more per 1000 (46 more to 510 more)		
	Failure and recurrence	126 (1 RCT)	000 Very low ^{abidatg}	RR 0.52 (0.22 to 1.18)	Stu 258 per 1000	dy population 124 fewer per 1 000		
	Lost to follow up	126 (1 RCT)	000 Very low ^{abcdeth}	RR 0.60 (0.24 to	Stu 197 per 1000	(201 fewer to 46 more) dy population 79 fewer per 1 000		
	Adverse events	210 (1 RCT)	000 Very low ^{abcdalg}	1.56) RR 0.38 (0.24 to 0.60)	Stu 509 per 1 000	(150 fewer to 110 more) dy population 316 fewer per 1 000 (387 fewer to 204 fewer)		
		Nº of	Certainty of	Relative	Anticipated a	absolute effects* (95% CI)		
	Outcomes	participants (studies) Follow-up	(GRADE)	effect (95% CI)	Risk with TB-PRACTECAL comparator	Risk difference with BPaL (Lzd 600mg/300mg)		
	Death	126 (1 RCT)	OCO Very low ^{stodely}	RD -0.03 (-0.10 to 0.03)	30 per 1 000	30 fewer per 1 000 (1 00 fewer to 30 more)		
PHC/ADULT HOS	certainty of th	e evidence.		additional	considerations, t	he GDG judged that BPaL m	nave large desirable effects and noted the very low	
∘Trivial	The ERC cons the review tea	idered all resea	arch relevant to		BPaL to various		5.3 and 6.6. No additional research was presented by rated statistically significant increases in successful	
 Small Moderate X Large Varies Don't know 	and reduced p	tcomes and ree	duced mortality	, and a tre			rence, combined with a shorter treatment duration	highlighted by the ERC relevant to the comparisons in this EtD include: • That sub-PICO's 4.1, 5.2 and 5.3
 Moderate X Large Varies 		tcomes and reopill burden that	duced mortality t may favour adl	, and a tre herence, tl	ne ERC judged th	iced treatment failure or re	rence, combined with a shorter treatment duration	 comparisons in this EtD include: That sub-PICO's 4.1, 5.2 and 5.3 are indirect comparisons of tria data to programmatic data. Clinical outcomes in clinical
 Moderate X Large Varies Don't know 		tcomes and reo pill burden that l are the undes	duced mortality t may favour adl	, and a tre herence, tl	ne ERC judged th	iced treatment failure or re	rence, combined with a shorter treatment duration	 highlighted by the ERC relevant to the comparisons in this EtD include: That sub-PICO's 4.1, 5.2 and 5.3 are indirect comparisons of triadata to programmatic data. Clinical outcomes in clinical
 Moderate Large Varies Don't know Undesirable effect	ts: How substantia RESEARCH EVI	tcomes and reo pill burden that l are the undes	duced mortality t may favour adl	, and a tre herence, tl	ne ERC judged th	iced treatment failure or re	rence, combined with a shorter treatment duration	 highlighted by the ERC relevant to the comparisons in this EtD include: That sub-PICO's 4.1, 5.2 and 5.3 are indirect comparisons of triadata to programmatic data. Clinical outcomes in clinical trials tend to be better.

○Trivial○ Small	BPaL comp	pared to WHO_Lo	ng in pulmonary	preXDR TB (W	HO sub-PICO 4.	1)			Additional considerations and judgments related to all comparisons
x Moderate	Research E	vidence							Jauginenie relateu te un comparierie
○ Large									Pretomanid safety
∘ Varies ∘ Don't know	quinolone re	00–26 arm of the esistance was com f MDR/RR-TB desig	pared to a cohort	of MDR/RR-TB	patients with flu	for 26 weeks, and loroquinolone resi	l population included patients stance from 2021 IPD, receivi	with MDR/RR-TB with ing longer regimens for	Monkey Toxicology Studies – no evidence
	longer regim to 1.40); low vs 9.9%), i.e. 0.09, 95%CI	nens for MDR/RR-7 ver levels of failure a 10% absolute re -0.11 to -0.01); h	'B (n=839) experi and recurrence (0 duction (RD=-0.10 igher levels of adv	enced higher leve 0.0% vs 6.6%), i.e 0, 95%CI -0.12 to verse events (15	els of treatment s e. a 7% absolute a -0.01); lower lev % vs 4.4%), i.e.	uccess (100% vs 75 reduction (RD=-0.0 els of loss to follow	PaL 600–26 (n=33) compared t 5%), i.e. a 34% relative increase 07, 95%CI -0.08 to -0.04); lowe -up (0.0% vs 9.1%), i.e. a 9% at to (RR=3.44, 95%CI 1.44 to 8.1 to -0.03).	e (RR=1.34, 95%CI 1.20 er levels of deaths (0.0% psolute reduction (RD=	to declining physical condition Hormone Data from Clinical Studies – no changes in FSH 1 H Inhibin B consistent
		6 may improve tre nts but the evidenc			ence, death, loss	to follow-up and a	mplification of drug-resistance	e while leading to more	e 38 men (12%) who participated in pretomanid studies of 4 -6 months treatment duration
	Outcomes	Nº of participan	ts Certainty of t evidence			absolute effects* 5% CI)			Semen Study – ongoing study measuring semen in men undergoing pretomanid
	Outcomes	(studies) Follow-up	(GRADE)	effect (95% CI)	Risk with WHO_long	Risk difference with BPaL			treatment.
	Adverse	872	. 0 000			population	_		The panel was reassured by the presentation of preclinical and clinical
	events	(15 observationa studies)	Il Very low ^{a,b,c,d}	e,f (1.44 to 8.17)	44 per 1 000	108 more per 1000 (19 more to 316 more)			data relevant to testicular toxicity of Pretomanid, judging that clinically relevant effects appeared to be unlikely.
	Research E The BPaL 60 without quir for MDR/RR Participants (without qui a 32% relativ to 3.8); lowe 12% absolut 95%CI 1.67	00-26 arm of the Z nolone resistance v -TB constructed in with MDR/RR-TB inolone resistance ve increase (RR=1 er levels of death (G re reduction (RD=	eNix trial, where l vas compared to co line with 2020 W (with or without of receiving WHO ro 32, 95%CI 1.19 to 1% vs 11%), i.e. 11 -0.12, 95%CI -0.14 • levels of amplifie	inezolid 600 mg bhort of MDR/RR HO guidelines. quinolone resista commended lon 1.39); lower leve % absolute reduc to -0.04); higher d resistance (0%	daily was used f R-TB patients (wi ance) receiving B ger regimens (n= ls of failure and r ction (RD= -0.11 levels of grade 3 vs 2%), i.e. 2% a gimen on all outc	or 26 weeks, and p thout quinolone res PaL 600-26 regime =850) experienced ecurrence (2% vs 3 , 95%CI -0.12 to -0. to 5 adverse events bsolute decrease (f	opulation included patients w sistance) from 2021 IPD, treate en (n=43) compared to partici higher levels of treatment succ %), i.e. a 29% relative reductio 030; lower levels of loss to foll s (14% vs 5%), i.e. a 4 fold relat RD= - 0.02, 95%CI -0.04 to 0.00	ed with longer regiment pants with MDR/RR-TH cess (100% vs 74%), i.e on (RR=0.71, 95%CI0.12 ow-up (0% vs 12%), i.e ive increase (aRR=3.99	s 3 2. 2.
	Outcomes Adverse events ()	participants Certai (studies) ev Follow-up (G	hty of the Relative dence effect (95% CI) (00 RR 3.99 (1.67 to 957)	(95% CI) Risk with Risk d WHO_long with Study populatio 47 per 1 000 141 m	lifference h BPaL				
				(32 mc	ore to 403 nore)				

BPaL compared to SA_new in MDR/RR TB (WHO sub-PICO 5.3) Research Evidence

The BPal 600-26 arm of the ZeNix trial, where linezolid 600 mg daily was used for 26 weeks, and population included patients with MDR/RR-TB with or without quinolone resistance was compared to cohort of MDR/RR-TB patients (without quinolone resistance) treated in South Africa with 9-month regimen with linezolid for two months.

Participants with MDR/RR-TB (with or without quinolone resistance) receiving BPaL with Linezolid 600-26 (n=43) compared to participants with MDR/RR-TB (without quinolone resistance) receiving 9-month regimen with linezolid (n=4 216) experienced higher levels of treatment success (100% vs 66%) i.e. 52% relative increase (RR= 1.52, 95%CI 1.38 to 1.55), lower levels of failure and recurrence (0% vs 1%), i.e.1% absolute reduction (RD= -0.01, 95%CI -0.02 to 0.07); lower levels of death (0% vs 18%), i.e. 18% absolute reduction (RD= -0.18, 95%CI -0.19 to-0.1); lower levels of loss to follow up (0% vs 15%), i.e. 15% absolute reduction (RD= -0.15, 95%CI -0.16 to -0.07); higher levels of grade 3 to 5 adverse events (14% vs 5%), i.e. a 3 fold increase (aRR=2.92, 95%CI 1.38 to 6.18); and lower levels of amplified resistance (0% vs 1%), i.e. 1% absolute reduction (RD= -0.01, 95%CI -0.01 to 0.08). The evidence is very uncertain about the effect of BPaL 600-26 regimen on all outcomes.

	Nº of	Certainty of the	Relative	Anticipated	absolute effects* (95% CI)
Outcomes	participants (studies) Follow-up	evidence (GRADE)	effect (95% CI)	Risk with SA_new	Risk difference with BPaL
Adverse	4259	0000	RR 2.92	S	tudy population
events	(2 observational studies)	Very low ^{abcde}	(1.38 to 6.18)	49 per 1000	95 more per 1 000 (19 more to 256 more)

The panel discussed the importance of adverse events in the treatment of RR/MDR-TB and noted the significantly higher number of adverse events observed with BPaL. It was acknowledged that recording of AEs as part of the ZeNix trial is much more detailed than for data sets arising from routine care (i.e. data for the longer regimens).

Considering the increased number of adverse events with BPaL, the GDG judged that BPaL may have moderate undesirable effects and noted the very low certainty of the evidence.

BPaL compared to TB-PRACTECAL comparator in pulmonary MDR/RR-TB and pre-XDR TB (WHO sub-PICO 6.6) Research Evidence

The BPaL (B-Pa-Linezolid600->300) regimen arm of the TB-PRACTECAL trial with population including patients with MDR/RR-TB with or without quinolone resistance (MDR/RR-TB or pre-XDR-TB) was compared to comparator arm of the TB-PRACTECAL trial comprised of MDR/RR-TB or pre-XDR-TB patients treated with multiple local SoC regimens (including: 9–12-month injectable containing regimen; 18–24-month long WHO regimen (pre-2019); 9–12 month all oral regimen; 18–20 month all oral regimen).

Participants with MDR/RR-TB (with or without quinolone resistance) receiving BPaL (n=60) compared to participants receiving WHO recommended standard of care regimens used in TB-PRACTECAL trial (n=66) experienced higher levels of treatment success (77% vs 52%), i.e. a 47% relative increase (RR=1.47, 95%CI 1.09 to 1.99); lower levels of failure and recurrence (13% vs 26%), i.e. a 48% relative reduction (RR=0.52, 95%CI 0.22 to 1.18); lower levels of deaths (0.0% vs 3.0%), i.e. a 3% absolute reduction (RD=-0.03, 95%CI -0.10 to 0.03); lower levels of loss to follow-up (10% vs 20%), i.e. a 40% (Judgement for WHO relative reduction (RR=0.60, 95%CI 0.24 to 1.56); lower levels of adverse events (20% vs 51%), i.e. a 62% relative reduction (RR=0.38, 95%CI 0.24 to 0.60); and higher levels of amplification of drug-resistance (2.9% vs 1.9%), i.e. a 59% relative increase (RR=1.59, 95%CI 0.32 to 7.84). BPaL may improve treatment success, failure and recurrence, death, loss to follow-up and adverse events while leading to more amplification of drug-

resistance but the evidence is very uncertain.

sub-PICO 6.6)

X Trivial

Small

○ Moderate					Analatanada	Lastan all and (OFO) CD		
 ○ Large ○ Varies ○ Don't know 	Outcomes	Nº of participants (studies) Follow-up	Certainty of the evidence (GRADE)	Relative effect (95% CI)	Risk with TB-PRACTECAL comparator	absolute effects* (95% CI) Risk difference with BPaL (Lzd 600mg/300mg)	-	
	Amplification	210	000⊕	RR 1.59		udy population		
	of drug resistance	(1 RCT)	Very low ^{ab.cde,f}	(0.32 to 7.84)	19 per 1 000	11 more per 1 000 (13 fewer to 127 more)	_	
	certainty of the	evidence.		nal consider	ations, the GDG jud	ged that BPaL may have trivial	undesirable effects and noted the very low	
PHC/ADULT HOS	PITAL LEVEL C	OMMITTEE'S JU	DGEMENT					
 Trivial Small Moderate Large Varies Don't know 	Based on the r differences in ERC recomme contributing to	nore doubled incr reporting betwee ended a summary o data for this don	rease in relative ri n clinical trial and judgment that th nain, the high degr	sk of advers programma ie undesirab ree of uncert	e events in 3 of 4 co itic data, as well as	the fact that there were trivial atervention (BPaL) are moder	and 5.3), but which may have arisen from l differences between TB PRACTECAL, the ate. The ERC highlighted the few studies	 Additional considerations and limitations highlighted by the ERC relevant to the comparisons in this EtD include: That sub-PICO's 4.1, 5.2 and 5.3 are indirect comparisons of trial data to programmatic data. Programmatic data may underreport of adverse events. That in sub-PICO 6.6, the BPaL arm of TB-PRACTECAL used reduced Linezolid dosing from 16 weeks, and thus adverse events reported for this arm may not reflect adverse events associated with a regimen of 26 weeks of Linezolid 600mg daily dosing.
Certainty of evidenc	e: What is the ov	verall certainty of	the evidence of eff	ects?				
JUDGEMENT	RESEARCH EVI	IDENCE						ADDITIONAL CONSIDERATIONS
• WHO Guideline pa	anel							
X Very low ○ Low ○ Moderate	-		g in pulmonary p	ore-XDR TB	R (WHO sub-PICO	4.1)		Additional considerations applicable to WHO sub-PICO 4.1, 5.2 and 5.3
 ○ Moderate ○ High 	Research Evid	dence						This is an indirect comparison of
\circ No included studies	600–26 group	that precluded adj	justment for differ	ences in base	eline covariates (m	easured confounding) and likel	ounding, small event numbers in the BPaL y measurement bias due to underestimates the outcomes between cohorts in the WHO	patients treated within a clinical trial to data from patients treated under routine programmatic conditions so selection

IPD 2021 (downgraded one level). We did not downgrade for indirectness. Imprecision was very serious, due to the small sample size in the intervention criteria, support during treatment and other interventions are likely to differ.

The GDG acknowledged that the indirect comparison and the propensity adjustment is leaving us with very low certainty.

Additional considerations applicable to WHO sub-PICO 6.6

As noted in the CoE assessment, it is important to highlight that:

.

- the population included in the trial that gave rise to the data is a mix of MDR/RR and pre-XDR/XDR TB patients (82– 92% RR/MDR, depending on study arm)
- treatment outcomes for the comparator regimen differ for these populations and that 24% of patients were treated with regimens no longer recommended by WHO, e.g. containing injectable drugs and not containing Bdq

a. Lack of allocation concealment in the intervention arm. In the ZENIX study, participants, trial investigators and staff (including laboratory staff) were blinded to the dose and scheduled duration of linezolid. Participants were unblinded to the use of bedaquiline and pretomanid. However, this comparison is between one arm of ZENIX and an individual participant data meta-analysis of 14 datasets – i.e. a non-randomised comparison. Therefore, we have not downgraded due to the partial blinding of ZENIX b. Confounding bias. Baseline imbalances were observed in the age, gender, HIV status, prior TB and prior drug-resistant TB history, smear status and culture positivity at baseline between the two groups. In most comparisons we were unable to adjust for measured confounding as the small number of

culture positivity at baseline between the two groups. In most comparisons we were unable to adjust for measured confounding as the small number of events in the intervention group did not allow this (<5 individuals with a positive or negative outcome). Confounding bias is therefore likely. This imbalance in measured covariates suggests unmeasured confounding is also likely.

c. Potential misclassification bias: As the WHO IPD data were collected under programmatic conditions, there is considerable potential to underestimate relapse, as details pertaining to the follow-up period is often missing. Misclassification of death during the follow-up period is also possible as there is no death registry to link to the cohort data for deaths that occurred after treatment completion.

d. Considerable variability was observed in the effect estimates between cohorts in the comparator group. The overall effect in the comparator is strongly influenced by a small number of larger cohorts, which have varying effect estimates.

e. The ZENIX study was a clinical trial conducted in the Russian Federation, Republic of Moldova and South Africa. The procedures within the trial in these settings are not necessarily comparable with those used in other programmatic settings in which MDR-TB commonly occurs (e.g. countries in Southeast Asia). The decision as to whether to downgrade for indirectness is a difficult one. Given that the study was conducted in three countries, the intervention and outcomes are more likely to reflect practice in a range of other settings. Hence, we have chosen not to downgrade the certainty due to indirectness f. The small number of individuals included in both the intervention group (n=43) results in a very serious risk of imprecision. Therefore, the certainty has been downgraded by two levels.

Adolopment_WHO_DRTB_Guidelines_4May2023_Final

Nº of

participants

(studies)

Follow-up

872

(15 observational

studies)

872

(15 observational

studies)

937

(15 observational

studies)

872

(15 observational

studies)

872

(15 observational

studies)

872

Outcomes

Failure and

recurrence

Lost to follow up

Adverse events

Amplification of drug

Death

Treatment success

Certainty of the

evidence

(GRADE)

000

Very lowated at

0000

Very lowabcdet

000

Very low^{ab,c,d,e,f}

000

Very lowancae,

000

Very low^{a.c.detg}

0000

g. Confounding bias. Baseline imbalances were observed in the age, gender, HIV status, prior TB and prior drug-resistant TB history, smear status and culture positivity at baseline between the two groups. While we were able to adjust for these baseline covariates for the outcome of adverse events, this imbalance in measured covariates suggests unmeasured confounding is also likely.

BPaL compared to WHO_Long in pulmonary MDR/RR TB (WHO sub-PICO 5.2) Research Evidence

Adjustment for baseline covariates was not possible for any of the outcomes, except adverse events, owing to the small number of events occurring in one or more groups. Certainty was rated *very low* for all outcomes. Risk of bias was very serious, with confounding bias evident in the imbalance between baseline covariates between groups (adjustment not possible). Downgraded two levels for risk of bias. Indirectness was not serious. Inconsistency was serious, with variation in the outcomes between the WHO IPD 2021 cohorts. Imprecision was very serious, with small numbers in the intervention group (n=43), leading to a downgrading by two levels.

Outcomes	№ of participants (studies) Follow-up	Certainty of the evidence (GRADE)
Treatment success	893 (15 observational studies)	COO Very low ^{allocker}
Failure and recurrence	893 (15 observational studies)	HOOO Very low ^{attocke}
Death	893 (15 observational studies)	⊕OOO Very low ^{athoda} r
Lost to follow up	893 (15 observational studies)	COO Very low ^{abcde/}
Adverse events	893 (15 observational studies)	COO Very low ^{abcds3}
Amplification of drug resistance	893 (15 observational studies)	⊕⊖⊖⊖ Very low ^{abcde!}

is between one arm of ZENIX and the WHO long (WHO IPD 2021) cohort – a non-randomised comparison. Therefore, we have not downgraded due to the partial blinding of ZENIX.

b. Confounding bias. Baseline imbalances were observed in the gender, HIV status, prior TB history, past DR-TB treatment status, smear status, culture status and fluoroquinolone-resistance status between the two groups (although by including FQ-R TB it is likely to result in worse outcomes for the intervention group due to unmeasured confounding factors linked to FQ-R). We were able to adjust for the aforementioned measured confounders for the outcomes of success, failure/recurrence, loss to follow-up and grade 3 and above adverse events. However, the small number of events precluded adjustment for these factors for death or amplified resistance. The substantial imbalance in measured covariates suggests unmeasured confounding is also likely.

c. Potential misclassification bias: As the WHO IPD 2021 (WHO long) cohort data were collected under programmatic conditions, there is considerable potential to underestimate recurrence, as details pertaining to the follow-up period were often missing. Misclassification of death during the follow-up period was also possible, with no linked death registry data available in the comparator cohort.

d. Considerable variability was observed in the effect estimates between cohorts in the comparator group. The overall effect in the comparator is strongly influenced by a small number of larger cohorts, which have varying effect estimates.

e. The ZENIX study was a clinical trial conducted in the Russian Federation, Republic of Moldova and South Africa. The procedures within the trial in these settings are not necessarily comparable with those used in other programmatic settings in which MDR-TB commonly occurs (e.g. countries in Southeast Asia). The decision as to whether to downgrade for indirectness is a difficult one. Given that the study was conducted in three countries, the intervention and outcomes are more likely to reflect practice in a range of other settings. There was serious indirectness because the intervention was in a clinical trial, while the comparator was a programmatic dataset. Therefore, we have downgraded for indirectness.

f. The small number of individuals included in both the intervention group (n=43) results in a very serious risk of imprecision. Therefore, the certainty has been downgraded by two levels.

BPaL compared to SA_new in MDR/RR TB (WHO sub-PICO 5.3) Research Evidence

Adjustment for baseline covariates was not possible for any of the outcomes owing to the small number of events in one or more groups. Certainty was rated *very low*. Risk of bias was very serious, with confounding bias evident in the imbalance between baseline covariates between groups (adjustment not possible). Downgraded two levels for risk of bias. Indirectness was rated as not serious. Imprecision was very serious, with small numbers in the intervention group (n=43), leading to a downgrading by two levels

№ of participants (studies) Follow-up	Certainty of the evidence (GRADE)
4 259 (2 observational studies)	000 Very low ^{a,bc,d,e}
4 259 (2 observational studies)	⊕OOO Very low ^{a,bc,d,e}
4 259 (2 observational studies)	000 Very low ^{a,bc,d,e}
4 259 (2 observational studies)	000 Very low ^{a,bc,d,e}
4 259 (2 observational studies)	000 Very low ^{a,bc,d,e}
4 259 (2 observational studies)	000 Very low ^{a,bc,d,e}
	participants (studies) Follow-up 4 259 (2 observational studies) 4 259 (2 observational

a. Confounding bias. Baseline imbalances were observed in the gender, HIV status, prior TB treatment, smear status, culture positivity and fluoroquinolone resistance status between the two groups. In all comparisons we were unable to adjust for measured confounding as the small number of events in the intervention group did not allow this (<5 individuals with a positive or negative outcome). Confounding bias is due to measured confounding therefore serious. The substantial imbalance in measured covariates suggests unmeasured confounding is also likely.

b. Lack of allocation concealment in the intervention arm. In the ZENIX study, participants, trial investigators and staff (including laboratory staff) were blinded to the dose and scheduled duration of linezolid. Participants were unblinded to the use of bedaquiline and pretomanid. However, this comparison is between one arm of ZENIX and the WHO short (SA 2017) cohort – a non-randomised comparison. Therefore, we have not downgraded due to the partial blinding of ZENIX.

c. Potential misclassification bias: As the SA 2019 cohort data were collected under programmatic conditions, there is considerable potential to underestimate relapse, as details pertaining to the follow-up period is often missing. Misclassification of death during the follow-up period is also possible, although deaths reported in the South African death registry were linked to the participant follow-up data (using a national identification number).

d. The ZENIX study (intervention arm) was a clinical trial conducted in the Russian Federation, Republic of Moldova and South Africa. The procedures within the trial in these settings are not necessarily comparable with those used in other programmatic settings in which MDR-TB commonly occurs. The decision as to whether to downgrade for indirectness is a difficult one. Given that the study was conducted in three countries, the intervention and outcomes are more likely to reflect practice in a range of other settings. Given the important difference between a trial and programmatic setting, we have downgrade for indirectness.

e. The small number of individuals included in both the intervention group (n=43) results in a very serious risk of imprecision. Therefore, the certainty has been downgraded by two levels.

BPaL compared to TB-PRACTECAL comparator in pulmonary MDR/RR-TB and pre-XDR TB (WHO sub-PICO 6.6) Research Evidence

Certainty was rated *very low*. Risk of bias was serious or very serious, for different outcomes. There was a lack of blinding, early termination of the trial for benefit, measured confounding and likely unmeasured confounding and small event numbers precluding adjustment for some comparisons. These

concerns resulted in downgrading by one or two levels depending upon outcome. We did not downgrade for inconsistency. We downgraded for indirectness due to differences in the population, definitions of outcomes and the comparator regimen. Imprecision was serious or very serious according to outcomes, with a small number of events for some outcomes.

The overall certainty is generally based on the lowest certainty for the agreed critical outcomes

	Nº of participants (studies) Follow-up	Certainty of the evidence (GRADE)	
Treatment success	126 (1 RCT)	⊕OOO Very low ^{abcdefg}	
Failure and recurrence	126 (1 RCT)	Very low ^{abcdefg}	
Death	126 (1 RCT)	000 Very low ^{abc.detg}	_
Lost to follow up	126 (1 RCT)	000 Very low ^{ab.cde.th}	
Adverse events	210 (1 RCT)	000 Very low ^{abcdefg}	
Amplification of drug resistance	210 (1 RCT)	HOOO Very low ^{ab.c.de, f}	_
noted in the d. The trial v 2013). e. Multiple co putcomes se for inconsist C. A single tr Gome compa evel. g. The numb very serious	comparator was stopped omparator r en between tency as the cial. Serious urator regim er of particij imprecisior	group, which learly for bene egimens were countries (Bel issue of compa indirectness (ens are sub-op pants in both in . We downgra	givers and those adjudicating outcomes may introduce bias in the conduct of the trial. Higher loss to follow-up is an outcome that may be influenced by patient or clinician knowledge of the regimen. hefit, with few events (<200). This can introduce bias. Formal stopping rules do not reduce bias (GRADE Hander e used, varying across site. This may explain some of the substantial inconsistency in the point estimates for treat elarus, South Africa and Uzbekistan). The decision whether to downgrade is a difficult decision. We did not down warators was addressed under indirectness. (i) Populations: Differences in population of a trial and population to which guidelines will apply. (ii) Compa- ptimal, not according with the WHO standard of care (at the time or presently) and vary by country. Downgrad intervention and comparator groups was small (n=60 and n=66). Very few events in the outcomes of interest, c aded two levels for imprecision for some outcomes, and one level for others. biss to follow-up, and adverse event reporting where participant and clinician knowledge of the regimen may inf
1. A IACK OF D	elating to tr		


• PHC/ADULT HOSPITAL LEVEL COMMITTEE


X Very low • Low • Moderate • High • No included studies	The ERC considered all information and research presented by the WHO GDG and agreed that the certainty of evidence is very low.	
Values: Is there importa	nt uncertainty about or variability in how much people value the main outcomes?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
• WHO Guideline pa	nel	
 Important uncertainty or variability Possibly important uncertainty or variability X Probably no important uncertainty or variability No important uncertainty or variability No known undesirable outcomes 	BPaL compared to WHO_Long in pulmonary preXDR TB (WHO sub-PICO 4.1) BPaL compared to WHO_Long in pulmonary MDR/RR TB (WHO sub-PICO 5.2) BPaL compared to SA_new in MDR/RR TB (WHO sub-PICO 5.3) BPaL compared to TB-PRACTECAL comparator in pulmonary MDR/RR-TB and pre-XDR TB (WHO sub-PICO 6.6) Research Evidence No evidence research searched for. Higher treatment efficacy, shorter duration of treatment, lower pill burden and less adverse events are usually valued by patients. The panel judged that there was probably no important uncertainty or variability in how much people value the main outcomes.	
• PHC/ADULT HOSPIT	AL LEVEL COMMITTEE'S JUDGEMENT	
 Important uncertainty or variability Possibly important uncertainty or variability X Probably no important uncertainty or variability No important uncertainty or variability No known undesirable outcomes 	No additional research was presented by the review team. The ERC agreed with the WHO GDG that there is probably no important uncertainty or variability in how much people value the main outcomes.	


JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
• WHO Guideline pa	nel	
• Favours the comparison	BPaL compared to WHO_Long in pulmonary preXDR TB (WHO sub-PICO 4.1)	Additional considerations relevant to sub-PICO's 4.1 and 5.2 only
 Probably favours the comparison Does not favour either the intervention or the comparison x Probably favours the intervention Favours the intervention 	BPaL compared to WHO_Long in pulmonary MDR/RR TB (WHO sub-PICO 5.2) Research Evidence Nil additional	The panel highlighted (as noted in the CoE assessment) that we are comparing data from patients treated within a clinical trial to data from patients treated under routine programmatic conditions so selection criteria, support during treatment etc. are likely to differ. E.g. treatment outcomes are typically better
 Varies Don't know 	BPaL compared to SA_new in MDR/RR TB (WHO sub-PICO 5.3) Research Evidence	under trial conditions while AEs are typically underreported under programmatic conditions.
	Nil additional BPAL compared to TB-PRACTECAL comparator in pulmonary MDR/RR-TB and pre-XDR TB (WHO sub-PICO 6.6) Research Evidence Nil additional The GDG judged the benefits of BPaL to be large and the undesirable effects to be trivial compared to WHO recommended standard of care regimens. The certainty of evidence was judged to be very low. Based on this, the panel determined that the balance of health effects probably favours BPaL regimen.	The GDG judged the benefits of BPaL with Linezolid 600-26 to be large and the undesirable effects to be moderate compared to WHO recommended longer regimens. The certainty of evidence was judged to be very low. Based on this, the panel determined that the balance of health effects probably favors BPaL with Linezolid 600-26.
		Additional considerations relevant to sub-PICO 5.3 only
		This is an indirect comparison of patients treated within a clinical trial to data from patients treated under routine programmatic conditions so selection criteria, support during treatment and other interventions are likely to differ.
		Treatment outcomes are typically better under trial conditions while AEs are typically underreported under programmatic conditions.
		The GDG acknowledged that the indirect comparison and the propensity adjustment is leaving us with very low certainty.
		The GDG judged the benefits of BPaL with linezolid 600-26 to be large and the undesirable effects to be moderate

		compared to receiving 9-month regimen with linezolid. The certainty of evidence was judged to be very low. Based on this, the panel determined that the balance of health effects probably favours BPaL with linezolid 600-26. Additional considerations relevant to sub-PICO 6.6 only As noted in the CoE assessment, it is important to highlight that:
		 the population included in the trial that gave rise to the data is a mix of MDR/RR and pre-XDR/XDR TB patients (82–92% RR/MDR, depending on study arm) treatment outcomes for the comparator regimen differ for these populations and that 24% of patients were treated with regimens no longer recommended by WHO, e.g., containing injectable drugs and not containing Bdq As a result, the balance of effects may be
		different in settings/populations with different FQ-resistance prevalence and if only currently recommended regimens are used.
PHC/ADULT HOSPIT.	AL LEVEL COMMITTEE	
 Favours the comparison Probably favours the comparison Does not favour either the intervention or the comparison X Probably favours the intervention Favours the intervention Varies Don't know 	The ERC considered all evidence presented by the WHO GDG and no additional research was presented. Considering the ERC judgements of large desirable effects, including reduction in treatment duration and pill burden, and moderate undesirable effects, with very low certainty evidence, the balance of effect s was judged to probably favour the intervention.	


Resources required:	How large are the resource requirements (costs)?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
• WHO Guideline pa	anel	
 WHO Guideline pa Large costs Moderate costs Negligible costs and savings Moderate savings X Large savings Varies Don't know 	Intel BPaL compared to WHO_Long in pulmonary pre-XDR TB (WHO sub-PICO 4.1) BPaL compared to WHO_Long in pulmonary MDR/RR TB (WHO sub-PICO 5.2) Research Evidence Summary of findings from three publications on the cost of BPaL compared to WHO_long (further detail on each study below) • From these three publications, the total cost (drugs+delivery) of WHO_long appear to be between ~1.5x to 6x higher than for BPaL when looking at comparative estimates within country • Note that studies are not 100% addressing the comparison of interest: Mulder and Gomez papers based on Linezolid dose of 1 200 (so cost of Linezolid in these publications is higher than intervention of interest here) and Sweeney is based on 600-300 for 24 weeks and a mixed RR/MDR/pre-XDR population Mulder et al, 2022: Cost and budget impact analysis [noting co-authors from TB Alliance and KNCV] Methods • Per-patient treatment cost of BPaL regimen was compared head-to-head with the conventional XDR-TB treatment regimen (i.e. WHO_long) in Indonesia, Kyrgyzstan and Nigeria based on cost estimates primarily assessed using microcosting method and expected frequency of each TB service • The 5-year budget impact of gradual introduction of BPaL against the status quo was assessed using a Markov model that represented patient's treatment management and outcome pathways Findings • The cost per patient completing treatment with BPaL was US\$ 7142 in Indonesia, US\$ 4782 in Kyrgyzstan and US\$ 7152 in Nigeria - 57%, 78% and 68% lower than the conventional regimens in the respective countries. • A gradual adoption of the	Additional considerations relevant to sub-PICO 4.1 and 5.2 only Regimen cost at GDF prices: ~800 \$ BPaL (600-26), ~1 300\$ longer regimen. The panel judged that the costs for BPaL among patients with pulmonary pre- XDR-TB and among patients with pulmonary MDR/RR-TB are lower because costs of drugs are lower and cost of delivery are also lower due to the shorter duration of treatment and lower complexity Additional considerations relevant to sub-PICO 5.3 only Comparative costing analyses from Mulder and Gomez papers not applicable here since they are comparing to WHO_long (and, less importantly, are based on Linezolid dose of 1 200) Additional considerations relevant to sub-PICO 6.6 only
	BPaL regimen can be highly cost-saving compared with the conventional regimens to treat patients with XDR-TB in high drug-resistant TB burden settings.	The panel judged that the costs for BPaL are lower because costs of drugs are lower and cost of delivery are also lower due to the shorter duration of treatment and lower complexity. The GDG judged that the reduction in costs varies between moderate and large.







	Results by cour	AL		ve appi
	Results DV COUL		omustin	
	ricounto o j cour	iti y. cons	civativ	ic appr
	Country and regimen	Total costs per person To		per person
	Philippines SOC long	\$2,127	6.2	8
	SOC short	\$1,286	5.1	-\$841
	BPaL BPaLC	\$1,050 \$1,146	5.1	-\$236 \$96
	BPaLM	\$1,099	4.4	-\$47
	South Africa SOC long	\$6,896	6.9	
	SOC short	\$4,120	6.3	-\$2,776
	BPaL BPaLC	\$3,554 \$3,687	6.3 6.2	-\$566 \$132
	BPaLM	\$3,739	5.7	\$52
	India SOC long	\$1,531	6.8	
	SOC short	\$923	6.1	-\$608
	BPaL BPaLC	\$838 \$923	6.1 6.0	-\$84 \$85
	BPaLM	\$872	5.5	-531
	Georgia SOC long	\$4,499	4.7	
	SOC short	\$3,290	4.1	-\$1,209
	BPaL BPaLC	\$3,164 \$3,264	4.1	-\$125 \$100
	BPaLM	\$3,246	3.3	-\$19
L vs. long course imens for MDR and -XDR TB (sub-PICO 5.2, 6.6) arge costs	AL LEVEL COMMITTEE Additional information pre meeting, and on which WHC Updated version of Sedona S) GDG judgem	ent is bas	sed) , and the
L vs. long course mens for MDR and XDR TB (sub-PICO 5.2, 6.6) urge costs oderate costs legligible costs and ngs oderate savings rge savings rge savings uries	Additional information pres meeting, and on which WHC) GDG judgem	ent is bas	sed) , and the
BPaL vs. long course	Additional information pres meeting, and on which WHC) GDG judgem	ent is bas	sed) , and th
BPaL vs. long course regimens for MDR and pre-XDR TB (sub-PICO 4.1, 5.2, 6.6) • Large costs • Moderate costs • Negligible costs and savings • Moderate savings • Large savings • Varies	Additional information pres meeting, and on which WHC) GDG judgem	ent is bas	sed) , and t
BPaL vs. long course regimens for MDR and pre-XDR TB (sub-PICO 4.1, 5.2, 6.6) • Large costs • Moderate costs • Negligible costs and savings • Moderate savings • Large savings • Varies	Additional information pres meeting, and on which WHC) GDG judgem	ent is bas	sed) , and t
BPaL vs. long course regimens for MDR and pre-XDR TB (sub-PICO 4.1, 5.2, 6.6) • Large costs • Moderate costs • Negligible costs and savings • Moderate savings • Large savings • Varies	Additional information pres meeting, and on which WHC) GDG judgem	ent is bas	sed) , and the



	Total costs per person		Comparison with current SOC mix			
Country and regimen		Total DALYs per person	Incremental Costs Per Person	Incremental DALYs Averted Per Person		
Philippines						
Current SOC regimen mix	\$1,329	5.4				
(99% short, 1% long)						
BPaL	\$1,078	5.4	-\$251	0.0		
BPaLC	\$1,174	5.3	-\$155	0.1		
BPaLM	\$1,124	4.6	-\$204	0.8		
South Africa						
Current SOC regimen mix	\$4,517	6.8				
(74% short, 26% long)						
BPaL	\$3,344	6.6	-\$1,173	0.2		
BPaLC	\$3,470	6.5	-\$1,047	0.3		
BPaLM	\$3,520	6.0	-\$997	0.8		

Appendix 3.xlsx

	Normative cost analysis based on specific direct costs second sec							
							Contractor and a second second	
		Landon companya a c	Bacteriological tests	Other lab tests		treated incl. clinic visit	Total costs per patient treated excl. clinic visit	
	Regimen	Drug costs (ZAR)	(Costs in ZAR)	(Costs in ZAR)	Clinic visit costs (ZAR)	costs (ZAR)	costs (ZAR)	
	Short oral course (Min)	11 437,70	1 058,58	472,42				
	Short oral course (Max)	13 650,99	1 058,58	472,42				
	BPal (Ltd_Adjusted dose)	11 710,64	705,72	2 158,89				
	BPaUM (Lasi_Adjusted dese)	12 307,68	705,72	2 158,89				
	BPuLM (Las_Standard)	11 787,08	705,72	2 158,89				
	Long course 1 (Basic) Long course 2	27 159,16 49 601,58	2 117,16 2 117,16	783,55 2 028,07				
	mil man a	49.007.00	4.857,58	2 Mallar	0 301,40	67 418,11	33 746,83	
	6.527							
	Note: Where weight adlianted desing is recommended, dag too 1955 ergelwiert to K18.30 Deg calculations all haved on a 28 day cycle per moeth Diagnetic Zpert, microscope, rubban and DST not included Clinic with classified according to nature of clinical white a	t in costs for bacteric/ogical lesits						
	The ERC noted that drug costs, WHO GDG and the normative co when compared to the long con regimen.	osts analysis conducte	ed for the locally rele	evant context, the I	ERC felt that BPaL r	egimen was associa	ted with large savings	
Certainty of evidence o	f resource requirements: What	t is the certainty of the	evidence of resourc	e requirements (co	osts)?			
JUDGEMENT	RESEARCH EVIDENCE							ADDITIONAL CONSIDERATIONS
• WHO Guideline pa	nel							
x Very low ○ Low	BPaL compared to WHO_Lon							
○ Moderate○ High	BPaL compared to WHO_Lon							
 No included studies 	BPaL compared to TB-PRAC							
	Research Evidence							
	No research evidence searched	for.						
	<i>BPaL compared to SA_new in</i> Research Evidence							
	The panel reviewed available d preparatory pre-GDG webinars			n from trial embeo	lded study on cost	effectiveness presen	ted during one of the	

	The panel judged the certainty of evidence of required resources to be very low since the study presented by Sweeney is not addressing the PICO of interest directly as it is based on a mixed RR/MDR/pre-XDR population (and thus mixed comparator), on BPaL 600–300 for 24 weeks, instead of BPaL 600–26 and on the 9-month regimen using Ethionamide instead of Linezolid.	
• PHC/ADULT HOSPI	TAL LEVEL COMMITTEE	
 Very low Low X Moderate High No included studies 	The ERC considered the evidence of resources required to be moderate as the normative cost analysis of direct costs was performed for the locally relevant context increasing the certainty.	
Cost effectiveness: D	oes the cost-effectiveness of the intervention favor the intervention or the comparison?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
• WHO Guideline pan	el	
 Favours the comparison Probably favours the comparison Does not favour either the intervention or the comparison x Probably favours the intervention Favours the intervention Varies No included studies 	BPaL compared to WH0_Long in pulmonary preXDR TB (WH0 sub-PIC0 4.1) BPaL compared to WH0_Long in pulmonary MDR/RR TB (WH0 sub-PIC0 5.2) Research Evidence Gomez et al, 2021: Cost & cost-effectiveness [noting co-authors from TB Alliance] some indirectness as analyses were based on efficacy estimates from Nix study and a different comparator cohort but overall estimates of effect were similar Methods CEA using Markov model of BPaL (Nix regimen) in South Africa, Philippines and Georgia Primary and secondary outcome measures (1) Incremental cost per disability-adjusted life years averted by using BPaL against standard of care at the Global Drug Facility list price; (2) The potential maximum price at which the BPaL regimen could become cost neutral Findings BPaL for XDR-TB is likely to be cost saving in all study settings when BPaL is introduced to a wider population, including MDR-TB treatment failure and treatment intolerant, we observe increased savings and clinical benefits Cost savings from the introduction of the BPaL regimen are higher in settings with a more expensive current standard of care consequently, the threshold price at which BPaL becomes cost neutral is higher in less expensive settings: US3 3 650 and US\$ 500 for South Africa for our base case of only patients with XDR-TB, after factoring in incremental cost of ART <td< td=""><td></td></td<>	

Sedona Sweeney's presentation on cost & CEA of PRACTECAL regimens from pre-GDG webinar

- From the data presented: "strong evidence that BPaL would be cost-effective" in the setting studied (costs reduced and DALYs averted)
- Note that estimates of effectiveness (from which DALYs averted were derived) are different from those presented in the evidence profile for this PICO (CEA assumes smaller benefits of BPaL over comparator and thus estimates for DALYs averted would be conservative vis a vis data from the evidence profile)

Results by country: conservative approach

Country and regimen	Total costs per person	Total DALYs	Incremental Costs per person	Averted Fer Person	per DALY
Philippines	person	Terrar and alla	per person	President Contraction	peronel
SOC iong	\$2,127	6.2			
SOC short	\$1,286		-5841	1.04	Domina
BPaL	\$1,050	5.1	-\$236	0.00	Domina
BPaLC	\$1,146		\$96	0.11	\$84
BPaLM	\$1,099	4.4	-\$47	0.62	Domina
South Africa					
SOC long	\$6,896	6.9			
SOC short	\$4,120	6.3	-\$2,776	0.57	Domina
BPaL	\$3,554	6.3	-\$366	0.00	Domina
BPaLC	\$3,687	6.2	\$132	0.10	\$1,37
BPaLM	\$3,739	5.7	\$52	0.54	55
India					
SOC long	\$1,531	6.8			
SOC short	\$923	6.1	-\$608	0.70	Domina
BPaL	\$838	6.1	-\$84	-0.04	Domina
BPaLC	\$923	6.0	\$85	0.10	\$83
BPaLM	\$872	5.5	-\$51	0.57	Domina
Georgia					
SOC long	\$4,499	4.7			
SOC short	\$3,290	4.1	-\$1,209	0.57	Domina
BPaL	\$3,164	4.1	-\$125	0.02	Domina
BPaLC	\$3,264	4.0	\$100	0.12	\$83
BPaLM	\$3,246	3.3	-\$19	0.67	Domina

(sub-PICO 5.3 judgement) Given their prior judgements (balance of effects probably favours the intervention; intervention leads to moderate to large savings), the panel judged that the cost-effectiveness of the intervention probably favours the intervention.

BPaL compared to SA_new in MDR/RR TB (WHO sub-PICO 5.3) Research Evidence

Favours the comparison
Probably favours the comparison
Does not favour either the intervention or the

Sedona Sweeney's presentation on cost & CEA of PRACTECAL regimens from pre-GDG webinar

• From the data presented: "strong evidence that BPaL would be cost-effective" in the setting studied (costs reduced and DALYs averted)

 Probably favours the intervention Favours the intervention Varies X No included studies 	 The study presented by Sweeney is not addressing the PICO of interest directly as it is based on a mixed RR/MDR/pre-XDR population (and thus mixed comparator) and on BPaL 600–300 for 24 weeks, instead of BPaL 600–26 and using WHO_short rather than SA_new (i.e. Eto instead of Linezolid) as the comparator Estimates of effectiveness (from which DALYs averted were derived) are different from those presented in the evidence profile for this PICO (CEA assumes smaller benefits of BPaL over comparator and thus estimates for DALYs averted would be conservative vis a vis data from the evidence profile) Comparative costing analyses from Gomez papers not applicable here since they are comparing to long WHO regimen (+ are based on Linezolid dose of 1 200 and efficacy estimates from Nix study). For sub-PICO 5.3 no studies of cost-effectiveness were included. 	
PHC/ADULT HOSPIT	ral level committee	
 Favours the comparison Probably favours the comparison Does not favour either the intervention or the comparison X Probably favours the intervention Favours the intervention Varies No included studies 	The ERC considered all research evidence included in the WHO GDG judgement. No new cost-effectiveness studies were presented or considered. Based on the normative cost analysis of direct costs for South Africa performed by the review team, showing costs savings when the intervention is compared to current South African long course, the intervention would favour cost-effectiveness. However, evidence for cost-effectiveness for the intervention when compared to the current South African short course is based on the evidence from the study by Sweeney et al. that indirectly compared BPaL to South African standard of care regimens (a mix of 75% short course and 25% long course) and showed cost savings and reduced DALYs associated with the intervention. The ERC judged that overall, cost-effectiveness probably favours the intervention.	
Equity: What would be	the impact on health equity?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
• WHO Guideline pane	31	
	BPaL compared to WHO_Long in pulmonary preXDR TB (WHO sub-PICO 4.1)	The panel considered the treatment duration and the ability to decentralize

 Reduced Probably reduced Probably no impact X Probably increased Increased Varies Don't know Acceptability: Is the image of the second	The ERC considered no additional research. The ERC agreed with the WHO GDG judgment that the intervention would probably increase health equity.	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
• WHO Guideline p	anel	
 ○ No ○ Probably no x Probably yes 	BPaL compared to WHO_Long in pulmonary preXDR TB (WHO sub-PICO 4.1) BPaL compared to WHO_Long in pulmonary MDR/RR TB (WHO sub-PICO 5.2)	Additional considerations relevant to sub-PICO 4.4 and 5.2 only
 Yes Varies Don't know 	Research Evidence van de Berg et al, 2021 (based on 2019 KNCV report, funded by TB Alliance) on the provider perspective Methods • Mixed-methods study among a cross-section of health care workers, programmatic and laboratory stakeholders between May 2018 and May 2019 in Indonesia, Kyrgyzstan, and Nigeria • 188 stakeholders participated in this study: 63 from Kyrgyzstan, 51 from Indonesia, and 74 from Nigeria; majority were health care workers (110), other stakeholders interviewed were Laboratory stakeholders and Programmatic Stakeholders • semi-structured interviews and focus group discussions to assess perceptions on acceptability and feasibility of implementing BPaL • acceptability: anticipated benefits and challenges regarding DR TB management with the BPaL regimen by the stakeholders; recorded 3-point Likert scale (acceptable; neutral; unacceptable)	For sub-PICO 5.2 findings from the study by van de Berg et al, 2021 (based on 2019 KNCV report, funded by TB Alliance) on the provider perspective are listed under other considerations (instead of under research evidence) as acceptability was assessed for the pre- XDR population. For sub-PICO 5.3 analyses from van de Berg paper are not applicable here since in their study they asked about acceptability of using BPaL for pre-XDR
	Findings • Acceptability: overall high and rated as acceptable by >80% across domains • Stakeholders • appreciated that BPaL would reduce workload and financial burden on the health care system • expressed concerns regarding BPaL safety (monitoring), long-term efficacy, and national regulatory requirements • stressed the importance of addressing current health systems constraints as well, especially in treatment and safety monitoring systems Beverly Stringer's presentation on PROs from pre-GDG webinar (qualitative study) on the patient perspective • Positive impact of shorter treatment on employment status welcomed	patients and when compared to the long WHO regimen The panel considered patients and health care providers as key stakeholders. The panel considered the following aspects as critical with regards to acceptability: regimen duration and drug safety monitoring needs (both relating to necessary travel, loss of income and general disruption of the life of patients;
	BPaL compared to SA_new in MDR/RR TB (WHO sub-PICO 5.3) Research Evidence No research evidence searched for. Beverly Stringer's presentation on PROs from pre-GDG webinar (qualitative study) on the patient perspective: Positive impact of shorter treatment on employment status welcomed.	workload for the health care system), needs for drug susceptibility testing. The panel judged that the BPaL regimen would probably be acceptable. Additional considerations relevant to sub-PICO 5. 3 only

	BPaL compared to TB-PRACTECAL comparator in pulmonary MDR/RR-TB and pre-XDR TB (WHO sub-PICO 6.6) Research Evidence Beverly Stringer's presentation on PROs from pre-GDG webinar (qualitative study) on the patient perspective Positive impact of shorter treatment on employment status welcomed.	The panel considered patients and health care providers as key stakeholders. The panel considered the following aspects as critical with regards to acceptability: regimen duration and drug safety monitoring needs (both relating to necessary travel, loss of income and general disruption of the life of patients; workload for the health care system), needs for drug susceptibility testing. The panel judged that the BPaL regimen would probably be acceptable. Additional considerations relevant to
		 sub-PICO 6.6 only van de Berg et al, 2021 (based on 2019 KNCV report, funded by TB Alliance) on the provider perspective Noting that analyses from van de Berg paper are only partially applicable here since in their study they asked about acceptability of using BPaL for pre-XDR patients and when compared to the long WHO regimen Findings Acceptability: overall high and rated as acceptable by >80% across domains
		The panel considered patients and health care providers as key stakeholders. The panel considered the following aspects as critical with regards to acceptability: regimen duration and drug safety monitoring needs (both relating to necessary travel, loss of income and general disruption of the life of patients; workload for the health care system), needs for drug susceptibility testing. The panel judged that the BPaL regimen would probably be acceptable
PHC/ADULT HOSPIT	TAL LEVEL COMMITTEE	

 No Probably no x Probably yes Yes Varies Don't know 	Additional Research Evidence presented by TB-PRACTECAL-PRO team: All trial participants respiratory-specific QOL scores improved with treatment, irrespective of the regimen they received. However, faster improvement in the investigational arms as compared to SoC was noted by both the individual and their friends/family with a positive effect on treatment support. It was noted that a participant in the intervention arm experiences a 15% reduction (95% CI 12 to 18%) in the mean SGRQ symptom score per month versus an average of 5% (95% CI 0 – 9%) reduction experienced by a participant in the SoC arm. It was highlighted that South African participants were slightly underrepresented in the trial (32 South Africans of 137 participants) and that no analysis of QoL outcomes across countries was performed. For interviewees, in the qualitative study, supportive care experienced was as important as satisfaction and tolerability of the novel drug regimen. The ERC judged that the intervention is probably acceptable to key stakeholders.	
Feasibility: Is the interv	vention feasible to implement?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
• WHO Guideline Pane		
 No Probably no X Probably yes Yes Varies Don't know 	BPaL compared to WHO_Long in pulmonary preXDR TB (WHO sub-PICO 4.1) BPaL compared to TB-PRACTECAL comparator in pulmonary MDR/RR-TB and pre-XDR TB (WHO sub-PICO 6.6) Research Evidence van de Berg et al, 2021 (based on 2019 KNCV report, funded by TB Alliance) on the provider perspective Methods • Mixed-methods study among a cross-section of health care workers, programmatic and laboratory stakeholders between May 2018 and May 2019 in Indonesia, Kyrgyzstan, and Nigeria • Is 8 stakeholders participated in this study: 63 from Kyrgyzstan, 51 from Indonesia, and 74 from Nigeria; majority were health care workers (110) • semi-structured interviews and focus group discussions to assess perceptions on acceptability and feasibility of implementing BPaL. • feasibility: stakeholders' expectations regarding the practical requirements for implementing the BPaL regimen within the context of their health system; recorded as overall likelihood of implementing BPaL. (likely; neutral; unlikely) Findings • Feasibility: 88% (146/166) of the stakeholders would likely implement BPaL once available • Stakeholders • appreciated that BPaL would reduce workload and financial burden on the health care system • expressed concerns regarding BPaL safety (monitoring), long-term efficacy, and national regulatory requirements • appreciate that BPaL would reduce workload and financial burden on the health care system • expressed concerns regarding BPaL safety (monitoring), long-term efficacy, and national regulator	Additional considerations applicable to sub-PICO 4.1 and 6.6 only Noting that analyses from van de Berg paper are only partially applicable to sub-PICO 6.6 since in their study they asked about feasibility of using BPaL for pre-XDR patients and when compared to the long WHO regimen The panel considered the following aspects to affect feasibility (i.e. to be potential barriers to implementation): requirements for drug safety monitoring and requirements for drug susceptibility testing. The panel noted limited availability of drugs in the BPaL regimen for use in DST as a potential barriers to implementation and also noted that data on the critical concentration of Pretomanid for use in DST is limited. However, given the reduced duration, complexity and associated workload, the panel judged that implementation is probably feasible
(sub-PICO 5.2 and 5.3 judgement) \circ No \circ Probably no \circ Probably yes x Yes	BPaL compared to WHO_Long in pulmonary MDR/RR TB (WHO sub-PICO 5.2) BPaL compared to SA_new in MDR/RR TB (WHO sub-PICO 5.3) Research Evidence	Additional considerations applicable to sub-PICO 5.2 and 5.3 only The panel considered the following aspects to affect feasibility (i.e. to be

 ○ Varies ○ Don't know 	Nil	potential barriers to implementation): requirements for drug safety monitoring and requirements for drug susceptibility testing.
		The panel noted limited availability of drugs in the BPaL regimen for use in DST as a potential barrier to implementation and also noted that data on the critical concentration of Pretomanid for use in DST is limited.
		However, given the reduced duration, complexity and associated workload, the panel judged that implementation is feasible.
		Listing findings from the study by van de Berg et al, 2021 (based on 2019 KNCV report, funded by TB Alliance) on the provider perspective here under other considerations (instead of under research evidence) as feasibility was assessed for the pre-XDR population.
		Methods
		Methods Mixed-methods study among a cross-section of health care workers, programmatic and laboratory stakeholders between May 2018 and May 2019 in Indonesia, Kyrgyzstan, and Nigeria 188 stakeholders participated in this study: 63 from Kyrgyzstan, 51 from Indonesia, and 74 from Nigeria; majority were health care workers (110) semi-structured interviews and focus group discussions to assess perceptions on acceptability and feasibility of implementing BPaL feasibility: stakeholders' expectations regarding the practical requirements for
		implementing the BPaL regimen within the context of their health

		system; recorded as overall likelihood of implementing BPaL (likely; neutral; unlikely) Findings • Feasibility: 88% (146/166) of the stakeholders would likely implement BPaL once available • Stakeholders • appreciated that BPaL would reduce workload and financial burden on the health care system • expressed concerns regarding BPaL safety (monitoring), long-term efficacy, and national regulatory requirements • stressed the importance of addressing current health systems constraints as well, especially in treatment and safety monitoring systems Analyses from van de Berg paper not applicable for sub-PICO 5.3 since in their study they asked about feasibility of introducing BPaL for pre-XDR patients and when compared to the long WHO regimen.
PHC/ADULT HOSPIT	AL LEVEL COMMITTEE	
 No Probably no x Probably yes Yes Varies Don't know 	All research presented by the WHO GDG was considered by the ERC. The ERC also considered the impact of Pretomanid stock availability on feasibility of implementation of the regimen, and was reassured by the NDoH TB programme that stock and funding for drug costs is available, and that no supply issues are expected. The ERC also considered the need for enhanced pharmacovigilance to accompany implementation of the intervention. The ERC heard from the NDOH TB programme that feasibility could be impacted if the level of prescriber be restricted to medical officer only, as clinical nurse practitioners and clinical associates are important human resources for decentralized care. The ERC judged that the intervention is probably feasible to implement.	

Version	Date	Reviewer(s)	Recommendation and Rationale
Initial	23 March 2023	FB, NN, GM,	Initial ERC discussion took place on 16 th March 2023, with ongoing discussion and updated ERC decision at an extraordinary meeting of the ERC on 23 March 2023, where a conditional recommendation for the use of the BPaL in the treatment of drug resistant TB with or without fluoroquinolone resistance was suggested. The recommendation is conditional based on the very low quality of evidence underlying the WHO recommendation.

b) Is BPaLM (intervention 2) non-inferior to, and/or safer than the South African standard of care (comparator 1 and 2) in the treatment of adults with rifampicin-resistant tuberculosis without additional fluoroquinolone resistance?


Should BPaLM vs. local SoC regimens (TB-PRACTECAL comparator) be used for pulmonary MDR/RR-TB or pre-XDR-TB? (WHO Sub-PICO 6.1)

(Note: Where judgements differed, both WHO and PHC/Adult Hospital Level's assessments have been described)

JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
• WHO Guideline	e panel	
 No Probably no Probably yes X Yes Varies Don't know 	Research evidenceThe COVID-19 pandemic has reversed years of progress in providing essential TB services and reducing TB disease burden. The most obvious impact is a large global drop in the number of people newly diagnosed with TB and reported. This fell from 7.1 million in 2019 to 5.8 million in 2020, an 18% decline back to the level of 2012 and far short of the approximately 10 million people who developed TB in 2020.Reduced access to TB diagnosis and treatment has resulted in an increase in TB deaths. Best estimates for 2020 are 1.3 million TB deaths among HIV- negative people (up from 1.2 million in 2019) and an additional 214 000 among HIV-positive people (up from 209 000 in 2019), with the combined total back to the level of 2017.Other impacts include reductions between 2019 and 2020 in the number of people provided with treatment for drug-resistant TB (-15%, from 177 100 to 150 359, about 1 in 3 of those in need).Globally in 2020, 71% (2.1/3.0 million) of people diagnosed with bacteriologically confirmed pulmonary TB were tested for rifampicin resistance, up from 61% (2.2/3.6 million) in 2019 and 50% (1.7/3.4 million) in 2018. Among these, 132 222 case of MDR/RR-TB and 25 681 cases of pre-XDR-TB or XDR-TB were detected, for a combined total of 157 903. This was a large fall (of 22%) from the total of 201 997 people detected with drug-resistant TB in 2019, consistent with similarly large reductions in the total number of people newly diagnosed with B (18%) and the total number of people diagnosed with bacteriologically confirmed pulmonary TB (17%) observed between 2019 and 2020. Worldwide, 150 359 people with MDR/RR-TB were enrolled on treatment in 2020, down 15% from the total of 177 100 in 2019. This level of enrolment was equivalent to about one in three of the people who develop MDR/RR-TB each year.More positively, there have been improvements in treatm	Drug-resistant TB is a global challenge and access to treatment often problematic, with regimens typically being long, toxic, and expensive. More efficacious and shorter treatmen regimens for DR-TB are necessary to optimize and improve treatment outcomes while minimizing adverse events and preventing acquisition of additional drug resistance.

 No Probably no Probably yes X Yes Varies Don't know 	In addition to the research evidence considered by the WHO GDG, the ERC considered the burden of disease in the locally relevant population. A cross- sectional study of identified tuberculosis cases, conducted in South Africa between 2012 and 2014, reported the prevalence of RR-TB as 4.6%, MDR-TB as 2.8% (95% CI 2.0, 3.6) and the prevalence of XDR-TB as 4.9% (95% CI 1.0, 8.8). (Ismail et al. 2018). More recently for the year 2021, the WHO reported an estimated 21 000 incident cases of RR-TB in South Africa. (WHO Global Tuberculosis Report, 2022) The ERC judged the problem to be a priority.	
Desirable effects: H	Iow substantial are the desirable anticipated effects?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
• WHO Guideline pa	nel	
 Trivial Small Moderate X Large Varies Don't know 	Research evidence The BPaLM regimen arm of the TB-PRACTECAL trial with population including patients with MDR/RR-TB or pre-XDR-TB patients treated with multiple local SoC regimens (including: 9-12-month injectable containing regimen; 18-24-month long WHO regimen (pre-2019); 9-12 month all oral regimen; 18- 20 month all oral regimen). Participants with MDR/RR-TB (with or without quinolone resistance) receiving BPaLM regimen (n=62) compared to participants receiving WHO recommended standard of care regimens used in TB-PRACTECAL trial (n=66) experienced higher levels of tratument success (89% vs 25%), i.e. 73% relative increase (aRR-173, 95%CI 1.31 to 2.27); lower levels of failure and recurrence (8% vs 26%) i.e. 74% relative reduction (aRR=0.26, 95%CI 1.01 to 0.17); lower levels of death (0% vs 3%), i.e. 3% absolute reduction (RD=-0.03, 95%CI -0.1 to 0.03;) lower levels of follow-up (3% vs 20%), i.e. 84% of 0.61) and lower levels of amplified resistance (0% vs 2%), i.e. 2% absolute reduction (RD=-0.02, 95%CI -0.07 to 0.02). BPaLM may improve treatment success, failure and recurrence, death, loss to follow-up, amplification of drug-resistance and adverse events but the evidence is very uncertain. Considering this research evidence and the additional considerations, the GDG judged that BPaLM may have large desirable effects and noted the very low certainty of the evidence.	The panel also considered the duration and pill burden with the intervention and comparator regimens. The duration of the intervention regimen is 24 weeks (5.5 months) so treatment duration is reduced compared to the control arm by between 3–18 months. The exact magnitude of reduction in time on treatment depends on the specific comparator regimen, which includes shorter (9–12 months) and longer (18– 24 months) regimens. The pill burden of the intervention regimen is lower than that for the comparator regimens. The exact magnitude of reduction in pill burden depends on the specific comparator regimen. Beyond the outcomes captured directly as research evidence in the presented statistical analyses, the WHO 'Target Regimen Profile for rifampicin-resistant tuberculosis' (WHO, 2016) identified certain regimen characteristics as having desirable anticipated effects. These include a shorter treatment duration, reduced pill burden and number of component drugs and manageable DDIs. Decrease in the treatment duration was therefore identified as an additional important desirable effect.

	Nº of participants	Certainty of the	Relative		osolute effects* % CI)		
Outcomes	(studies) Follow-up	evidence (GRADE)	effect (95% CI)	Risk with TB-PRACTECAL comparator	Risk difference with BPaLM		
Treatment success	128 (1 RCT)	HOOO Very low ^{abcdefg}	RR 1.73 (1.31 to 2.27)	Study po 515 per 1 000	376 more per 1000 (160 more to 654 more)		
Failure and recurrence	128 (1 RCT)	HOOO Very low ^{abcdefg}	RR 0.26 (0.10 to 0.71)	Study po 258 per 1 000	opulation 191 fewer per 1000 (232 fewer to 75 fewer)		
Lost to follow up	128 (1 RCT)	⊕OOO Very low ^{ahodatg}	RR 0.16 (0.04 to 0.61)	Study po 197 per 1 000			
Adverse events	213 (1 RCT)	⊕OOO Very low ^{ahotete}	RR 0.41 (0.26 to 0.63)	Study po 509 per 1 000			
	1	Nº of participants	Cert	ainty of the	Relative	Anticipated ab (95%	
Outcomes		(studies) Follow-up	e	GRADE)	effect (95% CI)	Risk with TB-PRACTECAL comparator	Risk difference with BPaLM
Amplification	n of	of 213		000	RD -0.02	Study po	pulation
drug resistan	ce	(1 RCT)	Very	y low ^{ab,cd,e} ig	(-0.07 to 0.02)	19 per 1000	19 fewer per 1000 (20 fewer to 18 fewer)
Death		128	đ	000	RD -0.03	Study po	pulation
		(1 RCT)	Verj	y low ^{shotelg}	(-0.10 to 0.03)	30 per 1 000	31 fewer per 1000 (33 fewer to 29 fewer)



Interven	tion	BPaLM (FQ-r) TB-PRACTECAL									
		~~~~									
				WHO long (FQ-r) - IPD 2021 (multiple cohorts, all-oral regimens co							
Time of	follow-up	1	18 months post treatment initiation								
Į	Regimens		Outcom	e measures				Propensity score mode			
	BPalM	WHO long	Unadj. RR	(95% CI)	Adj. RR (or RD)	(95% CI)	p-value	Covariates included in r			
1	n (%)	n (%)									
Total	11	839									
Outcomes											
Treatment success	9 (82%)	625 (74%	1.1	(0.7, 1.28)	1.11	(0.84, 1.45)	0.4732	Age, sex, HIV status, ART trea AFB smear, previous DRTB			
Failure & recurrence	2 (18%)	55 (7%	2.77	(0.77, 7.63)			0.1647				
Death	0 (0%)	83 (10%	.0.10	(-0.12, 0.16, RD)			0.613				
Loss to follow-up	0 (0%)	76 (9%	) -0.09	(-0.11, 0.17, RD)			0.612				
Grade 3 or more AE	5/18 (28%)	37 (4%	) 6.3	(2.81, 14.14)	5.78	(2.39, 14.01)	0.0001				
Amplified resistance	0/18 (0%)	62 (7%	-0.07	(-0.09, 0.1)RD			1				
shortened re and analysis compared to	gimen with reduced	pill burden, jı sists of too fe ard or care re	udged the d ew participa egimens spe	esirable effects to ints to show any o	be large. T	his judgemen	t considers	PRACTECAL, as well as the that the sub-group analysis at population only or when			
ion oubotainth		anticipatoa ono									

• WHO Guideline	panel	
<b>X Trivial</b> • Small	Research Evidence	Additional considerations
<ul> <li>Moderate</li> <li>Large</li> <li>Varies</li> <li>Don't know</li> </ul>	SoC regimens (including: 9–12-month injectable containing regimen; 18–24-month long WHO regimen (pre-2019); 9–12 month all oral regimen; 18–20 month all oral regimen).	Considering this research evidence and
	Participants with MDR/RR-TB (with or without quinolone resistance) receiving BPaLM regimen (n=62) compared to participants receiving WHO recommended standard of care regimens used in TB-PRACTECAL trial (n=66) experienced higher levels of treatment success (89% vs 52%), i.e. 73% relative increase (aRR=1.73, 95%CI 1.31 to 2.27); lower levels of failure and recurrence (8% vs 26%) i.e. 74% relative reduction (aRR=0.26, 95%CI 0.1 to 0.71); lower levels of death (0% vs 3%), i.e. 3% absolute reduction (RD= 0.03, 95%CI 0.1 to 0.03); lower levels of loss to follow-up (3% vs 20%), i.e. 84% of relative reduction (RR=0.16, 95%CI 0.12 to 0.52); lower levels of grade 3 to 5 adverse events (21% vs 51%), i.e. 59% relative reduction (aRR=0.41, 95%CI 0.04 to 0.61) and lower levels of amplified resistance (0% vs 2%), i.e. 2% absolute reduction (RD= 0.02, 95%CI 0.07 to 0.02).	
	BPaLM may improve treatment success, failure and recurrence, death, loss to follow-up, amplification of drug-resistance and adverse events but the evidence is very uncertain.	
	There were no undesirable effects among the specified outcomes Pretomanid safety	
	Rodent Toxicology Studies – evidence of direct testicular toxicity Monkey Toxicology Studies – no evidence of direct testicular toxicity; abnormal sperm findings considered to be secondary to declining physical condition Hormone Data from Clinical Studies – no changes in FSH, LH, Inhibin B consistent with testicular toxicity Paternity Survey – 44 children fathered by 38 men (12%) who participated in pretomanid studies of 4 -6 months treatment duration Semen Study – ongoing study measuring semen in men undergoing pretomanid treatment.	
PHC/ADULT HC	SPITAL LEVEL COMMITTEE'S JUDGEMENT	
x Trivial • Small • Moderate • Large • Varies • Don't know	Subgroup analysis of safety by country: Less SAE or Grade ≥ 3 were reported for in South African participants receiving BPaLM than those receiving South African standard of care regimes (16.1% vs 49.1%; RD -33.0%; 95% CI -50.9 to -15.1%)	The ERC noted that only one RCT with a very small sample size contributed to the data relating to efficacy and safety of BPaLM. However, this should be considered in light of the fact that current and previous standard of care regimens for the treatment of drug resistant TB were based on even less evidence . The ERC noted that the limitations of the available evidence and the resulting Imprecision do not prohibit a recommendation.

Country		BOC BPath	BPate	BPat	
BY	n	29	28	21	21
	Grade 23 or SAE	9	4	6	5
	N	31.0%	14.3%	28.6%	23.8%
	Risk difference	0	-16.7%	-2.5%	-26.0%
	lower		-39.7%	-28.1%	-39.0%
	upper		6.2%	23.2%	-13.0%
UZ	n	69	67	57	55
	Grade ≥3 or SAE	37	21	19	13
	w	53.6%	31.3%	33.3%	23.6%
	Risk difference	0	-22.3%	-20.3%	-19.5%
	lower		-39.8%	-37.3%	-39.9%
	upper		-4.8%	-3.3%	0.99
SA	n	53	56	48	46
	Grade ≥3 or SAE	26	9	13	11
	*	49.1%	16.1%	27.1%	23.9%
	Risk difference	0	-33.0%	-16.0%	-22.0%
	lower		-50.9%	-37.9%	-40.4%
	upper		-15.1%	5.8%	0.9%


From WHO presentation of sub-PICO 7.1 (BPaLM (fluoroquinolone -resistant) vs WHO_long (fluoroquinolone-resistant) – IPD 2021) sent by Gregory Fox: Based upon the point estimates with wide confidence intervals crossing no effect, BPaLM was associated with higher rates of failure/recurrence (unadjusted RR 2.77, 95% CI 0.77, 7.63), lower mortality (RD - 0.10; 95% CI -0.12, 0.16), less loss to follow-up (RD -0.09; 95% CI -0.11, 0.17). BPaLM was associated with more Grade  $\geq$  3 adverse events (adjusted RR 5.78; 95% CI 2.39, 14.01). (Certainty of evidence very low for all outcomes)

ntervention BPaLM (FQ-r) TB-PRACTECAL					CIECA	L.			
Comparator WHO long (FQ-r) - IPD 2021 (multiple cohorts, all-oral regimens conta						(FQ-r) - IPD 2021 (multiple cohorts, all-oral regimens containing Bdg)			
Time of fo	ollow-up	1	18 mont	hs post treat	ment ini	tiation			
	Regimens		Outcom	e measures				Propensity score model	
	BPalM	WHO long	Unad). RR	(95% CI)	Adj. RR (or RD)	(95% CI)	p-value	Covariates included in model	
	n (%)	n (%)							
lotal Outcomes	11	839							
Freatment luccess	9 (82%)	625 (74%)	1.1	(0.7, 1.28)	1.11	(0.84, 1.45)		Age, sex, HIV status, ART treatment (for those with HIV), AFB smear, previous DRTB treatment, site of disease	
failure & recurrence	2 (18%)	55 (7%)	2.77	(0.77, 7.63)			0.1647	Adjustment not possible	
Death	0 (0%)	83 (10%)	-0.10	(-0.12, 0.16, RD)			0.613	Adjustment not possible	
oss to follow-up	0 (0%)	76 (9%)	-0.09	(-0.11, 0.17, RD)			0.612	Adjustment not possible	
Grade 3 or nore AE	5/18 (28%)	37 (4%)	6.3	(2.81, 14.14)	5.78	(2.39, 14.01)	0.0001		
Amplified resistance	0/18 (0%)	62 (7%)	-0.07	(-0.09, 0.1)RD			1	Adjustment not possible	


OGEMENT	RESEARC	H EVID	ENCE		ADDITIONAL CONSIDERATIONS
WHO Guideline	panel				
Very low Low Moderate High No included studies	Research The certa early tern some com downgrad to outcom	As noted in the CoE assessment, it important to highlight that: • the population included the trial that gave rise t data is a mix of MDR/RI pre-XDR/XDR TB patien (82–92% RR/MDR,			
	Batterne Later	Line of the second seco	BOOOD Wry teathorne		<ul> <li>depending on study arr treatment outcomes fo comparator regimen di</li> </ul>
	follow and television	13 (1.875	BOOO Wry topentia		for these populations, and that • 24% of patients were trea with regimens no longer recommended by WHO, e. containing injectable drug and not containing Bdq
	Death	ara	0000 Wy 0000		
	Laitti filex a	128 () 401)	90000 W		
	Aught day of	20 0.00	@000		
	adjusted b. Small r c. A lack c in the cor d. The tri 2013). e. Multipl outcomes inconsist f. A single comparat g. The nu	analyse umber if blindi nparato al was e comp s seen s seen trial. S or regi	s will acco s of events ng of patio or group, v stopped e arator reg between o the issue erious ind mens are s	ured covariates (gender, prior DR-TB, smear status) likely arises from the small number of participants in each group. While the ount for measured confounding, unmeasured confounding is also likely. Is in some outcomes precludes adjustment in some comparisons. It is an outcome that may be influenced by patient or clinician knowledge of the regimen. It is an outcome that may be influenced by patient or clinician knowledge of the regimen. It is an outcome that may be influenced by patient or clinician knowledge of the regimen. It is an outcome that may be influenced by patient or clinician knowledge of the regimen. It is an outcome that may be influenced by patient or clinician knowledge of the regimen. It is an outcome that may be influenced by patient or clinician knowledge of the regimen. It is an outcome that may be influenced by patient or clinician knowledge of the regimen. It is an outcome that may be influenced by patient or clinician knowledge of the regimen. It is an outcome that may be influenced by patient or clinician knowledge of the regimen. It is an outcome that may be influenced by patient or clinician knowledge of the regimen. It is an outcome that may be influenced by patient or clinician knowledge of the regimen. It is an outcome that may be influences in patient or clinician knowledge of the regimen. It is an outcome that may be influences in population of a trial and population to which guidelines will apply. (ii) Comparator: Some sub-optimal, not according with the WHO standard of care (at the time or presently) and vary by country. Downgraded one level. It is both intervention and comparator groups was small (n=60 and n=66). Very few events in the outcomes of interest, causing We downgraded two levels for imprecision for some outcomes, and one level for others.	

<ul> <li>X Very low</li> <li>Low</li> <li>Moderate</li> <li>High</li> <li>No included studies</li> </ul>	No additional research evidence was provided. The ERC agreed with the judgment that the certainty of evidence is very low.	
Values: Is there impor	tant uncertainty about or variability in how much people value the main outcomes?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
WHO Guideline p	panel	
<ul> <li>Important uncertainty or variability</li> <li>Possibly important uncertainty or variability</li> <li>X Probably no important uncertainty or variability</li> <li>No important uncertainty or variability</li> <li>No known undesirable outcomes</li> </ul>	Research Evidence No evidence research searched for. Higher treatment efficacy, shorter duration of treatment, lower pill burden and less adverse events are usually valued by patients. The panel judged that there was probably no important uncertainty or variability in how much people value the main outcomes.	
• PHC/ADULT HOSP	ITAL LEVEL COMMITTEE'S JUDGEMENT	
<ul> <li>Important uncertainty or variability</li> <li>Possibly important uncertainty or variability</li> <li>X Probably no important uncertainty or variability</li> <li>No important uncertainty or variability</li> <li>No known undesirable outcomes</li> </ul>	No additional research was searched for by the review team. The ERC agreed with the WHO GDG judgement that there is probably no important uncertainty or variability in how much people value the main outcomes.	
Balance of effects: [	Does the balance between desirable and undesirable effects favour the intervention or the comparison?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
• WHO Guideline p	panel	
Adolopment_	_WHO_DRTB_Guidelines_4May2023_Final 52	

<ul> <li>Favours the comparison</li> </ul>	Research Evidence	As noted in the CoE assessment, it is important to highlight that:
<ul> <li>Probably favours the comparison</li> <li>Does not favour either the intervention or the comparison</li> </ul>	Nil The GDG judged the benefits of BPaLM to be large and the undesirable effects to be trivial compared to WHO recommended standard of care regimens. The certainty of evidence was judged to be very low. Based on this, the panel determined that the balance of health effects probably favours BPaLM regimen	<ul> <li>the population included in the trial that gave rise to the data is a mix of MDR/RR and pre-XDR/XDR TB patients (82–92% RR/MDR, depending on study arm)</li> </ul>
x Probably favours the intervention • Favours the intervention • Varies		<ul> <li>treatment outcomes for the comparator regimen differ for these populations, and that</li> </ul>
○ Don't know		• 24% of patients were treated with regimens no longer recommended by WHO, e.g., containing injectable drugs and not containing Bdq
		As a result, the balance of effects may be different in settings/populations with different FQ-resistance prevalence and if only currently recommended regimens are used.
PHC/ADULT HOSP	ITAL LEVEL COMMITTEE	
<ul> <li>Favours the comparison</li> <li>Probably favours the comparison</li> <li>Does not favour either the intervention or the comparison</li> <li><b>x Probably favours the intervention</b></li> <li>Favours the intervention</li> <li>Varies</li> <li>Don't know</li> </ul>	The ERC considered that even if the benefits of BPaLM in comparison to South African SoC specifically are smaller than in the comparison of BPaLM to SoC arm in TB-PRACTECAL, the shortened duration of treatment and less complex treatment regimen that may favour adherence probably favours the intervention.	
Resources required	: How large are the resource requirements (costs)?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
• WHO Guideline p	panel	



	Total costs per		Incremental Costs
Country and regimen Philippines	person To	otal DALYs	per person
Philippines			
SOC long	\$2,127	6.2	Name I.
SOC short	\$1,286	5.1	-\$841
BPaL	\$1,050	5.1	-\$236
BPaLC	\$1,146	5.0	-\$236 \$96 -\$47
BPaLM	\$1,099	4.4	-547
South Africa			
SOC long	\$6,896 \$4,120	6.9	
SOC short	\$4,120	6.3	-\$2,776
BPaL	\$3,554	6.3	-\$366
BPaLC	\$3,687	6.2	\$132 \$52
BPaLM	\$3,739	5.7	\$52
India			
SOC long	\$1,531	6.8	
SOC short	\$923	6.1	-\$608
BPaL	\$838 \$923	6.1 6.0	-584
BPaLC	\$923	6.0	\$85
BPaLM	\$872	5.5	-584 583 -531
Georgia			
SOC long	\$4,499	4.7	
SOC short	\$3,290	4.1	-\$1,209 -\$123
BPaL	\$3,164	4.1	-\$123
BPaLC	\$3,264	4.0	\$100
BPaLM	\$3,246	3.3	-\$19



	Appendix 3.xisx							
		Normati	ve cost analysis based on spe	cific direct costs			Sensitivity analysis excl.clinic vist costs	
	<u>[</u>							
	Regimen	Drug costs (ZAR)	Bacteriological tests (Costs in ZAR)	Other lab tests (Costs in ZAR)	Clinic visit costs (ZAR)		Total costs per patient treated excl. clinic visit costs (ZAR)	
	Short oral course (Min)	11 437,70	1 058,58	472,42	2 680,79	15 649,49	12 968,70	
	Short oral course (Max) BPaL (Lzd_Adjusted dose)	13 650,99 11 710,64	1 058,58 705,72	472,42 2 158,89				
	BPaLM (Lzd_Adjusted close)	12 307,88	705,72	2 158,89				
	BPsLM (Lad_Standard)	11 787,08	705,72	2 158,89				
	Long course 1 (Basic) Long course 2	27 159,15 49 601,58	2 117,16	783,55 2 028,07				
	tong course a	43 001,30	2 117,10	2 020,07	0 361/40	00 320,22	55 740,81	
	Note: When weight calibrated desing is recommended, db 1.055 equivalent to 818.50 Dag calculations all hased on a 28 day tycle per mor Diagnostic Agent, microscopy, culture and DBT ont into Clinic visits classified according to nature of clinical v	uth fudled in costs for bacteriological tests						
	Marginally increased drug costs a costs of treatment monitoring lab- which is not entirely offset by the Based on the normative cost ana	oratory tests (such as monthl reduced number of bacterio	y full blood and differen logical treatment monito	tial counts as recomm	end by WHO) driving t	he increased direct cost		
	associated with negligible costs and with large savings.	nd/or savings. BPaLM when	compared to the curren	t South African long c	ourses (for MDR and fl			
Certainty of evidence	associated with negligible costs a	nd/or savings. BPaLM when	compared to the curren	t South African long c	ourses (for MDR and fl			
Certainty of evidence	associated with negligible costs and with large savings.	nd/or savings. BPaLM when	compared to the curren	t South African long c	ourses (for MDR and fl			
	associated with negligible costs as with large savings. e of resource requirements: V RESEARCH EVIDENCE	nd/or savings. BPaLM when	compared to the curren	t South African long c	ourses (for MDR and fl			
JUDGEMENT  WHO Guideline  x Very low	associated with negligible costs as with large savings. e of resource requirements: V RESEARCH EVIDENCE	nd/or savings. BPaLM when	compared to the curren	t South African long c	ourses (for MDR and fl			
JUDGEMENT  • WHO Guideline  x Very low  • Low	associated with negligible costs and with large savings. e of resource requirements: V RESEARCH EVIDENCE panel	nd/or savings. BPaLM when	compared to the curren	t South African long c	ourses (for MDR and fl			
JUDGEMENT  WHO Guideline	associated with negligible costs and with large savings. e of resource requirements: V RESEARCH EVIDENCE panel	nd/or savings. BPaLM when	compared to the curren	t South African long c	ourses (for MDR and fl			
JUDGEMENT • WHO Guideline j x Very low • Low • Moderate • High	associated with negligible costs and with large savings. c of resource requirements: V RESEARCH EVIDENCE panel Research Evidence	nd/or savings. BPaLM when	compared to the curren	t South African long c	ourses (for MDR and fl			
JUDGEMENT  WHO Guideline  X Very low  Low	associated with negligible costs and with large savings. c of resource requirements: V RESEARCH EVIDENCE panel Research Evidence	nd/or savings. BPaLM when	compared to the curren	t South African long c	ourses (for MDR and fl			
JUDGEMENT • WHO Guideline p • Low • Low • Moderate • High • No included studies	associated with negligible costs and with large savings. c of resource requirements: V RESEARCH EVIDENCE panel Research Evidence	nd/or savings. BPaLM when	compared to the curren	t South African long c	ourses (for MDR and fl			
JUDGEMENT • WHO Guideline p x Very low • Low • Moderate • High • No included studies • PHC/ADULT HOSE	associated with negligible costs as with large savings. c of resource requirements: V RESEARCH EVIDENCE panel Research Evidence Nil PITAL LEVEL COMMITTEE	nd/or savings. BPaLM when	compared to the curren	t South African long c	ourses (for MDR and fl	uoroquinolone resistan	ces) would be associated	
JUDGEMENT • WHO Guideline p x Very low • Low • Moderate • High • No included studies • PHC/ADULT HOSF • Very low	associated with negligible costs as with large savings. cof resource requirements: V RESEARCH EVIDENCE panel Research Evidence Nil PITAL LEVEL COMMITTEE The ERC considered the cert	nd/or savings. BPaLM when	compared to the curren	t South African long c	ourses (for MDR and fl	uoroquinolone resistan	ces) would be associated	
JUDGEMENT • WHO Guideline p x Very low • Low • Moderate • High • No included studies • PHC/ADULT HOSE • Very low • Low	associated with negligible costs as with large savings. c of resource requirements: V RESEARCH EVIDENCE panel Research Evidence Nil PITAL LEVEL COMMITTEE	nd/or savings. BPaLM when	compared to the curren	t South African long c	ourses (for MDR and fl	uoroquinolone resistan	ces) would be associated	
JUDGEMENT • WHO Guideline p × Very low • Low • Moderate • High • No included studies • PHC/ADULT HOSE • Very low • Low × Moderate	associated with negligible costs as with large savings. cof resource requirements: V RESEARCH EVIDENCE panel Research Evidence Nil PITAL LEVEL COMMITTEE The ERC considered the cert	nd/or savings. BPaLM when	compared to the curren	t South African long c	ourses (for MDR and fl	uoroquinolone resistan	ces) would be associated	
JUDGEMENT • WHO Guideline p x Very low • Low • Moderate • High • No included studies • PHC/ADULT HOSF • Very low • Low	associated with negligible costs as with large savings. cof resource requirements: V RESEARCH EVIDENCE panel Research Evidence Nil PITAL LEVEL COMMITTEE The ERC considered the cert	nd/or savings. BPaLM when	compared to the curren	t South African long c	ourses (for MDR and fl	uoroquinolone resistan	ces) would be associated	

#### **Cost effectiveness:** Does the cost-effectiveness of the intervention favor the intervention or the comparison? JUDGEMENT **RESEARCH EVIDENCE** ADDITIONAL CONSIDERATIONS

•	WHO	Guideline	panel
---	-----	-----------	-------

• Favours the comparison • Probably favours the comparison • Does not favour either the intervention or the comparison intervention Favours the

## **Research Evidence**

Poculte by country

PICO

### Sedona Sweeney's presentation on cost & CEA of PRACTECAL regimens from pre-GDG webinar

From the data presented: «strong evidence that BPaLM would be cost-effective» in the setting studied (costs reduced and DALYs averted) Note that estimates of effectiveness (from which DALYs averted were derived) are different from those presented in the evidence profile for this

### x Probably favours the

intervention

Varies

~ N	In i	nclud	ad at	diag
	401	nciua	eu siu	luies

Country and regimen	Total costs per person	Totel DALVS	Incremental Costs per person	Incremental DALYs Averted Per Person	per DALY
Philippines	100				
SOC long	\$2,127	6.2			
SOC short	\$1,286		-5841	1.04	Dominant
SPaL	\$1,050	5.1	-\$236	0.00	Dominant
PalC	\$1,146	5.0	\$96	0.11	\$867
BFaLM	\$1,099	4.4	-\$47	0.62	Dominant
South Africa					
SOC long	\$6,896	6.9			
SOC short	\$4,120	6.3	-\$2,776	0.57	Dominant
BPaL	\$3,334	6.3	-\$566	0.00	Dominant
BPaLC	\$3,687	6.2	\$132	0.10	\$1,375
BPaLM	\$3,739	5.7	\$52	0.54	\$97
India					
SOC long	\$1,531	6.8			
SOC short	\$923	6.1	-\$608	0.70	Dominant
BPaL	\$838	6.1	-584	-0.04	Dominant
BFaLC	\$923	6.0	\$85	0.10	\$838
BPaLM	\$872	3.5	-551	0.57	Dominant
Georgia					
SOC long	\$4,499	4.7			
OC short	\$3,290	4.1	-\$1,209	0.57	Dominant
BPaL	\$3,164	4.1	-\$125	0.02	Dominant
BPaLC	\$3,264	4.0	\$100	0.12	\$833
BFaLM	\$3,246	3.3	-\$19	0.67	Dominant

conconvative approa

Given their prior judgements (balance of effects probably favours the intervention; intervention leads to moderate to large savings), the panel judged that the cost-effectiveness of the intervention probably favours the intervention

### • PHC/ADULT HOSPITAL LEVEL COMMITTEE

No additional research evidence was considered by the ERC. Based on the data and studies considered by WHO GDG, the ERC agreed that cost-effectiveness Favours the comparison of the intervention probably favours the intervention. • Probably favours the comparison Does not favour either the intervention or the

comparison <b>x Probably favours the</b> <b>intervention</b> • Favours the intervention • Varies • No included studies								
<b>Equity:</b> What would b	e the impact on health equity?							
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS						
• WHO Guideline pa	nel							
<ul> <li>Reduced</li> <li>Probably reduced</li> <li>Probably no impact</li> <li><b>x Probably increased</b></li> <li>Increased</li> <li>Varies</li> <li>Don't know</li> </ul>	Research Evidence No research evidence searched for. Despite not being able to identify relevant research evidence, the panel used their collective experience to judge that there would likely be advantages associated with the use of the BPaLM regimen due to its reduced complexity and shorter duration. The panel judged that use of the BPaLM regimen would probably increase equity.	The panel considered the treatment duration and the ability to decentralize treatment (to enable access for remote, underserviced settings and disadvantaged populations) to affect equity.						
PHC/ADULT HOSP	ITAL LEVEL COMMITTEE							
<ul> <li>Reduced</li> <li>Probably reduced</li> <li>Probably no impact</li> <li>X Probably increased</li> <li>Increased</li> <li>Varies</li> <li>Don't know</li> </ul>	No additional research evidence was considered by the ERC. The ERC was in agreement with the WHO GDG that due to the reduced complexity and shorter duration of the treatment regimen with resultant ability to decentralize care, the use of BPaLM would probably increase equity.							
Acceptability: Is the	Acceptability: Is the intervention acceptable to key stakeholders?							
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS						
WHO Guideline	WHO Guideline panel							
<ul> <li>No</li> <li>Probably no</li> <li>x Probably yes</li> <li>Yes</li> <li>Varies</li> <li>Don't know</li> </ul>	Research Evidence Beverly Stringer's presentation on PROs from pre-GDG webinar (qualitative study) on the patient perspective Positive impact of shorter treatment on employment status welcomed.	<ul> <li>van de Berg et al, 2021 (based on 2019 KNCV report, funded by TB Alliance) on the provider perspective:         <ul> <li>Noting that analyses from van de Berg paper are only partially applicable here since in their study they asked about acceptability of using</li> </ul> </li> </ul>						

	The panel considered patients and health care providers as key stakeholders. The panel considered the following aspects as critical with regards to acceptability: regimen duration and drug safety monitoring needs (both relating to necessary travel, loss of income and general disruption of the life of patients; workload for the health care system), needs for drug susceptibility testing. The panel judged that the BPaLM regimen would probably be acceptable.	<ul> <li>BPaL for pre-XDR patients and when compared to the long WHO regimen.</li> <li>Findings: Acceptability: overall high and rated as acceptable by &gt;80% across domains</li> </ul>
• PHC/ADULT HOS	PITAL LEVEL COMMITTEE	
<ul> <li>No</li> <li>Probably no</li> <li>X Probably yes</li> <li>Yes</li> <li>Varies</li> <li>Don't know</li> </ul>	Additional Research Evidence presented to the ERC by TB-PRACTECAL-PRO team:         All trial participants respiratory-specific QOL scores improved with treatment, irrespective of the regimen they received (intervention or SoC).         However, faster improvement in the investigational arm as compared to SoC was noted. It was noted that a participant in the intervention arm experiences a 15% reduction (95% CI 12 to 18%) in the mean SGRQ symptom score per month versus an average of 5% (95% CI 0 – 9%) reduction experienced by a participant in the SoC arm. (Note: lower SGRQ symptom score associated with greater quality of life). The qualitative data showed that the improvement in QOL was noted by both the individual and their friends/family, with a resultant positive effect on treatment support.         It was highlighted that South African participants were slightly underrepresented in the trial (32 South Africans of 137 participants) and that no subgroup analysis of QOL outcomes across countries or by site was performed.         For participants interviewed in this qualitative study, the supportive care experienced was as important as the tolerability of the novel drug regimen.         The ERC concluded that based on the research considered by the WHO GDG and additional information form the TB-PRACTECAL-PRO team the intervention is probably acceptable to stakeholders.	
Feasibility: Is the ir	tervention feasible to implement?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
WHO GUIDELINE	S, 2020	
• No		
<ul> <li>Probably no</li> <li><b>X Probably yes</b></li> <li>Yes</li> <li>Varies</li> <li>Don't know</li> </ul>	Nil additional The panel considered the following aspects to affect feasibility (i.e. to be potential barriers to implementation): requirements for drug safety monitoring and requirements for drug susceptibility testing.	van de Berg et al, 2021 (based on 2019 KNCV report, funded by TB Alliance) on the provider perspective: Noting that analyses from van de Berg paper are only partially applicable here since in their study they asked about feasibility of using BPaL for pre-XDR patients and when compared to the long WHO regimen.
<b>x Probably yes</b> • Yes • Varies • Don't know	Nil additional The panel considered the following aspects to affect feasibility (i.e. to be potential barriers to implementation): requirements for drug safety monitoring and requirements for drug susceptibility testing. The panel noted limited availability of drugs in the BPaLM regimen for use in DST as a potential barrier to implementation and also noted that data on the critical concentration of Pretomanid for use in DST is limited.	KNCV report, funded by TB Alliance) on the provider perspective: Noting that analyses from van de Berg paper are only partially applicable here since in their study they asked about feasibility of using BPaL for pre-XDR patients and when compared to the long

<ul><li>○ Varies</li><li>○ Don't know</li></ul>	With regard to the impact of drug resistance testing on the feasibility of implementation, the ERC heard that resistance testing for Bdq and Linezolid is already available, and provisions for resistance testing for pretomanid are being made.	
	The ERC heard from the NDOH TB programme that feasibility could be impacted if the level of prescriber be restricted to medical officer only, as clinical nurse practitioners and clinical associates are important human resources for decentralized care.	
	After consideration of these potential barriers to implementation, the ERC judged that BPaLM is probably feasible to implement.	

Version	Date	Reviewer(s)	Recommendation and Rationale
Initial	23 March 2023	FB, NN, GM,	Initial ERC discussion took place on 16 th March 2023, with ongoing discussion and updated ERC decision at an extraordinary meeting of the ERC on 23 March 2023, where a conditional recommendation for the use of the BPaLM in the treatment of drug resistant TB with or without fluoroquinolone resistance was suggested. The recommendation is conditional based on the very low quality of evidence underlying the WHO recommendation.

c) Is BPaL (intervention 1) non-inferior to, and/or safer than BPaLM (intervention 2) in the treatment of rifampicin-resistant tuberculosis without additional fluoroquinolone resistance?

### Should BPaLM vs. BPaL (Linezolid 600mg/300mg) be used for pulmonary MDR/RR-TB and pre-XDR-TB? (sub-PICO 6.2)

(Note: Where judgements differed, both WHO and PHC/Adult Hospital Level's assessments have been described)

Problem: Is the	e problem a priority?						
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS					
• WHO Guide	WHO Guideline panel						
<ul> <li>No</li> <li>Probably no</li> <li>Probably yes</li> <li>X Yes</li> <li>Varies</li> <li>Don't know</li> </ul>	Research evidence         The COVID-19 pandemic has reversed years of progress in providing essential TB services and reducing TB disease burden. The most obvious impact is a large global drop in the number of people newly diagnosed with TB and reported. This fell from 7.1 million in 2019 to 5.8 million in 2020, an 18% decline back to the level of 2012 and far short of the approximately 10 million people who developed TB in 2020.         Reduced access to TB diagnosis and treatment has resulted in an increase in TB deaths. Best estimates for 2020 are 1.3 million TB deaths among HIV-negative people (up from 1.2 million in 2019) and an additional 214 000 among HIV-positive people (up from 209 000 in 2019), with the combined total back to the level of 2017.         Other impacts include reductions between 2019 and 2020 in the number of people provided with treatment for drug-resistant TB (-15%, from 177 100 to 150 359, about 1 in 3 of those in need).         Globally in 2020, 71% (2.1/3.0 million) of people diagnosed with bacteriologically confirmed pulmonary TB were tested for rifampicin resistance, up from 61% (2.2/3.6 million) in 2018. Among these, 132 222 cases of MDR/RR-TB and 25 681 cases of pre-XDR-TB were detected, for a combined total of 557 903. This was a large fall (of 22%) from the total of 201 997 people detected with drug-resistant TB in 2019, consistent with similarly large reductions in the total number of people newly diagnosed with TB (18%) and the total number of people diagnosed with bacteriologically confirmed pulmonary TB (17%) observed between 2019 and 2020. Worldwide, 150 359 people with MDR/RR-TB were enrolled on treatment in 2020, down 15% from the total of 177 100 in 2019. This level of enrolment is a equivalent to about one in three of the people who develop MDR/RR-TB each year.						

	More positively, there have been improvements in treatment success rates. Globally in 2018 (the latest patient cohort for which data are available), the treatment success rate for MDR/RR-TB was 59%, reflecting steady improvements in recent years from 50% in 2012. (Global TB Report 2021)	
• PHC/ADULT	' HOSPITAL LEVEL COMMITTEE'S JUDGEMENT	
<ul> <li>No</li> <li>Probably no</li> <li>Probably yes</li> <li>X Yes</li> <li>Varies</li> <li>Don't know</li> </ul>	In addition to the research evidence considered by the WHO GDG, the ERC considered the burden of disease in the locally relevant population. A cross-sectional study of identified tuberculosis cases, conducted in South Africa between 2012 and 2014, reported the prevalence of RR-TB as 4.6%, MDR-TB as 2.8% (95% CI 2.0, 3.6) and the prevalence of XDR-TB as 4.9% (95% CI 1.0, 8.8). (Ismail et al. 2018). More recently for the year 2021, the WHO reported an estimated 21 000 incident cases of RR-TB in South Africa. (WHO Global Tuberculosis Report, 2022)	
	The ERC judged the problem to be a priority.	
Destrable elle	ects: How substantial are the desirable anticipated effects?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
JUDGEMENT  • WHO Guidel		ADDITIONAL CONSIDERATIONS

	Nº of	C	D. L. C.	Anticipated abso	olute effects* (95% CI)
Outcomes	participants (studies) Follow-up	Certainty of the evidence (GRADE)	Relative effect (95% CI)	Risk with BPaL (Lzd 600mg/300mg)	Risk difference with BPaLM
Treatment	122	000	RR 1.15	Study	population
success	(1 RCT)	Very low ^{a,b,c,d,e,fg}	(0.95 to 1.38)	767 per 1 000	115 more per 1 000 (38 fewer to 291 more)
Failure and	122	000	RR 0.53	Study	population
recurrence	(1 RCT)	Very low ^{a,b,c,d,e,fg}	(0.17 to 1.63)	133 per 1 000	63 fewer per 1 000 (111 fewer to 84 more)
Lost to follow up	122	0000	RR 0.32	Study	population
	(1 RCT)	Very low ^{a,b,c,d,e,tg}	(0.08 to	100 per 1 000	68 fewer per 1000
	(2.1.0.1)	veryion	1.34)		(92 fewer to 34 more)
	Nº of				(92 fewer to 34 more)
Outcomes		Certainty of the evidence (GRADE)	1.34) Relative effect (95% CI)		
<b>Outcomes</b> Death	Nº of participants (studies)	Certainty of the evidence	Relative	Anticipated abso Risk with BPaL (Lzd 600mg/300mg)	lute effects* (95% CI) Risk difference with
	Nº of participants (studies) Follow-up	Certainty of the evidence (GRADE)	Relative effect (95% CI)	Anticipated abso Risk with BPaL (Lzd 600mg/300mg)	lute effects* (95% CI) Risk difference with BPaLM
	Nº of participants (studies) Follow-up 122	Certainty of the evidence (GRADE)	Relative effect (95% CI) RD 0.00 (-0.06 to	Anticipated abso Risk with BPaL (Lzd 600mg/300mg) Study 0 per 1 000	Risk difference with BPaLM population 0 fewer per 1 000

	Considering this the evidence.	s research e	vidence and th	ne addition	nal considerations, t	he GDG judged that BP	aLM may have moderate desirable effects and noted the very low certainty a	of
• PHC/ADULT	HOSPITAL LEVE	EL COMMI'	TTEE'S JUDG	EMENT				
<ul> <li>○Trivial</li> <li>○Small</li> <li>○ Moderate</li> <li>○ Large</li> <li>○ Varies</li> <li>× Don't know</li> </ul>	Based on the wi substantial the o					parison of BPaLM vs BF	PaL from TB-PRACTECAL, the ERC judged that it is not known how	
Undesirable of	effects: How subs	tantial are t	the undesirabl	e anticipa	ted effects?			
JUDGEMENT	RESEARCH EVIDE	ENCE						ADDITIONAL CONSIDERATIONS
WHO Guid	leline panel							
<ul> <li>Trivial</li> <li>X Small</li> <li>Moderate</li> <li>Large</li> <li>Varies</li> <li>Don't know</li> </ul>	TB) was compare Participants with (n=60) experience Outcomes par (s Fo Adverse events (	nen arm of ed to BPaL a n MDR/RR-' ced higher l Nº of rticipants studies) illow-up 207 (1 RCT)	arm of the TB- TB (with or w levels of grade ertainty of the evidence (GRADE) $\oplus$ Very low ^{abc,desg}	Relative effect (95% CI) RR 1.07 (0.61 to 1.88)	AL trial comprised o nolone resistance) in verse events (21% v Anticipated absol Risk with BPaL (Lzd 600mg/300mg) Study ( 196 per 1000	f MDR/RR-TB or pre-X receiving BPaLM regin 's 20%), i.e., 7% relativ lute effects* (95% CI) Risk difference with BPaLM population 14 more per 1 000 (76 fewer to 173 more)	MDR/ RR-TB with or without quinolone resistance (MDR/RR-TB or pre-XD KDR-TB patients. nen (n=62) compared to participants receiving BPaL in TB-PRACTECAL tr re increase (aRR=1.07, 95%CI 0.62 to 1.88).	ial
• PHC/ADU • Trivial • Small • Moderate • Large • Varies x Don't know	For sub-PICO 7. arm in participa 0.52, 0.95) and 1	ence was pr 2, the comp ants with flu higher rates ed on point o	resented to the parison of BPal poroquinolone s of treatment estimate, with	ERC by the E	ne review team from om TB-PRACTECAL TB (n = 33), BPaLM currence (RD 0.18, '	only in participants wi 4 was associated with 95% CI 0.05, 0.48). The	sub-PICO 7.2 provided by Gregory Fox. ith fluoroquinolone -resistant TB (n = 11) vs. BPaL from the ZeNix 600-26 statistically significant less treatment success (unadjusted RR 0.82; 95% CI ere was no difference in mortality, loss-to-follow-up or amplification of aLM in this population was also associated with more grade $3 \ge$ adverse	

The ERC considered that the possible increased risk of treatment failure and reduced treatment success reported in the additional research presented may have occurred as a result of chance (noting the small sample size), however, an alternate explanation is that the reduction in Linezolid dosing from 600mg to 300mg at 16 weeks in the BPaLM arm in TB PRACTECAL as compared to 600mg of Linezolid used for 26 weeks in the ZeNix trial may account for this difference in outcomes in the fluoroquinolone resistant population.

However, based on the wide confidence intervals that cross no effect for adverse events, in the comparison of the BPaLM and BPaL arms in TB-PRACTECAL, and the potential for more undesirable effects when used in those with fluoroquinolone resistance, the ERC judged that it is currently not known how substantial the undesirable effects of the intervention are.

• (%) 11	8	PaL (Ze 8 monti	Q-r) TB-PRA nix 600-26) ns post treati measures (95% CI)	1		p-value	Propensity score model Covariates included in mod
a (%)	BPaL n (%)	8 month Outcome Unadj.	ns post treati measures	ment init Adj. RR		p-value	AND A DESCRIPTION OF A
a (%)	BPaL n (%)	Outcome Unadj.	e measures	Adj. RR		p-value	AND A DESCRIPTION OF A
a (%)	n (%)	Unadį.	2002年1月1日に	100000000000000000000000000000000000000	(95% CI)	p-value	AND A DECIDENCE AND A DECIDE AND A DECIDA AND A DECIDA
a (%)	n (%)	- which which which	(95% CI)	100000000000000000000000000000000000000	(95% CI)	p-value	Covariates included in mo
11	33						
(82%)	33 (100%)	0.82	(0.52, 0.95)			0.0581	Age, sex, HIV status, ART treatme AFB smear, previous DRTB treatm
(18%)	0 (0%)	0.18	(0.05, 0.48) RD			0.0581	As above
0 (0%)	0 (0%)	0	(-0.11, 0.26)RD			1	As above
0 (0%)	0 (0%)	0	A CONTRACTOR			1	As above
(28%)	5 (15%)	1.83	(0.61, 5.5)	1.19	(0.34, 4.21)	0.7854	
8 (0%)	0 (0%)	0	(-0.11, 0.18)			1	Adjustment not possible
	0 (0%) (28%)	0 (0%) 0 (0%) (28%) 5 (15%)	0 (0%) 0 (0%) 0 (28%) 5 (15%) 1.83	0 (0%) 0 (0%) 0 (+0.11, 0.26)RD (28%) 5 (15%) 1.83 (0.61, 5.5)	0 (0%) 0 (0%) 0 (-0.11, 0.26)RD (28%) 5 (15%) 1.83 (0.61, 5.5) 1.19 8 (0%) 0 (0%) 0 (-0.11, 0.18)	0 (0%) 0 (0%) 0 (-0.11, 0.26)RD (28%) 5 (15%) 1.83 (0.61, 5.5) 1.19 (0.34, 4.21) 8 (0%) 0 (0%) 0 (-0.11, 0.18)	0 (0%) 0 (0%) 0 (+0.11, 0.26)RD 1 (28%) 5 (15%) 1.83 (0.61, 5.5) 1.19 (0.34, 4.21) 0.7854

### **Certainty of evidence**: What is the overall certainty of the evidence of effects?

#### IUDGEMENT

RESEARCH EVIDENCE

ADDITIONAL CONSIDERATIONS

### WHO Guideline panel

x Very low

No included

### **Research Evidence**

 Low  $\circ$  Moderate High

studies

Confidence limits were wide for most estimates. Certainty was rated *very low*. Risk of bias was serious or very serious, for different outcomes. There was a lack of blinding, early termination of the trial for benefit, measured confounding and likely unmeasured confounding and small event numbers precluding adjustment for some comparisons. These concerns resulted in downgrading by one or two levels depending upon outcome. We did not downgrade for inconsistency. We downgraded for indirectness due to differences in population and the comparator regimen by one level. Imprecision was serious or very serious according to outcome, with a small number of events for some outcomes resulting downgrading by one to two levels according to outcomes.

Outcomes	Nº of participants (studies) Follow-up	Certainty of the evidence (GRADE)
Treatment success	122 (1 RCT)	OOO Very low ^{a,b,c,d,efg}
Failure and recurrence	122 (1 RCT)	HOOO Very low ^{a,bc,d,etg}
Death	122 (1 RCT)	000 Very low ^{ab,cdeg}
Lost to follow up	122 (1 RCT)	OOO Very low ^{a,b,c,d,eig}
Adverse events	207 (1 RCT)	HOOO Very low ^{a,bc,d,etg}
Amplification of drug resistance	207 (1 RCT)	Very low ^{a,b,c,d,etg}

a. An imbalance in measured covariates (gender, past TB treatment, past DR-TB treatment, smear positivity, culture positivity and FQ-S proportion) likely arises from the small number of participants in each group. While the adjusted analyses will account for measured confounding, unmeasured confounding is also likely.

b. Small numbers of events in some outcomes precludes adjustment in some comparisons

c. A lack of blinding of patients, caregivers and those adjudicating outcomes may introduce bias in the conduct of the trial. Higher loss to follow-up was noted in the comparator group, which is an that may be influenced by patient or clinician knowledge of the regimen.

d. The trial was stopped early for benefit, with few events (<200). This can introduce bias. Formal stopping rules do not reduce bias (GRADE Handbook, 2013).

e. Multiple comparator regimens were used, varying across site. This may explain some of the inconsistency in the point estimates for treatment outcomes seen between countries (Belarus, South Africa and Uzbekistan). The decision whether to downgrade is a difficult decision. Confidence limits for these estimates do overlap, and so we have chosen not to downgrade for inconsistency.

f. A single trial. Serious indirectness (i) Populations: Differences in population of a trial and population to which guidelines will apply. (ii) Comparator: Some comparator regimens are sub-optimal, not according with the WHO standard of care (at the time or presently) and vary by country. Downgraded one level.

g. The number of participants in both intervention and comparator groups was small (n=62 and n=60). Very few events in the outcomes of interest, causing very serious imprecision. We downgraded two levels for imprecision for some outcomes, and one level for others.

• PHC/ADULT	PHC/ADULT HOSPITAL LEVEL COMMITTEE					
<ul> <li>x Very low</li> <li>Low</li> <li>Moderate</li> <li>High</li> <li>No included studies</li> </ul>	The ERC agrees with the WHO GDG panel judgement that the overall certainty of the evidence of the effects is very low.					
Values: Is there	important uncertainty about or variability in how much people value the main outcomes?					
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS				
WHO Guid	eline panel					
<ul> <li>Important uncertainty or variability</li> <li>Possibly important uncertainty or variability</li> <li><b>X</b> Probably no important uncertainty or variability</li> <li>No important uncertainty or variability</li> <li>No known undesirable outcomes</li> </ul>	Research Evidence No evidence research searched for. Higher treatment efficacy, shorter duration of treatment, lower pill burden and less adverse events are usually valued by patients. The panel judged that there was probably no important uncertainty or variability in how much people value the main outcomes.	Higher treatment efficacy, shorter duration of treatment, lower pill burden and less adverse events are usually valued by patients.				
• PHC/ADULT	HOSPITAL LEVEL COMMITTEE'S JUDGEMENT					

<ul> <li>Important uncertainty or variability</li> <li>Possibly important uncertainty or variability</li> <li>Probably no important uncertainty or variability</li> <li>No important uncertainty or variability</li> <li>No known undesirable outcomes</li> </ul>	No additional research evidence was presented to the ERC by the review team. The ERC agrees with the WHO GDG judgment that there is probably no important uncertainty or variability in how much people value the main outcomes.	
Balance of effe	ects: Does the balance between desirable and undesirable effects favour the intervention or the comparison?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
WHO Guide	eline panel	
<ul> <li>Favours the comparison</li> <li>Probably</li> <li>favours the comparison</li> <li>Does not</li> <li>favour either</li> <li>the intervention</li> <li>or the comparison</li> <li>x Probably</li> <li>favours the intervention</li> <li>Favours the intervention</li> <li>Favours the intervention</li> <li>Varies</li> <li>Don't know</li> </ul>	Research Evidence Nil additional The GDG judged the benefits of BPaLM to be moderate and the undesirable effects to be small compared to BPaL. The certainty of evidence was judged to be very low. Based on this, the panel determined that the balance of health effects probably favours BPaLM.	
• PHC/ADULT	' HOSPITAL LEVEL COMMITTEE	
<ul> <li>Favours the comparison</li> <li>Probably favours the comparison</li> <li>X Does not</li> </ul>	Considering the previous ERC judgements, that the size of desirable and undesirable effects of the BPaLM intervention in comparison to the BPaL intervention is unknown, the ERC judged that based on the currently available data (or lack thereof) the balance of undesirable and desirable effects does not favour the intervention or the comparison. However, clinicians in the review team had concern that many patients may require termination of treatment with linezolid as a result of intolerance, in which case a treatment would only comprise two drugs. Therefore, the committee suggested that a fluoroquinolone be included in the regimen initially, and be continued for the duration of treatment if fluoroquinolone resistance is excluded. This recommendation is based on expert opinion rather than the data presented by WHO. In those	

 ${\tt Adolopment_WHO_DRTB_Guidelines_4May2023_Final}$ 

		1
favour either the intervention or the comparison $\circ$ Probably favours the intervention $\circ$ Favours the intervention $\circ$ Varies $\circ$ Don't know	whom fluoroquinolone resistance is detected, the fluoroquinolone may be omitted from the regimen. The ERC deliberated whether levofloxacin should be recommended rather than moxifloxacin as the fluoroquinolone of choice. The primary consideration by the Committee in support of levofloxacin over moxifloxacin as the fluoroquinolone of choice is the better safety profile of levofloxacin, specifically with regard to cardiotoxicity (specifically reduced QTc prolonging effects) which is well-documented in the literature. (20-22) In terms of the relative efficacy of levofloxacin and moxifloxacin, the consideration of interchangeability was based primarily on expert opinion, and supported by two publications.(23, 24)	
Resources req	uired: How large are the resource requirements (costs)?	
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
• WHO Guid	eline panel	1
<ul> <li>Large costs</li> <li>Moderate</li> <li>costs</li> <li>Negligible</li> <li>costs and</li> <li>savings</li> <li>Moderate</li> <li>savings</li> <li>Large savings</li> <li>X Varies</li> <li>Don't know</li> </ul>	Research Evidence Nil additional	Additional considerations The cost savings from improved health outcomes were felt to be an important consideration as they could be substantial. However, the panel also felt that some of the cost will vary e.g., the savings from improved health outcomes will depend on underlying fluoroquinolone resistance prevalence. Cost may also be affected by access to fluoroquinolone DST and accordingly the ability to drop Moxi if resistance is found. Therefore, the GDG judged the resources required to vary.
• PHC/ADULT	HOSPITAL LEVEL COMMITTEE	

<ul> <li>Large costs</li> <li>Moderate costs</li> <li>x Negligible costs and savings</li> <li>Moderate savings</li> <li>Large savings</li> <li>Varies</li> <li>Don't know</li> </ul>	The ERC considered the normative							
	Normative cost analysis based on specific direct costs							
	Regimen Short oral course (Min)	Drug costs (ZAR) 11 437,70	Bacteriological tests (Costs in ZAR) 1 058,58	Other lab tests (Costs in ZAR) 472,42	Clinic visit costs (ZAR)	costs (ZAR)	treated excl. clinic visit costs (ZAR)	
	Short oral course (Max) BPaL (Jzd_Adjusted dose) BPaLM (Jzd_Adjusted dose) BPaLM (Jzd_Adjusted dose) Long course 1 (Basic) Long course 2	13 650,99 11 710,64 12 307,88 11 787,08 27 159,16 49 601,58	1 058,58 705,72 705,72 705,72 2 117,15 2 117,15	472,42 2 158,89 2 158,89 2 158,89 785,55 2 028,07	2 680,79 2 632,56 2 632,56	17 862,78 17 207,81 17 805,05 17 284,25 34 467,47	15 181,99 14 575,25 15 172,49 14 651,69 30 059,67	
	Note: When weight calibrated desirg is recommended, drug 1.955 equivalent to 818.80 Drug calculations all based on a 28 day tycle per month Diagnostic Xpert, microscopy, culture and Diff not indu Clinic visits classified according to nature of clinical visit The differences in cost between BPaLM							
JUDGEMENT	dence of resource requirements	S: What is the certainty of t	he evidence of resource	e requirements (cost	s)?			ADDITIONAL CONSIDERATIONS
WHO Guide	eline panel							
x Very low • Low • Moderate • High • No included studies	Research Evidence Nil							
• PHC/ADULT	HOSPITAL LEVEL COMMITTEE							
<ul> <li>○ Very low</li> <li>○ Low</li> <li>X Moderate</li> <li>○ High</li> <li>○ No included studies</li> </ul>	The ERC considered the certainty relevant.	y of evidence of resource ro	equirements to be mod	lerate considering th	e normative cost anal	ysis performed by the	review team is locally	

<b>Cost effectiveness:</b> Does the cost-effectiveness of the intervention favor the intervention or the comparison?							
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS					
WHO Guideline panel							
<ul> <li>Favours the comparison</li> <li>Probably favours the comparison</li> <li>Does not favour either the intervention or the comparison</li> <li>Probably favours the intervention</li> <li>Favours the intervention</li> <li>Varies x No included studies</li> </ul>	Research Evidence The cost-effectiveness study embedded in TB-PRACTECAL trial (Sweeney et al.) compared BPaL regimens to other longer regimens, therefore may not be useful for comparison between BPaL and BPaLM HOSPITAL LEVEL COMMITTEE	Both regimens are of 6 months duration.					
<ul> <li>Favours the comparison</li> <li>Probably favours the comparison</li> <li>Does not favour either the intervention or the comparison</li> <li>Probably favours the intervention</li> <li>Favours the intervention</li> <li>Favours the intervention</li> <li>Varies x No included studies</li> </ul>	Nil additional research comparing the cost-effectiveness of BPaLM to BPaL was available for presentation to the ER.						

Equity: What would be the impact on health equity?								
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS						
WHO Guideline panel								
<ul> <li>Reduced</li> <li>Probably reduced</li> <li><b>x</b> Probably no impact</li> <li>Probably increased</li> <li>Increased</li> <li>Varies</li> <li>Don't know</li> </ul>	Research Evidence No research evidence searched for. Implementation in some countries may be hampered by lack of availability of DST and that could have an impact on equitable roll out if DST for moxifloxacin is a requirement for implementation. However, the WHO GDG judged that the intervention would probably have no impact on health equity over the comparison.	The panel considered the treatment duration and the ability to decentralize treatment (to enable access for remote, underserviced settings and disadvantaged populations) to affect equity.						
PHC/ADULT HOSPITAL LEVEL COMMITTEE								
<ul> <li>○ Reduced</li> <li>○ Probably reduced</li> <li>× Probably no impact</li> <li>○ Probably increased</li> <li>○ Increased</li> <li>○ Varies</li> <li>○ Don't know</li> </ul>	Considering that both the intervention and the comparison are of similar durations, and not significantly complex, the ERC judged that they are likely to have the same impact on equity.							
Acceptability: Is the intervention acceptable to key stakeholders?								
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS						
WHO Guideline panel								
<ul> <li>No</li> <li>Probably no</li> <li><b>x Probably yes</b></li> <li>Yes</li> <li>Varies</li> <li>Don't know</li> </ul>	Research Evidence No research evidence searched for. The panel considered patients and health care providers as key stakeholders. The panel considered the following aspects as critical with regards to acceptability: regimen duration and drug safety monitoring needs (both relating to necessary travel, loss of income and general disruption of the life of patients; workload for the health care system), needs for drug susceptibility testing. The panel judged that the BPaLM regimen would probably be acceptable.	Both regimens are 6month regimens, only difference is Moxifloxacin in BPaLM.						

• PHC/ADULT	PHC/ADULT HOSPITAL LEVEL COMMITTEE				
<ul> <li>No</li> <li>Probably no</li> <li><b>X Probably yes</b></li> <li>Yes</li> <li>Varies</li> <li>Don't know</li> </ul>	No additional evidence was presented to ERC committee. Considering previous judgements that BPaLM (EtD and PICO c) is probably acceptable to key stakeholder and that BPaL (EtD and PICO a) is probably acceptable to key stakeholders, the ERC judged that BPaLM (when compared to BPaL) would probably be acceptable to key stakeholders. stakeholders .				
Feasibility: Is	the intervention feasible to implement?				
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS			
WHO Guidel	ine panel				
<ul> <li>No</li> <li>Probably no</li> <li>X Probably yes</li> <li>Yes</li> <li>Varies</li> <li>Don't know</li> </ul>	Research Evidence No research evidence searched for. The panel noted that rapid DST to moxifloxacin is not available in all settings and that this is a potential barrier to implementation. The panel judged that implementation is probably feasible.	The panel considered the following aspects to affect feasibility (i.e., to be potential barriers to implementation): requirements for drug safety monitoring and requirements for drug susceptibility testing. Both BPaLM and BPaL are 6month regimens, only difference is Moxifloxacin in BPaLM.			
• PHC/ADULT	HOSPITAL LEVEL COMMITTEE				
<ul> <li>No</li> <li>Probably no</li> <li><b>X Probably yes</b></li> <li>Yes</li> <li>Varies</li> <li>Don't know</li> </ul>	The ERC considered the issues raised by the WHO GDG. Based on the indirect evidence of high feasibility of BPaL in preXDR-TB reported by van de Berg et al. and South Africa's ability to perform genotypic testing for fluoroquinolone resistance , the ERC judged the intervention (BPaLM) to be feasible. The ERC heard from the NDOH TB programme that feasibility could be impacted if the level of prescriber be restricted to medical officer only, as clinical nurse practitioners and clinical associates are important human resources for decentralized care.				

Version	Date	Reviewer(s)	Recommendation and Rationale
Initial	23 March 2023		Initial ERC discussion took place on 16th March 2023, with ongoing discussion and updated ERC decision at an extraordinary meeting of the ERC on
			23 March 2023, where a conditional recommendation for the use of the BPaLM in the treatment of drug resistant TB without fluoroquinolone
			resistance was suggested. The recommendation is conditional and based only on the expert opinion and not on data presented by the WHO GDG.
		КС	Furthermore, levofloxacin could be used instead of moxifloxacin as fluoroquinolone of choice for inclusion in the revised regimen.

#### 5. Recommendations

Through the GRADE adolopment process, the following recommendation has been adapted from the WHO by the PHC/Adult hospital level Committee:

1. We suggest the use of the 6-month treatment regimen composed of bedaquiline, pretomanid, linezolid (600mg) and a fluoroquinolone rather than 9-month or longer (18-month) regimens in MDR/RR-TB patients. (Conditional recommendation, very low certainty of evidence). Levofloxacin is to be used instead of moxifloxacin as fluoroquinolone of choice, for inclusion in the revised regimen.

The PHC/Adult hospital level committee has adopted the following remarks relevant to the recommendation above from the WHO:

- 2. Drug susceptibility testing (DST) for fluoroquinolones is strongly encouraged in people with MDR/RR-TB, and although it should not delay initiation of the BPaLM, results of the test should guide the decision on whether the fluoroquinolone can be retained or should be dropped from the regimen – in cases of documented resistance to fluoroquinolones, BPaL without the fluoroquinolone would be initiated or continued.
- 3. This recommendation applies to the following:
  - a. People with MDR/RR-TB or with MDR/RR-TB and resistance to fluoroquinolones (pre-XDR-TB).
  - b. People with confirmed pulmonary TB and all forms of extrapulmonary TB except for TB involving the CNS, osteoarticular and disseminated (miliary) TB.
  - c. Adults and adolescents aged 14 years and older.
  - d. All people regardless of HIV status.
  - e. Patients with less than 1-month previous exposure to bedaquiline, linezolid, pretomanid or delamanid. When exposure is greater than 1 month, these patients may still receive these regimens if resistance to the specific medicines with such exposure has been ruled out.
- 4. This recommendation does not apply to pregnant and breastfeeding women owing to limited evidence on the safety of pretomanid.
- 5. The recommended dose of linezolid is 600 mg once daily.

1. Ismail NA, Mvusi L, Nanoo A, Dreyer A, Omar SV, Babatunde S, et al. Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey. Lancet Infect Dis. 2018;18(7):779-87. 10.1016/S1473-3099(18)30222-6. <u>https://www.ncbi.nlm.nih.gov/pubmed/29685458</u>.

2. Global tuberculosis report 2022. Geneva: World Health Organization. 2022. <u>https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022/tb-disease-burden/2-3-drug-resistant-tb</u>.

3. Ndjeka N, Schnippel K, Master I, Meintjes G, Maartens G, Romero R, et al. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J. 2018;52(6). DOI: 10.1183/13993003.01528-2018. <u>https://www.ncbi.nlm.nih.gov/pubmed/30361246</u>.

4. South African Department of Health. Management of rifampicin-resistant tuberculosis: A clinical reference guide. 2019. <u>https://www.health.gov.za/wp-content/uploads/2020/11/management-of-rifampicin-resistant-tb-booklet-0220-v11.pdf</u>.

5. Tack I, Dumicho A, Ohler L, Shigayeva A, Bulti AB, White K, et al. Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis. Clinical Infectious Diseases. 2020;73(9):e3563-e71. 10.1093/cid/ciaa1894. <u>https://doi.org/10.1093/cid/ciaa1894</u>.

6. Jaspard M, Butel N, El Helali N, Marigot-Outtandy D, Guillot H, Peytavin G, et al. Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France. Emerg Infect Dis. 2020;26(8):1792-800. 10.3201/eid2608.191499.

7. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment 2022, IGO. update. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0. https://www.who.int/publications/i/item/9789240063129.

8. World Health Organization. Target regimen profiles for TB treatment: candidates: rifampicin-susceptible, rifampicin resistant and pan-TB treatment regimens. 2016(WHO/HTM/TB/2016.16).

https://apps.who.int/iris/handle/10665/250044.

9. Schünemann HJ, Wiercioch W, Brozek J, Etxeandia-Ikobaltzeta I, Mustafa RA, Manja V, et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol. 2017;81:101-10. 10.1016/j.jclinepi.2016.09.009.

10. Florez ID, Amer YS, McCaul M, Lavis JN, Brouwers M. Guidelines developed under pressure. The case of the COVID-19 low-quality "rapid" guidelines and potential solutions. J Clin Epidemiol. 2022;142:194-9. 10.1016/j.jclinepi.2021.11.012. <u>https://www.ncbi.nlm.nih.gov/pubmed/34780983</u>.

11. McCaul M, Tovey D, Young T, Welch V, Dewidar O, Goetghebeur M, et al. Resources supporting trustworthy, rapid and equitable evidence synthesis and guideline development: results from the COVID-19 evidence network to support decision-making (COVID-END). J Clin Epidemiol. 2022;151:88-95. 10.1016/j.jclinepi.2022.07.008. https://www.ncbi.nlm.nih.gov/pubmed/35868494.

12. Schünemann HJ, Wiercioch W, Etxeandia I, Falavigna M, Santesso N, Mustafa R, et al. Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. Cmaj. 2014;186(3):E123-42. 10.1503/cmaj.131237.

13. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182(18):E839-42. 10.1503/cmaj.090449. https://www.ncbi.nlm.nih.gov/pubmed/20603348.

14. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. 10.1136/bmj.j4008. <u>https://www.bmj.com/content/bmj/358/bmj.j4008.full.pdf</u>.

15. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook A, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. New England Journal of Medicine. 2020;382(10):893-902. 10.1056/NEJMoa1901814. https://www.nejm.org/doi/full/10.1056/NEJMoa1901814.

16. Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline–Pretomanid– Linezolid Regimens for Drug-Resistant Tuberculosis. New England Journal of Medicine. 2022;387(9):810-23. 10.1056/NEJMoa2119430. <u>https://www.nejm.org/doi/full/10.1056/NEJMoa2119430</u>. 17. Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. New England Journal of Medicine. 2022;387(25):2331-43. 10.1056/NEJMoa2117166. https://www.nejm.org/doi/full/10.1056/NEJMoa2117166.

18. Gomez GB, Siapka M, Conradie F, Ndjeka N, Garfin AMC, Lomtadze N, et al. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines. BMJ Open. 2021;11(12):e051521. 10.1136/bmjopen-2021-051521.

19. Sweeney S, Berry C, Kazounis E, Motta I, Vassall A, Dodd M, et al. Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis. PLOS Global Public Health. 2022;2(12):e0001337.

10.1371/journal.pgph.0001337. <u>https://doi.org/10.1371/journal.pgph.0001337</u>.

20. Täubel Jörg, Prasad Krishna, Rosano Giuseppe, Ferber Georg, Wibberley Helen, Cole Samuel Thomas, et al. Effects of the Fluoroquinolones Moxifloxacin and Levofloxacin on the QT Subintervals: Sex Differences in Ventricular Repolarization. The Journal of Clinical Pharmacology. 2020;60(3):400-8. <u>https://doi.org/10.1002/jcph.1534</u>. <u>https://accp1.onlinelibrary.wiley.com/doi/abs/10.1002/jcph.1534</u>.

21. Tsikouris James P., Peeters Michael J., Cox Craig D., Meyerrose Gary E., Seifert Charles F. Effects of Three Fluoroquinolones on QT Analysis After Standard Treatment Courses. Annals of Noninvasive Electrocardiology. 2006;11(1):52-6. <u>https://doi.org/10.1111/j.1542-474X.2006.00082.x</u>.

https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1542-474X.2006.00082.x.

22. Noel G. J., Natarajan J., Chien S., Hunt T. L., Goodman D. B., Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther. 2003;73(4):292-303. 10.1016/s0009-9236(03)00009-2.

23. Koh WJ, Lee SH, Kang YA, Lee CH, Choi JC, Lee JH, et al. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2013;188(7):858-64. 10.1164/rccm.201303-0604OC. https://www.ncbi.nlm.nih.gov/pubmed/23927582.

24. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR TB treatment, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821-34. 10.1016/S0140-6736(18)31644-1. <u>https://www.ncbi.nlm.nih.gov/pubmed/30215381</u>.



# AGREEII

## A critical group appraisal of: WHO consolidated guidelines on TB using the AGREE II Instrument

Created with the AGREE II Online Guideline Appraisal Tool.

No endorsement of the content of this document by the AGREE Research Trust should be implied.

Co-ordinator: Tasha Gloeck

Date: 20 February 2023

Email: natasha.gloeck@mrc.ac.za

URL of this appraisal: http://www.agreetrust.org/group-appraisal/18838

Guideline URL: https://www.who.int/publications/i/item/9789240063129

## Comments

# Domain 1. Scope and Purpose Item 1

• Appraiser 2: \"This evidence review aims to evaluate the efficacy and safety of novel short-course oral regimens to treat MDR/RR-TB, in comparison to the 2020 WHO- recommended regimens. This will be undertaken by conducting analyses of data from clinical trials and individual patient data meta-analyses of cohorts treated for MDR/RR-TB in programmatic settings.\" p313 Annexes. \

"This current module on DR-TB treatment provides specific recommendations on the treatment of DR-TB, including use of regimens for rifampicin-susceptible, isoniazid- resistant TB (Hr-TB), all-oral shorter regimens for MDR/RR-TB, longer regimens for MDR/RR-TB, monitoring patient response to MDR/RR-TB treatment, starting ART in patients on second-line anti-TB regimens and undertaking surgery for patients on MDR-TB treatment.\" p3

• Appraiser 3: \"provide specific recommendations on the treatment of DR-TB, including use of regimens for rifampicin-susceptible, isoniazid resistant TB (Hr-TB), all-oral shorter regimens for MDR/RR-TB, longer regimens for MDR/RR-TB, monitoring patient response to MDR/RR-TB treatment, starting ART in patients on second-line anti-TB regimens and undertaking surgery for patients on MDR-TB treatment.\"

Health intent: Treatment, monitoring, timing of ART initiation, use of surgery. Expected benefit: Not clearly stated; to inform national TB programmes and assist in policy development, reduced adverse effects associated with DR-TB treatment and shorten treatment duration. Targets: Patients with MDR/RR-TB and Hr-TB. Well written. Expected benefit or outcome not easy to find in the guideline.

#### Item 2

- Appraiser 2: Annex Population: Yes (p 313) Intervention: Yes (p 313) Comparator: Yes (p 314) Outcome: Yes (p 316) Context: inclusion criteria p 315, worldwide
- Appraiser 3: PICO questions including target population, intervention, comparator are clearly stated and easily found in each respective section. Health care setting/context is not explicitly stated.

PICO subquestions for Section 1 are not found in guideline document but can be found in the annexes document.

## Item 3

Appraiser 2: Pages 313 and 315 include population, as well as inclusion and exclusion criteria • Appraiser 3: Target population and clinical condition: All eople with DR-TB, Hr-TB.

No gender or age exclusions listed. No exclusions of specific severity or stages of disease. No exclusions of certain populations or comorbidites.

The lack of exclusionary criteria is not specifically highlighted in the guideline, but assumed based on the recommendations.

## Domain 2. Stakeholder Involvement

#### Item 4

- Appraiser 2: Web Annex 1. Methods and expert panels page 7 Name: YES Discipline/content expertise (e.g., neurosurgeon, methodologist): YES Institution (e.g., St. Peter's hospital): YES Geographical location (e.g., Seattle, WA): YES Description of the member's role in the guideline development group: YES Appraiser 3: For
- each member of guideline development group name, discipline/content expertise, institution and geographical location where stated. The description the members specific role in guideline development was not found.

Item easily found at start of the guideline. Members are appropriate match for the topic and scope. Methodological experts included in the development group.

#### Item 5

• Appraiser 2: Web Annex 1. Table A1.3 - perspectives from patients with recommendation.

ONE former MDR-TB Patient was included in the guideline development group. Not

really sufficient information.

• Appraiser 3: \"The methods used to develop and formulate the recommendations complied with WHO standards for guideline development and were based on up-to- date evidence reviews, complemented with additional information on values and preferences, feasibility and acceptability, and cost.\"

End-user\'s and former DR-TB patient are noted to have been included in the guideline development group and as external reviewers. However, there is no clear statement on additional strategies used to capture patients/public views and preferences.

This item was not easy to find in the guideline but is noted in the methods section of the annexe document.

## Item 6

Appraiser 2: Yes - p5 of module 4

• Appraiser 3: Page 5: policy makers in ministries of health, or managers of NTPs who formulate country-specific TB treatment guidelines or are involved in the planning of TB treatment programmes. For use by health professional, including doctors, nurse, educators.

Clear, concise and well written. Appropriate for scope of guideline.

## Domain 3. Rigour of Development

## Item 7

• Appraiser 2: \"Evidence gathering and analysis

Evidence provided for the GDG review on using 6-month novel regimens was from the TB-PRACTECAL trial (evidence on using BPaLM, BPaLC, BPaL regimens), ZeNix trial (evidence on using the BPaL regimen with difference dosing schemes of linezolid use) and Nix-TB study (evidence on using the BPaL regimen). Evidence on using a new 9- month shorter regimen was from the programmatic data provided by the National TB Programme in South Africa. In addition, evidence was available on the use of other treatment regimens that were used as external comparators required for comparisons with the intervention regimens. The evidence included data on the use of WHO recommended shorter all- oral bedaquiline-containing regimen, which were from the programmatic implementation provided by South Africa; and WHO recommended longer regimens, which were provided by several country programmes from Belarus, Republic of Moldova, Georgia, Russian Federation, India, South Africa, and Somalia; or cohort studies (EndTB studies) provided by Médecins Sans Frontières and Partners in Health.

In preparation to the guidelines update, WHO/GTB also received the data from the Newer and Emerging Treatment for MDR/RR-TB (NExT) trial that was a phase II/III open-label randomized controlled trial evaluating the effectiveness of an all-oral 6–9- month regimen for treatment of MDR-TB in South Africa (21), against a local standard of care regimen at the time. Sharing of the data by the principal Investigator and colleagues in the University of Cape Town and the South African Medical Research Council, is gratefully acknowledged\"

No search methods, no search strategy BUT data collated from various large trials and in collaboration with large TB programmes

• Appraiser 3: For the updated section of the guideline (section 1 and 2) no strategy for the search of evidence is provided. Evidence was obtained through collaboration and engagement with NTPs, researchers and TB alliance as well as the WHO call for data.

Evidence for section 3, 4,5 obtained from meta-analysis of IPD. No search strategy provided.

#### Item 8

• Appraiser 2: Annex p 315 A5.2 Eligibility for inclusion in this evidence review

Annex p 314 Regimens excluded from analyses

Also included in the GL page 3

• Appraiser 3: No description on criteria for evidence selection in guideline document. Web Annexes describe eligibility criteria for dataset inclusion and participant exclusion. Datasets from a public call for data were included.

## Item 9

- Appraiser 2: GRADE evidence summary tables available with five GRADE domains and reasons
- Appraiser 3: The WHO Guideline Development process uses specific criteria to assess the characteristics of a body of evidence, such as within-study bias (methodological quality), consistency, precision, directness or applicability of the evidence, and others.

The strengths and limitations of body of evidence are assessed, well written and clear and concisely described in the Web annex document in the Methods section and GRADE evidence summary tables but not in the main guideline.

## Item 10

- Appraiser 2: GRADE EtD tables available for each PICO with recommendations Appraiser 3:
- A formal process and evidence-to-decision framework was used to arrive at recommendations. Decisions reached through discussion and consensus, where consensus through discussion not reached, the GDG voted on decisions. Here, decisions were made based on the vote of the majority.

(information from annex. - not easily found.)

## Item 11

- Appraiser 2: Yes, included in EtD
- Appraiser 3: Supporting data and report of benefits included in the Etd frameworks in the web annexes per PICO and also in the guideline. Recommendations do reflect considerations of both benefits, harms and risks. This discussion is integral to the document.

## Item 12

- Appraiser 2: EtD available with link to evidence
- Appraiser 3: Each recommendation is linked to a discussion of the key evidence in the evidence-to-decision frameworks in the annexes document. Evidence summaries are provided for each sub-PICO in the guideline. Where evidence is lacking it is clearly stated in the guideline that recommendations are based on consensus of the guideline development group.

## Item 13

- Appraiser 2: An External review group is listed (Web Annex 1 page 7), there is a specific acknowledgment statement (GL page vi), otherwise scanty information as to what the external review group did
- Appraiser 3: An external review group was assembled to review the updated recommendations based on the inputs of the guideline development group. External review group members are listed with qualifications and affiliation and are appropriate. Not easily found in the guideline, but available in web annex document. No indication of how information provided by review group was used by guideline development group. No indication of the purpose or intent of the review, methods undertaken or a summary of key findings.

## Item 14

- Appraiser 2: This guideline is an update. No timescale found around when the next update will be
- Appraiser 3: No clear statement of when guideline will be update, the explicit time interval or criteria to guide decisions or methodology of updating procedure.

## Domain 4. Clarity of Presentation

## Item 15

• Appraiser 2: EtD tables - recommendations provided with remarks around applicability

Recommendations available in GL, also clear what updates/changes have been made from previous GLs

• Appraiser 3: The recommendations are concrete and precise, specifically in the remarks underlying each recommendation.

## Item 16

- Appraiser 2: Extensive information available in EtDs not necessarily alternatives thus rated down slightly. Recommendations in GL also quite specific
- Appraiser 3: Different options for management are presented: either BPAL, BPALM or BPLAC rather than SOC.

Different options for LZD dosing and BDQ dosing is presented.

Specific recommendations are made for children, pregnant women, HIV positive patients and patients with extrapulmonary TB. This information can be found under appropriate headings in the guideline.

## Item 17

- Appraiser 2: Yes, once the correct PICO is found.
- Appraiser 3: Recommendations are summarised in a box at the start of the guideline and are clear and concise.

## Domain 5. Applicability

Item 18

• Appraiser 2: Within the EtDs and GL, the guideline panel discussed acceptability, feasibility, equity, cost-effectiveness. required resources, balance of effects, etc.

There are also implementation and subgroup considerations.

• Appraiser 3: In Web Annexes document facilitators and barriers discussed in EtD frameworks that assessed acceptability, feasibility required resources, cost effectiveness etc.

## Item 19

- Appraiser 2: There are implementation and subgroup considerations listed with each PICO in the EtD but these do not necessarily provide sufficient information to actually implement.
- Appraiser 3: An implementation section is found in the guideline. No summary documents, algorithms or check lists are found, although a summary of the recommendations is listed at the start of the guideline.

Some references to guideline facilitators for example for sections \"Care and Support\" - reference supplied to WHO Consolidated guidelines on tuberculosis: Module 4: Treatment - tuberculosis care and support\"

Appendices do not contain useful implementation resources.

## Item 20

- Appraiser 2: Yes in the EtD, cost effectiveness and feasiblility have been considered. Appraiser
- 3: Regimen costs were estimated in US\$ for regimens based on GDF prices. Studies of costeffectiveness of regimens were included in the guideline.

Resource implications are considered in the EtD framework. It does not appear that any health economist were part of guideline development group.

### Item 21

- Appraiser 2: Yes, monitoring and evaluation section available in the EtDs
- Appraiser 3: No clear schedule of monitoring of relevant clinical and laboratory tests is provided, besides the following:
  - 1. Recommend monitoring patients with monthly sputum cultures

2. Patients should be followed up for 12 months after the completion of treatment for possible relapse with sputum culture and smear.

 $3.\ {\rm Test}\ {\rm samples}\ {\rm of}\ {\rm patients}\ {\rm with}\ {\rm no}\ {\rm bacteriological}\ {\rm conversion}\ {\rm after}\ {\rm month}\ 4\ {\rm on}\ {\rm BPaLM/BpAL}\ {\rm regimen}\ {\rm with}\ {\rm DST}.$ 

4. ECG should be done at baseline prior to start of treatment.

## Domain 6. Editorial Independence

#### Item 22

- Appraiser 2: The WHO is the funding agency through grants from USAID. WHO is also the publisher. No statement on influence.
- Appraiser 3: Statement that update was funded by grants provided to WHO by USAID. No statement that funding body did not influence content of guideline.

#### Item 23

- Appraiser 2: Web Annex 2: declarations of interest. Also listed in EtD where a GDG member was excluded in specific PICOs due to competing interests
- Appraiser 3: A description of competing interests is found in the Web Annexes document. The methods by which competing interests were sough was not clear.

WHO policy is noted to have been applied in the EtD frameworks to recuse panel members with potential-conflicts of interest.

## **Overall Assessment**

- Appraiser 2: Recommended for use for adolopment
- Appraiser 3: 1. No information provided regarding systematic search for evidence.
  - 2. Lack of implementation resources
  - 3. Complicated, information for AGREE II assessment not always easily found in the document.

4. Clearer descriptions on role, contributions and findings of end users, external reviewers should be provided.

5. More specific monitoring criteria should be described.

Created online at <u>www.agreetrust.org</u> 20 February 2023



# AGREEII

## A critical group appraisal of: WHO consolidated guidelines on TB using the AGREE II Instrument

Created with the AGREE II Online Guideline Appraisal Tool.

No endorsement of the content of this document by the AGREE Research Trust should be implied.

Co-ordinator: Tasha Gloeck

Date: 20 February 2023

Email: natasha.gloeck@mrc.ac.za

URL of this appraisal: http://www.agreetrust.org/group-appraisal/18838

Guideline URL: https://www.who.int/publications/i/item/9789240063129


Domain 1	Domain 2	Domain 3	Domain 4	Domain 5	Domain 6	OA 1	OA 2
86%	78%	63%	89%	65%	67%	83%	Yes - 1, Yes with modifications - 1, No - 0

Domain 1. Scope and Purpose					
	Appraiser 2	Appraiser 3			
Item 1	6	5			
Item 2	7	6			
Item 3	7	6			
	1	1			
Domain .	2. Stakeholder	Involvement			
	Appraiser 2	Appraiser 3			
Item 4	7	6			
Item 5	5	4			
Item 6	6	6			
Domain .	3. Rigour of D	evelopment			
	Appraiser 2	Appraiser 3			
Item 7	4	1			
Item 8	5	6			
Item 9	6	6			
Item 10	7	5			
Item 11	6	6			
Item 12	7	6			
Item 13	5	3			
Item 14	2	1			
	1	1			
Domain 4	4. Clarity of Pr	resentation			
	Appraiser 2	Appraiser 3			
Item 15	7	6			
Item 16	6	7			
Item 17	6	6			
Domain 5. Applicability					
	Appraiser 2	Appraiser 3			

Item 18	6	6			
Item 19	4	2			
Item 20	6	5			
Item 21	6	4			
Domain (	6. Editorial Ind	lependence			
	Appraiser 2	Appraiser 3			
Item 22	4	3			
Item 23	7	6			
Overall Assessment					
	Appraiser 2	Appraiser 3			
OA1	6	6			

Created online at <u>www.agreetrust.org</u> 20 February 2023

Sumayyah Logout	My Account
-----------------	---------------



for inclusion in the review?

For Yes, the review should satisfy ONE of the following:



# 9. Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the review?

#### RCTs

For Partial Yes, must have assessed RoB from	For Yes, must also have assessed RoB from:	
unconcealed allocation, and	allocation sequence that was not truly random, and	<ul> <li>Yes</li> <li>Partial Yes</li> </ul>
lack of blinding of patients and assessors when assessing outcomes (unnecessary for objective outcomes such as all-cause mortality)	selection of the reported result from among multiple measurements or analyses of a specified outcome	✓ No ○ Includes only NRSI
NRSI		
For Partial Yes, must have assessed RoB:	For Yes, must also have assessed RoB:	
from confounding, and	methods used to ascertain exposures and outcomes, and	Yes Partial Yes
☐ from selection bias	selection of the reported result from among multiple measurements or analyses of a specified outcome	No Includes only RCTs

## 10. Did the review authors report on the sources of funding for the studies included in the review?

For Yes

Must have reported on the sources of funding for individual studies included in the review. Note: Reporting that the reviewers looked for this information but it was not reported by study authors also qualifies

$\Box$	Yes
2	No

11. If meta-analysis was performed did the review authors use appropriate methods for statistical combination of results?

RCTs

For Yes:

15. If they performed quantitative synt	
carry out an adequate investigation of	
bias) and discuss its likely impact on the	ne results of the review?

performed graphical or statistical tests for publication	Yes
bias and discussed the likelihood and magnitude of impact of	O No
publication bias	🗹 No meta-
	analysis
	conducted

16. Did the review authors report any potential sources of conflict of interest, including any funding they received for conducting the review?

For Yes:

For Yes:

The authors reported no competing interests OR

Yes
No

The authors described their funding sources and how they managed potential conflicts of interest

To cite this tool: Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, Henry DA. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or nonrandomised studies of healthcare interventions, or both. BMJ. 2017 Sep 21;358:j4008.

Assess Article Copyright © 2021 AMSTAR All Rights Reserved

Nati	asha Logou	it My Account
AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR AMSTAR		
Home About Us Publications Checklist FAC	Qs Co	ntact Us
AMSTAR 2 Results		
Article Name: WHO consolidated guidelines on tuberculosis - module 4	Printer Fr	iendly Version
WHO consolidated guidelines on tuberculosis - I Critially Low quality review 1. Did the research questions and inclusion criteria for the review include the components of PICO?	Yes Yes	4 is a
	Yes Yes Yes	
2. Did the report of the review contain an explicit statement that to review methods were established prior to the conduct of the revies and did the report justify any significant deviations from the proto	w	'es
3. Did the review authors explain their selection of the study d for inclusion in the review?	esigns	Yes Yes
4. Did the review authors use a comprehensive literature searc strategy?	:h	No
5. Did the review authors perform study selection in duplicate?		No
6. Did the review authors perform data extraction in duplicate	,	No
7. Did the review authors provide a list of excluded studies and the exclusions?	l justify	No
8. Did the review authors describe the included studies in adec detail?	quate	Yes

9. Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the

review? RCT

NRSI

.0. Did the review authors report on the sources of funding for the tudies included in the review?	No
1. If meta-analysis was performed did the review authors use appropriate methods for statistical combination of results?	Yes
IRSI	
2. If meta-analysis was performed, did the review authors assess th octential impact of RoB in individual studies on the results of the me inalysis or other evidence synthesis?	
3. Did the review authors account for RoB in individual studies when	Yes
A. Did the review authors provide a satisfactory explanation for, and	Ves.
4. Did the review authors provide a satisfactory explanation for, and liscussion of, any heterogeneity observed in the results of the review	
4. Did the review authors provide a satisfactory explanation for, and liscussion of, any heterogeneity observed in the results of the review 15. If they performed quantitative synthesis did the review authors A	0
4. Did the review authors provide a satisfactory explanation for, and liscussion of, any heterogeneity observed in the results of the review 15. If they performed quantitative synthesis did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review? 16. Did the review authors report any potential sources of conflict of interest, including any funding they received for conducting the	o o r D, Tugwell P, atic reviews that

## 9. Appendix 3

	Normath	ve cost analysis based on spec	ific direct costs			Sensitivity analysis excl.clinic vist cost
					Total costs per patient	Total costs per patient
Regimen	Drug costs (ZAR)	Bacteriological tests (Costs in ZAR)	Other lab tests (Costs in ZAR)	Clinic visit costs (ZAR)	treated incl. clinic visit costs (ZAR)	treated excl. clinic visit costs (ZAR)
Short oral course (Min)	11 437,70	1 058,58	472,42	2 680,79	15 649,49	12 968,7
Short oral course (Max)	13 650,99	1 058,58	472,42	2 680,79	17 862,78	15 181,9
BPaL (Lzd_Adjusted dose)	11 710,64	705,72	2 158,89	2 632,56	17 207,81	14 575,2
BPaLM (Lzd_Adjusted dose)	12 307,88	705,72	2 158,89	2 632,56	17 805,05	15 172,4
BPaLM (Lzd_Standard)	11 787,08	705,72	2 158,89	2 632,56	17 284,25	14 651,6
Long course 1 (Basic)	27 159,16	2 117,16	783,55	4 407,60	34 467,47	30 059,8
Long course 2	49 601,58	2 117,16	2 028,07	6 581,40	60 328,21	53 746,8
Clinic visits classified according to nature of clinical vi	sits and based on secondary data representing	g a fully decentralised model.				
Descurre	requirement for Sub-DICO 4.1: BD	al us WHO Long in submons	ru proVDB TB and Sub BIO	TO 5 2: BDsl vs WHO Long	in subsenary MDB /BB.TB	
	requirement for Sub-PICO 4.1: BP	Bacteriological tests	Other lab tests		Total costs per patient treated incl. clinic visit	Total costs per patient treated excl. clinic visit
Regimen	Drug costs (ZAR)	Bacteriological tests (Costs in ZAR)	Other lab tests (Costs in ZAR)	Clinic visit costs (ZAR)	Total costs per patient treated incl. clinic visit costs (ZAR)	treated excl. clinic visit costs (ZAR)
Regimen BPal. (Lzd_Adjusted dose)	Drug costs (ZAR) 11 710,64	Bacteriological tests (Costs in ZAR) 705,72	Other lab tests (Costs in ZAR) 2 158,89	Clinic visit costs (ZAR) 2 632,56	Total costs per patient treated incl. clinic visit costs (ZAR) 17 207,81	treated excl. clinic visit costs (ZAR) 14 575,2
Regimen BPal. (Lzd_Adjusted dose) BPal.M (Lzd_Adjusted dose)	Drug costs (ZAR) 11 710,64 12 307,88	Bacteriological tests (Costs in ZAR) 705,72 705,72	Other lab tests (Costs in ZAR) 2 158,89 2 158,89	Clinic visit costs (ZAR) 2 632,56 2 632,56	Total costs per patient treated incl. clinic visit costs (ZAR) 17 207,81 17 805,05	treated excl. clinic visit costs (ZAR) 14 575,2 15 172,4
Regimen BPaL (Lzd_Adjusted dose) BPaLM (Lzd_Adjusted dose) BPaLM (Lzd_Standard)	Drug costs (ZAR) 11 710,64 12 307,88 11 787,08	Bacteriological tests (Costs in ZAR) 705,72 705,72 705,72 705,72	Other lab tests (Costs in ZAR) 2 158,89 2 158,89 2 158,89 2 158,89	Clinic visit costs (ZAR) 2 632,56 2 632,56 2 632,56 2 632,56	Total costs per patient treated incl. clinic visit costs (ZAR) 17 207,81 17 805,05 17 284,25	treated excl. clinic visit costs (ZAR) 14 575,2 15 172,4 14 651,6
Regimen BPaL (Lzd_Adjusted dose) BPaLM (Lzd_Adjusted dose) BPaLM (Lzd_Standard) Long course 1 (Basic)	Drug costs (ZAR) 11 710,64 12 307,88	Bacteriological tests (Costs in ZAR) 705,72 705,72	Other lab tests (Costs in ZAR) 2 158,89 2 158,89	Clinic visit costs (ZAR) 2 632,56 2 632,56	Total costs per patient treated incl. clinic visit costs (ZAR) 17 207,81 17 805,05 17 284,25 34 467,47	treated excl. clinic visit costs (ZAR) 14 575,2 15 172,4 14 651,6 30 059,8
Regimen BPaL (Lzd_Adjusted dose) BPaLM (Lzd_Adjusted dose)	Drug costs (ZAR) 11 710,64 12 307,88 11 787,08 27 159,16 49 601,58	Bacteriological tests (Costs in ZAR) 705,72 705,72 705,72 2 117,16 2 117,16	Other lab tests (Costs in ZAR) 2 158,89 2 158,89 2 158,89 783,55 2 028,07	Clinic visit costs (ZAR) 2 632,56 2 632,56 2 632,56 4 407,60 6 581,40	Total costs per patient treated incl. clinic visit costs (ZAR) 17 207,81 17 805,05 17 284,25 34 467,47	treated excl. clinic visit costs (ZAR) 14 575,2 15 172,4 14 651,6 30 059,8
Regimen BPaL (Lzd_Adjusted dose) BPaLM (Lzd_Adjusted dose) BPaLM (Lzd_Standard) Long course 1 (Basic)	Drug costs (ZAR) 11 710,64 12 307,88 11 787,08 27 159,16 49 601,58	Bacteriological tests (Costs in ZAR) 705,72 705,72 705,72 2 117,16	Other lab tests (Costs in ZAR) 2 158,89 2 158,89 2 158,89 783,55 2 028,07	Clinic visit costs (ZAR) 2 632,56 2 632,56 2 632,56 4 407,60 6 581,40	Total costs per patient treated incl. clinic visit costs (ZAR) 17 207,81 17 805,05 17 284,25 34 467,47 60 328,21	treated excl. clinic visit costs (ZAR) 14 575, 15 172, 14 651, 30 059, 53 746,
Regimen BPaL (Lzd_Adjusted dose) BPaLM (Lzd_Adjusted dose) BPaLM (Lzd_Standard) Long course 1 (Basic)	Drug costs (ZAR) 11 710,64 12 307,88 11 787,08 27 159,16 49 601,58	Bacteriological tests (Costs in ZAR) 705,72 705,72 705,72 2 117,16 2 117,16	Other lab tests (Costs in ZAR) 2 158,89 2 158,89 2 158,89 783,55 2 028,07	Clinic visit costs (ZAR) 2 632,56 2 632,56 2 632,56 4 407,60 6 581,40	Total costs per patient treated incl. clinic visit costs (ZAR) 17 207,81 17 805,05 17 284,25 34 467,47	treated excl. clinic visit costs (ZAR) 14 575,2 15 172,4 14 651,6 30 059,8 53 746,8
Regimen BPaL (Lzd_Adjusted dose) BPaLM (Lzd_Adjusted dose) BPaLM (Lzd_Standard) Long course 1 (Basic) Long course 2	Drug costs (ZAR) 11 710,64 12 307,88 11 787,08 27 159,16 49 601,58 Reso	Bacteriological tests (Costs in ZAR) 705,72 705,72 2 117,16 2 117,16 2 117,16 Durce requirement for Sub-PIC Bacteriological tests	Other lab tests (Costs in ZAR) 2 158,89 2 158,89 2 158,89 783,55 2 028,07 CO 5.3: BPaL vs. SA_new in Other lab tests	Clinic visit costs (ZAR) 2 632,56 2 632,56 4 407,60 6 581,40	Total costs per patient treated incl. clinic visit costs (ZAR) 17 207,81 17 805,05 17 284,25 34 467,47 60 328,21 Total costs per patient treated incl. clinic visit costs (ZAR)	treated excl. clinic visit costs (ZAR) 14 575,2 15 172,4 14 651,6 30 059,8 53 746,8 Total costs per patient treated excl. clinic visit costs (ZAR)
Regimen BPaL (Lzd_Adjusted dose) BPaLM (Lzd_Adjusted dose) BPaLM (Lzd_Standard) Long course 1 (Basic) Long course 2 Regimen	Drug costs (ZAR) 11 710,64 12 307,88 11 787,08 27 159,16 49 601,58 Reso Drug costs (ZAR)	Bacteriological tests (Costs in ZAR) 705,72 705,72 2 117,16 2 117,16 2 117,16 Bacteriological tests (Costs in ZAR)	Other lab tests (Costs in ZAR) 2 158,89 2 158,89 2 158,89 783,55 2 028,07 0 5.3: BPaL vs. SA_new in Other lab tests (Costs in ZAR)	Clinic visit costs (ZAR) 2 632,56 2 632,56 2 632,56 4 407,60 6 581,40 MDR/RR-TB Clinic visit costs (ZAR)	Total costs per patient treated incl. clinic visit costs (ZAR) 17 207,81 17 805,05 17 284,25 34 467,47 60 328,21 Total costs per patient treated incl. clinic visit costs (ZAR) 17 207,81	treated excl. clinic visit costs (ZAR) 14 575, 15 172, 14 651, 30 059, 53 746, 53 746, Total costs per patient treated excl. clinic visit costs (ZAR) 14 575,
Regimen BPaL (Lzd_Adjusted dose) BPaLM (Lzd_Adjusted dose) BPaLM (Lzd_Standard) Long course 1 (Basic) Long course 2 Regimen BPaL (Lzd_Adjusted dose)	Drug costs (ZAR) 11 710,64 12 307,88 11 787,08 27 159,16 49 601,58 Reso Drug costs (ZAR) 11 710,64	Bacteriological tests (Costs in ZAR) 705,72 705,72 2 117,16 2 117,16 Durce requirement for Sub-Pla Bacteriological tests (Costs in ZAR) 705,72	Other lab tests (Costs in ZAR) 2 158,89 2 158,89 2 158,89 783,55 2 028,07 CO 5.3: BPaL vs. SA_new in Other lab tests (Costs in ZAR) 2 158,89	Clinic visit costs (ZAR) 2 632,56 2 632,56 4 407,60 6 581,40 MDR/RR-TB Clinic visit costs (ZAR) 2 632,56	Total costs per patient treated incl. clinic visit costs (ZAR) 17 207,81 17 805,05 17 284,25 34 467,47 60 328,21 Total costs per patient treated incl. clinic visit costs (ZAR) 17 207,81 17 805,05	treated excl. clinic visit costs (ZAR) 14 575, 15 172,4 14 651,4 30 059,8 53 746,4 Total costs per patient treated excl. clinic visit costs (ZAR) 14 575, 15 172,4
Regimen BPaL (Lzd_Adjusted dose) BPaLM (Lzd_Adjusted dose) BPaLM (Lzd_Standard) Long course 1 (Basic) Long course 2 Eng course 2 BPaLM (Lzd_Adjusted dose) BPaLM (Lzd_Adjusted dose)	Drug costs (ZAR) 11 710,64 12 307,88 11 787,08 27 159,16 49 601,58 Reso Drug costs (ZAR) 11 710,64 12 307,88	Bacteriological tests (Costs in ZAR) 705,72 705,72 2 117,16 2 117,16 2 117,16 2 117,16 Durce requirement for Sub-Pice Bacteriological tests (Costs in ZAR) 705,72 705,72	Other lab tests (Costs in ZAR) 2 158,89 2 158,89 2 158,89 783,55 2 028,07 2 028,07 2 028,07 2 028,07 2 028,07 2 028,07 2 028,07 2 028,07 2 028,07 2 158,89 2 158,89 2 158,89 2 158,89	Clinic visit costs (ZAR) 2 632,56 2 632,56 2 632,56 4 407,60 6 581,40 MDR/RR-TB Clinic visit costs (ZAR) 2 632,56 2 632,56 2 632,56	Total costs per patient treated incl. clinic visit costs (ZAR) 17 207,81 17 805,05 17 284,25 34 467,47 60 328,21 Total costs per patient treated incl. clinic visit costs (ZAR) 17 207,81 17 805,05 17 284,25	treated excl. clinic visit costs (ZAR) 14 575,2 15 172,4 14 651,6 30 059,8 53 746,8 Total costs per patient treated excl. clinic visit costs (ZAR) 14 575,2 15 172,4 14 651,6